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CHAPTER 1 
Introduction 
1.1 Aims and objectives 
This study was undertaken in order to establish a detection 
system for luteinizing hormone releasing hormone (LRH) to facilitate in 
vivo and in vitro studies with this compound. Furthermore it was the 
intention to investigate conditions for testing the pituitary response to 
hypothalamic stimulation in man. 
Regulation of the reproductive function has been extensively 
studied on the gonadal level and to a lesser extent on the pituitary 
level. The structural identification of LRH as an oligopeptide (Schally 
et al. 1971a, Currie et al. 1971. Burgus et al. 1972) permitted the 
development of radioimmunoassay techniques for this hormone. It also 
provided the means for a test of the functional capacity of the pitui-
tary. In turn these two factors opened up the higher centres of 
reproductive control mechanisms to more direct studies. 
In this thesis we shall describe the development and character-
ization of a radioimmunoassay for LRH (chapters 3. 4 and 5) as well 
as measurements of the hormone in the general circulation (chapter €). 
and also in tissues and in Incubation media from in vitro studies 
(chapter 7). In chapter 8 we describe how the pituitary reacts in 
terms of gonadotrophin release in response to LRH administered in 
different ways and under various conditions. 
The studies were carried out at the University of Ulm during 
the author's tenure as head of the Peptide Hormone Laboratories of 
the Department of Obstetrics & Gynaecology between 1971 and 1977. 
Most of the results have previously been published in original publi-
cations (Dahlen, Keller & Schneider, 1974; Dahlen & Schneider. 1975; 
Dahlen, Voigt Λ Schneider, 1975 and 1976; Schneider & Dahlen. 1972a, 
1972b, 1973a, 1973b. 1973c and 1975). Our results are being discus­
sed in this thesis In the light of subsequent publications of other 
Investigators in this field. The application of radioimmunoassays to the 
study of reproductive neuroendocrinology has made during the past 
decade such great advances that the radioimmunoassay method has 
changed from a rather specialized technique used in only few labora­
tories to a well established and widely used routine method. In the 
process, this technique has revolutionized the entire discipline of 
endocrinology. Hence, while presenting our experiments, and the 
motivation for doing them, In the light of the state of knowledge in 
the seventies, we discuss our observations in the light of current 
knowledge. 
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1.2 General physiological background 
1.2.1 Anatomy of the hypothalamo-pituitary system 
The hypothalamus is a small part of the brain lying in the base 
and forms the floor of the 3rd ventricle and parts of its walls. It is a 
diffuse area without precise boundaries, but it can be divided into 
groups of nuclei on the basis of physiological functions. The 
hypothalamus joins the pituitary at a junction known as the median 
eminence. The pituitary stalk connects the hypothalamus to the 
pituitary gland. The pituitary gland is divided into two lobes, the 
anterior lobe or the adenohypophysis, and the posterior lobe or the 
neurohypophysis. In some species there is also an intermediate lobe. 
The neurohypophysis is connected to the hypothalamus by a large 
number of neurons. The adenohypophysis, however, is not innervated. 
Communication to higher centres is provided by a set of blood vessels, 
referred to as the hypothalamo-hypophysial portal vessels. These 
vessels are in close contact with terminals of hypothalamic nerve 
fibres in the median eminence and they distribute blood throughout the 
anterior pituitary. 
1.2.2 Physiological role of the hypothalamus 
The hypothalamus is a small but important region of the 
brain. It is concerned with a number of vital functions such as 
water metabolism, temperature regulation, pituitary secretion and 
it thus controls the gonads and the thyroid and adrenal glands. It 
also controls the secretion of growth hormone and prolactin. 
By tradition, hypothalamic action is divided into two parts 
on the basis of functional criteria. The first action is localized 
in the supraoptical and paraventricular nuclei and is concerned 
with the control of water metabolism, milk ejection during 
lactation and uterine contractions at partus. This function is 
performed by means of neurosecretory cells in the above mentioned 
nuclei. These neurons project down into the posterior pituitary 
and are capable of secreting the hormones which are responsible 
for the control of the above mentioned events. The hormones are 
produced in the hypothalamus and pass down the axons to the nerve 
terminals in the posterior pituitary where they are released into 
the general circulation to reach their target tissues. 
The other part of the hypothalamic action is referred to as 
the hypophysiotrophic function. This system consists of special 
neurons which produce hormones and transport them to nerve endings 
in the median eminence region. Here, the neurohormones enter the 
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blood stream in the capillary bed of a portal system. The hormones 
are then carried through these portal vessels into the anterior 
pituitary, where they cause the parenchymal cells to release or 
withhold their respective hormones. This vascular network is 
connecting the basal medial hypothalamus with the anterior 
pituitary, thus linking the central nervous system with the endocrine 
system. This is a unique type of delivery system, which requires only 
minute amounts of the hormone to be secreted. One consequence of 
this is that these hormones are greatly diluted upon reaching the 
general circulatory system. This makes their detection in the periphery 
a more than usually difficult matter. 
Apart from the above mentioned two groups of hypothalamic 
peptides, we now recognize that several other peptides are in fact 
found in vertebrate hypothalamic tissues. For instance, recently 
the endogenous opiate peptides (endorphins and enkephalins) as 
well as Substance Ρ and neurotensin have been identified. These 
hormones have also α widespread, albeit uneven, extra-hypothalamic 
distribution and their physiological roles are as yet largely 
speculative. Recent studies indicate, relevant to these studies, 
modulatory effects of endogenous opiates on the feed-back control 
by gonadal steroids on LRH release from the hypothalamus (Bruni et 
al. 1977. Drouva et al. 19811. 
1.2.3 Hypothalamic releasing and inhibiting hormones 
Hypothalamic releasing and inhibiting hormones are defined as 
substances of hypothalamic origin which stimulate or inhibit the 
release of the anterior pituitary hormones. The existence of such 
a control mechanism was suggested by the early studies of Harris 
and collegues (Green & Harris, 1947: Harris. 1948; Harris. 1955) 
and has since then been extensively investigated and proven. 
Since other cells of the hypothalamus were known to secrete 
the peptide hormones antidiuretic hormone and oxytocin, it was 
thought that the releasing hormones and inhibiting hormones would 
also be small polypeptides. Consequently, the purification of the 
hypothalamic extracts was carried out by means of classical poly­
peptide purification methods. Starting material were hypothalami 
collected in large quantities from local abattoirs, which were 
immediately frozen. The tissues were then subjected to lyophilization, 
delipidation, extraction with acetic acid, chromatography on ion-
exchange resins, partition chromatography, electrophoresis, counter 
current distribution and high voltage zone electrophoresis. The isolated 
peptides were subjected to amino acid analysis and amino acid 
sequence determination (Schelly et al. 1971a). In order to be able to 
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monitor the purification process, it was necessary to develop specific 
bioassays for the anterior pituitary hormones (McKenzie, 1958; Küss et 
al. 1963; Steelman & Pohley, 1953; Greenspan et al. 1949; Parlow, 
1961; Nicoli et al. 1970; Nicoli, 1972). Subsequently these were 
replaced by radioimmunoassays (Monroe et al. 1968; Niswender et al. 
1968; Hendrich et al. 1971; Landon et al. 1967a). Specific assays for 
the releasing hormones were also developed (Ramirez & McCann, 
1961: Saffran & Schally, 1955; Igarashi & McCann, 1961; Redding et 
al. 1966; Peeing et al. 1965). 
The first releasing hormone to be chemically identified was 
the thyrotrophin releasing hormone (TRH). The group of Guillemin 
reported the isolation of 1 mg pure TRH from 300,000 sheep hypo-
thalamic fragments (Burgus et al. 1969). Almost simultaneously 
Schally and his collaborators (Boehler et al. 1969) reported the 
purification of the porcine TRH. This hormone is composed of only 
three amino acids glutamic acid, histidine and proline in equi-
molar ratio (Schally et al. 1969a). Further studies led to the 
definition of the structure and its synthesis (Folkers et al. 
1969; Schally et al. 1969b). Comparisons between synthetic and the 
natural hormones proved that they were identical (Bowers et al. 1970). 
It has also been shown that this tripeptide (L-pyro-glutamyl-L-histidyl-
L-proline amide) is capable of releasing thyrotrophin in all mammals 
studied so far. An intact amide and the cyclized glutamic acid terminal 
are essential for activity. The hormone will also release prolactin in 
man and many animals (Bowers et al. 1971; Jacobs et al. 1971). 
McCann, Taleisnik • & Friedman (1960) demonstrated the 
existence of a luteinizing hormone releasing hormone in hypo-
thalamic extracts. Extensive physiological and biochemical studies 
in several laboratories culminated In the isolation of pure LRH 
from porcine hypothalami by Schally et αϊ. (1971a), from bovine 
hypothalami by Currie et al. (1971) and from ovine hypothalami by 
Burgus et al. (1972). Acid hydrolysis of the peptide yielded 9 
amino acids while the alkaline and acid hydrolysis in the presence 
of thioglycollic acid showed the presence of a 10th amino acid, 
tryptophane, which is destroyed by acid hydrolysis (Schally et al. 
1971b). Further studies indicated a blocked N-terminal and an 
aminated C-terminal, as in the case of TRH. Extensive physio­
logical studies showed that the synthetic product with the proposed 
structure (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) was identical 
to pure, natural LRH (Kastin et al. 1972; Schneider & Dahlen, 1972a; 
Nillius & Wide. 1972; Dahlen, Keller & Schneider, 1974; Schally et al. 
1976). The hormone was found to be able to elicit not only the 
release of luteinizing hormone (LH), but also that of follicle 
stimulating hormone (FSH) in man and many other species (Schally et 
al. 1976 and many others). 
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Scarcity of material prevented amino acid sequencing in many 
species, but the combined immunologic, chromatographic and physio-
logic evidence Indicates that this decapeptide is the LH-releasing 
hormone of all mammals, including man. The synthetic decapeptide 
has been shown to release both LH and FSH in a large number of 
species including rat, mouse. rabbit, hamster, mink, horse, 
cattle, pig, chicken, pigeon, trout, carp, monkey and man (Schally 
et al. 1973. 1976. 1978a & b; Wade 1981). Chromatographic evidence 
suggests that although the mammalian decapeptide is capable of 
releasing gonadotrophins in these species, slight modifications in 
the structure may be found in the avian, reptilian, amphibian and 
fish releasing hormone (King & Millar, 1980). This was confirmed 
for chicken LRH, which differs from mammalian LR H in that the 
arginine in position 8 is replaced by glutamic acid (Miyamoto et 
al. 1982; King et al. 1982a & 1982b). A second species of chicken 
LRH with three amino acids substituted (histidine in position 5, 
tryptophane in position 7 and tyrosine in position 8) has also 
been identified (Miyamoto et al. 1984). Sherwood et al. (1983) 
found a separate teleost LRH differing in two positions (trypto-
phane at 7 and leucine in B). 
Growth hormone release inhibiting hormone (GIH or somato-
statin) was the next hypothalamic "releasing hormone" to be 
identified. It was isolated by the group of Guillemin (Brazeau et 
al. 1973) from ovine hypothalamic extracts and by Schally et al. 
(1976) from the porcine hypothalamus. The primary structure (Ala-
Gly-Cys-Lys-Asn-Phe-Trp-Lys-Thr-Ser-Cys with a -S-S- link between 
the two cysteine moieties forming a cyclic peptide) is identical 
in both species. Larger biologically active forms were found in 
the pig hypothalamus by Schally et al. (1976) and in extracts of 
rat pancreas, stomach and duodenum by Arimura et al. (1975). It 
was initially thought that these forms may represent precursors of 
the hormone (Schally et al. 1979), but later it could be 
established that the larger forms of the hormone are also secreted 
and are in fact biologically active (Rorstad et al. 1979, 
Mandarino et al. 1981). 
Corticotrophin releasing hormone (CRH) was the first hypo-
thalamic releasing hormone whose existence could be proven (Guillemin 
& Rosenburg, 1955). However, it took many years before the chemical 
Identity of ovine CRH could be elucidated by Vale et al. (1981). This 
was followed by the structure of the murine releasing hormone by 
Rivier et al. (1983) and the human hormone by Shibahama et al. 
(1983). These releasing hormones are all peptides with 41 amino acids. 
The human and rat releasing hormones are identical, whereas the ovine 
hormone differs in 7 amino acids. 
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Growth hormone releasing hormone (GRH) activity was claimed 
by Schally et al. (1969b) for a decapeptide isolated from porcine 
hypothalamic fragments on the basis of controversial and 
complicated bioassays (tibia test and pituitary depletion test). 
The physiological significance of the substance is still in doubt. 
The amino acid sequence is similar to that of a part of haemo­
globin and it could be an artifact. Recently, however, the 
releasing hormone could be isolated from a human pancreatic tumour 
from a patient with acromegaly. It was identified as a 44 amino 
acid polypeptide by Guillemin et al. (19Θ3). A similar structure 
could be shown by Esch et al. (1983) for the bovine and by Boehler 
et al. (1983) for the porcine GRH. The structure of murine GRH 
proved to deviate considerably more from the above peptides 
(Spiess et al. 1983). 
Various physiological and clinical observations can best be 
explained by the presence In the hypothalamus of a specific FSH 
releasing hormone (Igarashi & McCann, 1964). The question of the 
existence of a hormone distinct from the above mentioned deca­
peptide, which stimulates both the LH and FSH secretion, is still 
open. Some prominent researchers in the field now discard the idea 
of the existence of such a hormone (Schally et al. 1979), whereas 
e.g. McCann (1983a & 1983b) still argues in the favour of the 
existence of a separate FSH-releasing hormone. More and more 
evidence in favour of the latter conclusion are accumulating. For 
instance, recent studies with LRH antiserum indicate two separate 
system for FSH release: the decapeptide referred to above and 
another immunologically different entity (Culler & Negro-Vilar, 
1986) 
As regards the existence of a prolactin releasing hormone 
(PRH), it has already been mentioned that TRH is able to elicit 
prolactin release. It remains to be seen whether TRH is the 
physiological releasing hormone. There is some evidence for the 
existence of a different hormone. Partially purified hypothalamic 
fractions, which do not appear to contain TRH, can stimulate the 
release of prolactin from pituitaries in vivo and in vitro 
(Schally et al. 1973; Vale et al. 1977; Boyd et al. 1976). A 
compound known to have prolactin releasing hormone activity is the 
octosapeptide vasoactive intestinal polypeptide (VIP). This 
compound can cause the release of prolactin in vivo in intact 
animals (Kato et al. 1978) and in etalk-transected monkeys 
(Frawley & Neill, 1981). Similar results were obtained in vitro 
with pituitary tissue (Ruberg et al. 1978; Shear et al. 1979; 
Frawley & Neill.1981). 
A prolactin release inhibiting hormone (PIH) has been demon­
strated by Talwalker, Ratner & Meites (1963) in rat hypothalami. 
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It was detected in other species by a number of investigators 
(Schelly et al. 1968). Hypothalamic extracts, highly purified in 
terms of bioassayable PIH, have been shown to contain large 
amounts of catecholamines. These are known to be able to inhibit 
prolactin secretion (MacLeod, 1969; Takahara et al. 1974). 
Administration of catecholamine inhibitors leads to incresed pro-
lactin release (Donoso et al. 1971; Friesen et al. 1972; Frohman & 
Stachura, 1975). L-DOPA, a precursor of dopamine, suppresses the 
prolactin output (Frohman & Stachura, 1975; Malarkey et al. 1971), 
as do the dopamine receptor antagonists apomorphine (Martin et al. 
1974) and bromocriptin (Del Pozo, 1974). Injection of apomorphine 
into the 3rd ventricle also supresses prolactin release (Vijayan & 
McCann, 1978a) There is little doubt that dopamine can act 
directly on the pituitary to inhibit prolactin release. MacLeod & 
Lehmayer (1974) have shown that this biogenic amine can inhibit 
prolactin release by the pituitary in vitro. In stalk-transected 
monkeys infusion of dopamine in physiological amounts lowered pro-
lactin levels to approximately normal values (Frawley & Neill, 
1983). Dopamine has been detected in the portal vessels by Ben-
Jonathan et al. (1977), and thus it is conceivable that dopamine 
is the prolactin release inhibiting hormone. 
1.2.4 Biosynthesis of LRH 
Neuropeptides are released by neurosecretory cells at sites 
located at the end of often very long axons projecting into the 
median eminence in the case of LRH secreting neurons. In a neuron 
the ribosomes and endoplasmatic reticulum are almost entirely 
confined to the perikarya. This implies that neuropeptides, such 
as LRH, must either be synthesized locally at the site of release 
by a non-ribosomal, mRNA-independent process or that it is synthe-
sized in the perikarya in the conventional manner and then transported 
down the axons before being released. Evidence for non-ribosomal 
biosynthesis in prokaryotes has been found for small peptides such as 
gramicidine S, thyrocldlne and the polymyxin-group of antibiotics 
(Lipman. 1971 and 1973; Laland. 1972; Kurahashi, 1974). In eukaryotes 
non-ribosomal synthesis has been reported for small peptides such as 
glutathione (Meister. 1973a & 1973b). 
Initial experiments concerning the identity of the biosynthetic 
mechanism involved in the production of LRH pointed to a non-ribo-
somal type (Johanson et al. 1973). This was also reported for GRH 
(Reichlin & Mitnick. 1973), TRH (Mitnick & Reichlin. 1971) and PRH 
(Mitnick et 'al. 1972). However, over the years evidence accumulated 
for the more ubiquitous ribosomal type of synthesis. E.g. Millar et al. 
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(19771 reported higher molecular forms of LRH , which are more likeiv 
to be the product of ribosomai synthesis. Gel chromatography on 
Sephadex G-25 of sheep hypothalamic extracts revealed three peaks of 
LRH actvity, one co-migrating with synthetic LRH and two containing 
higher molecular weight compounds. The latter could be converted into 
LRH-like material by means of exposure to peptidases but not by urea, 
indicating a peptide-structure rather than an aggregate structure. It 
is, therefore, possible that the two higher molecular compounds may in 
fact be precursors for LRH. Such precursors have been reported for 
many hormones and other secretory products (Gainer et al. 1977. Loh 
& Gainer 1983). 
Further evidence for the existence of LRH precursors was 
supplied by Galton, Pattou & Kordon (1981). They could show the 
presence of large molecular weight compounds related to LRH. not 
only in hypothalamic extracts, but also in cortical and placental 
extracts. Two forms were indicated, one with a molecular mass of 
about 1.8 kD (i.e. about twice that of LRH) and one with a 
molecular mass of approx. 26 kD. The large form was found in cyto-
plasmatic and axoplasmatic fractions, the smaller compound was 
located in the axoplasmatic and synaptosomal fractions and the 
decapeptide almost exclusively in the synaptosomal fractions. 
The existence of a precursor for LRH was recently confirmed 
using modern DNA cloning and sequencing techniques (Seeburg & 
Adelman. 1984). A sequence in human DNA was found which coded for 
a 92 amino acid sequence, preceded by a signal peptide in the 
expected manner, containing not only the decapeptide LRH sequence 
but also the expected amino acid sequences for C-terminal 
amidation and processing to LRH. The evidence, from these and the 
earlier experiments, suggests that LRH is synthesized as one or 
more large precursors in the perikarya, is transported down the 
axons and appears in the nerve terminals as the decapeptide, 
probably as the result of enzymatic processing. 
In analogy to the posterior pituitary peptides (Browstein et al. 
1980), the releasing hormone may be moved to the nerve terminals in 
granules that are being transported down the axons of the LRH 
secreting neurons. LRH containing granules have been demonstrated 
both in perikarya and in nerve endings (Goldsmith & Ganong, 1975; 
Silverman & Desnoyers, 1976; Kozlowski et al. 1980). Also favouring 
axonal transport is the effect of colchicine, which is known to block 
this type of mechanism (Schwartz, 1980). Addition of this drug in vitro 
decreases the release of LRH from hypothalamic fragments into the 
medium (Hartter & Ramirez, 1980). 
The release of LRH from the nerve terminals can be activated 
by depolarization or by direct electrical stimulation or by elevated 
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potassium levels The release depends on the external calcium concen­
tration and requires energy (Hartter & Ramirez. 1980. Drouva et al 
1981. Dyer et al. 19801 
1.2 5 Control of releasing hormone secretion 
One aspect of hypothalamic control of hypophyseal activities is 
the integration of a complex system of hormonal and neural inputs 
into coordinated outputs In the case of the control of gonadotrophin 
secretion there are external inputs such as photopenod (in seasonal 
breeders or Orcadian rhythms!, olfactory inputs (pheromones), tactile 
inputs (copulation-induced ovulation) In addition there are internal 
inputs from other hormones, e g effects of prolactin and steroid 
hormone or gonadotrophin feed back All these inputs must be inte­
grated and complied into one or more signals, which will lead to the 
required gonadotrophin secretion pattern This integration is thought to 
be achieved by a complex networn of neural connections inside and 
outside the hypothalamus 
The role of neurotransmitters is essentially indirect, but it is 
also true that almost any neuroendocrine function can be affected bv 
manipulation of neurotransmitters The main chemical neurotranmitters 
- dopamine, norepinephrine, epinephrine, serotonin and acetylcholine -
are all assumed to modulate interneural transmission. These mediators 
are thought to be involved in transfenng signals from other brain 
centres to the hypothalamic hypophysiotrophic neurons. 
Extrahypothalamic nerve structures may influence the 
peptidergic neurons in the hypothalamus (Halasz. 1969. Halasz, 
1972, Sawyer, 1975), although these neurons are capable of 
sustaining certain autonomous functions Many, but not all, 
pituitary trophic hormone functions are maintained when the hypo­
thalamus is disconnected from the rest of the brain E g basal LH 
levels are maintained and the normal pulsatile manner of release 
of the hormone from the pituitary is also observed (Blake & 
Sawyer, 1974, Soper Λ Weick, 1980). The ovulatory surge of this 
hormone, however, is lost (Krey, Butler & Knobil, 1975) However. 
when placing lesions within the arcuate nucleus gonadotrophin 
levels fall to very low (Plant et al 1978). comparable to post 
pituitary stalk section (Vaughan et al 1980) These findings 
suggest that though some hypothalamic functions can occur in 
isolation, stimulatory and/or inhibitory inputs from other areas 
of the brain are needed for full and complete function of the 
hypothalamus These studies and many others lead to the concept of 
a dual level control of anterior pituitary function One system 
regulates the basal secretion and the other regulates all other 
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functions such as diurnal rhythms and ovulatory gonadotropntn 
surge (Hutchinson, 1978). 
The first evidence concerning the nature of the neuro­
transmitter involved in the control of gonadotrophins (via releasing 
hormones) was the finding that adrenergic and cholinergic blockers 
could prevent ovulation (Sawyer, Markee & Everett. 1950) Later 
investigations by Schneider & McCann. (1969 and 1970a. 1970b. 1970c) 
indicated that dopamine is involved This synaptic transmitter is able 
to stimulate the release of luteinizing hormone. At the same time, 
however, evidence for a decreased turnover of tuberoinfundibular 
dopamine was presented by Fuxe & Hoekfelt (1969) Over the years 
the opinion shifted from a stimulatory role of dopamine to an inhibi­
tory one Recent findings suggest that dopamine is involved both in 
the stimulation as well as the inhibition of gonadotrophin release 
Which of the two actions prevails at a given moment probably depends 
on the steroid environment (McCann, 1983a) It has also been demon­
strated that high doses of the amine can inhibit LH release (Vijayan & 
McCann, 1978a. Gnodde & Schuilmg. 1976) 
It appears to be established beyond reasonable doubt that nor­
epinephrine is involved in the stimulatory effects leading to the 
release of LH This has been concluded from the studies of many 
investigators over a long period of time Donoso et al (1970), Bapma 
et al (1971), Chiocchio et al (1976), Selmanoff et al (1977), Vijayan 
& McCann (1978a). NegroVilar (1979). Ranee et al (1981). Ojeda et 
al (1982). These studies were carried out by blocking neurotransmitter 
receptors or enzymes involved in catecholamine biosynthesis or by 
determining catecholamine turnover 
Acetylcholine increases FSH release in vitro from incubated 
hypothalamo-pituitary tissue Its intraventricular injection induces LH 
release from the pituitary (Fionndo et al. 1975, Vijayan & McCann. 
1980). Since atropin can block this effect it seems that cholinergic 
neurons and muscarinic receptors play a role in the control of LH 
release. Furthermore, since the response to acetylcholine can be 
blocked by addition of a dopamine receptor blocker (Vijayan & 
McCann, 1980), it seems likely that a dopaminergic neuron is also 
involved in this effect Three other neurotransmitters have been 
implicated in the system: serotonin, gamma-aminobutyric acid and 
histamine (Schneider & McCann, 1970, Негу et al 1976, Libertun & 
McCann, 1976, McCann et al. 1981). The physiological significance of 
these findings cannot be assessed at this time 
Summing up the available evidence McCann (1983b) postulates 
that both norepinephrine and dopamine are involved in the preovulatory 
LH surge initiating ovulation, and that a complex interplay of 
noradrenergic, cholinergic and dopaminergic neurons is involved m the 
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regulation of the pulsatile release pattern of LH (i.e. maintenance of 
basal levels). 
Over the years overwhelming evidence has accumulated favouring 
dopaminergic inhibitory control of prolactin secretion (see above in 
section 1.2.3). However we must distinguish between dopamine as a 
neurotransmitter and as a "releasing hormone", and it seems that 
although this biogenic amine is undoubtably involved in the inhibition 
of prolactin release, the site of action is probably the pituitary and 
not any of the higher centres. Serotonin precursors release prolactin 
when administered to man (Maclndoe & Turkington, 1970) and rat 
(Kamberi, Schneider & McCann, 1970). Blocking of the 5-hydroxytrypto-
phane synthesis prevents suckling-induced prolactin release in the rat 
(Kordon et al. 1973). Thus it is possible that stimulatory effects on 
prolactin release occurs via a serotonergic pathway. 
It seems that adrenergic and noradrenergic pathways are 
involved in the control of growth hormone secretion Increases of 
hypothalamic GIH output have been demonstrated in vitro (Negro-
Vilar. 1978) and in vivo (Vijayan, Krulich & McCann, 1975; 
Turkelson et al. 1979). On the other hand, adrenergic and nor­
adrenergic stimulation has also been shown to be occurring via CRH 
(Eden et al. 1981; Terry & Martin 1981). It is difficult to reconcile 
these results. A dopaminergic pathway has been implicated by the 
studies of Negro-Vilar, 1978; Chibara et al. 1979; Vijayan, Krulich & 
McCann, 1975). The physiological role of such a pathway and that of 
a proposed serotonergic pathway remain obscure and the findings are 
controversial. 
The secretion of adrenocorticotrophin (ACTH) is inhibited by a 
noradrenergic system in the brain. There is evidence that the neurons 
exert their influence via alpha-adrenergic receptors on the cells that 
secrete corticotrophin releasing hormone (Ganong, 1974). Acetylcholine 
has also been thought to be involved, but other data do not support 
this hypothesis (Ganong, 1974). Evidence is accumulating that the 
biogenic amines norepinephrine and epinephrine also have direct 
effects on the pituitary (Vale & Rivier, 1977; Giguere et al. 1981; 
Vale et αϊ. 1983). Hence, the identity of the control mechanism 
remains uncertain. 
For the role of neurotransmitters in the control of thyrotrophine 
secretion there is alas much contradictory evidence. Although there is 
in vivo evidence for an alpha-adrenergic control (Montoya, Wilber & 
Lorincz, 1979), the In vitro studies indicate stimulatory actions by 
norepinephrine, dopamine, serotonin and histamine (Jackson & Lechan, 
1983). 
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1.2.6 Extrahypothalamic occurrences of releasing hormones 
It is now recoenized that the distribution of the releasing 
hormones is not restricted to the hypothalamus or even to the 
brain. They are aiso found in completely unrelated organs, where 
they apparently perform biological actions quite different from 
their hypophysiotrophic actions. E.g. TRH has been found to 
stimulate central nervous system motor activity (Segal & Mandell, 
1974) and to modify autonomic nervous activity, to increase the 
plasma content of catecholamines and to increase heart rate and 
blood pressure (Yarbrough. 1979). CRH decreases parasympathetic 
stimulation in the intestines (Tache et al. 1983) and the heart 
(Fisher & Brown, 1983). It also increases peripheral norepi-
nephrine sympathetic actions as well as the secretion of epi-
nephrine from the adrenal medulla (Brown et al. 1982). In addition 
it can increase blood pressure, heart rate and hepatic glucose 
production (Fisher et al. 1982; Brown et al. 1982). Growth hormone 
inhibiting hormone inhibits epinephrine secretion (Brown, Rivier & 
Vale. 1981). 
LRH has effects on the central nervous system in that it is 
capable of increasing libido after intraperitonal injection (Moss et al. 
(1973), which effect is not dependent on the pituitary (Pfaff, 1973). 
Administration of anti-LRH sera (Kozlowski and Hofstetter. 1978) and 
inhibitory LRH-analogues can suppress mating (Moss & Dudley, 1981). 
The releasing hormone has also been found in the mid-brain, a region 
known to be important in the control of mating behaviour (Samson et 
al. 1980). Furthermore, LRH has been detected in olfactory pathways 
in the hamster, and the olfactory sense is known to play a critical 
role in reproductive behaviour in this species (Philips et al. 1980). 
LRH has also been found outside the nervous system, as large 
quantities were reported in placental cell cultures and in placental 
extracts (Siler-Khodr & Khodr, 1978; Khodr & Siler-Khodr, 1980; 
Gibbons. Mitnick & Chieffo, 1975). The hormone behaves in a manner 
indistinguishable to synthetic LRH in bioassays, radioimmunoassays and 
physico-chemical assays. Milk is another source of extrahypothalamic 
LRH. Baram et al. (1977) isolated a substance which showed LH-
releasing activity in vitro, cross-reacted in a radioimmunoassay and 
co-migrated with LRH in chromatographic analysis. 
Receptors for LRH have been identified in peripheral organs 
such as ovaries (Clayton, Harwood & Catt. 1979) and testes (Bourne et 
al. 1980). The hormone itself was detected by Pauli et al. (1980). 
Evidence for direct luteolytic effects by LRH has been obtained 
(MacDonald, Greeley & Beattie, 1980). testicular steroidogenesis can 
also be inhibited by LRH, albeit only with pharmacological doses 
(Hsueh & Erickson. 1979). 
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It is obvious that the group of peptides known as hypothalamic 
releasing hormones have in fact many more effects and sites of 
actions than was originally thought. It is not very difficult to explain 
the the distribution of LRH in a teleologica! manner. It is concerned 
with reproduction on a number of levels: mating behaviour, gameto-
genesis, ovulation, gonadal steroidogenesis, placental function and 
neonatal sex differentiation. It might, therefore, be considered as a 
universal "reproduction hormone". 
1.2.7 Nomenclature of releasing hormones 
The releasing hormone nomenclature is still rather confused. 
Luteinizing hormone releasing hormone is for instance referred to as: 
luteinizing hormone releasing factor, acronym "LRF"; luteinizing 
hormone releasing hormone, acronyms "LRH" or "LH-RH" or "LHRH"; 
luteinizing hormone/follicle stimulating hormone releasing hormone (in 
view of its dual action), acronym "LH/FSH-RH"; gonadotrophin 
releasing hormone, acronyms "GnRH" or" Gn-RH": with recommended 
names "gonadoliberin" (IUPAC-IUB) and "gonadorelin" (WHO). 
Many commonly occurring peptides are known under trivial names, 
indicating either the source (e.g. insulin) or the physiological action 
(e.g. prolactin). Others are known by acronyms or abbreviations of 
overly long names (e.g. FSH). In dealing with hypothalamic releasing 
hormones it became common practice to call these substances 
"releasing factors" until their chemical identity could be established. 
whereafter they are referred to as "releasing hormones". As it was 
rather cumbersome to pronounce these long names, it quickly became a 
habit to use acronyms. The trivial names proposed by the above 
organizations have not reached common acceptance. The most common 
acronyms for luteinizing hormone releasing hormone are at the moment 
LHRH and GnRH but LRH and LRF are also used. At the time when 
these studies were carried out. LRH was very common. This, and the 
fact that a three-letter acronym is easier to use and pronounce than a 
four-letter one, led us to use the term LRH throughout this thesis. 
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CHAPTER 2 
Fundamental aspects of radioimmunoassay 
2.1 Introduction 
One of the most urgent needs in the field of hormone research 
is the development of techniques of sufficient specificity and 
sensitivity to enable measurements to be performed in biological fluids 
at short time intervals and in small amounts of material. This is 
necessary in order to study acute physiological changes in hormone 
levels. 
For the assay of biologically active substances we have, in 
addition to physico-chemical methods, two general types of tech-
niques based on biological principles : the bioassay and the ligand-
binding assay (the latter is also known as saturation analysis). A 
bioassay utilizes a biological effect of a hormone in order to compare 
unknown samples with standardized quantities of the biologically active 
substance. A binding assay estimates a substance on the basis of a 
specific binding characteristic of the whole molecule or a part of it. 
The ligand is usually a polypeptide derived from a biological system 
and may be an antigen, a receptor protein or any other compound, 
capable of specifically binding the substance be determined. 
In this study we shall deal with a special type of binding assay. 
the immunoassay, where the ligand is an antibody. More specifically, 
we use a radioimmunoassay, where the measured parameter used for 
calculation of results is the degree of displacement from binding of a 
radiolabeled antigen by its non-labeled counterpart. 
2.2 Advantages and disadvantages 
Radioimmunoassays offer several advantages over the earlier 
determination methods such as bioassays. High sensitivity is the most 
important advantage, a radioimmunoassay, at least in theory, permitting 
the determination of quantities as small as femtomoles 
(0.000000000000001 moles). High specificity is a second advantage as 
they offer an excellent ability to measure only the desired compound. 
High precision and reproducibility, even at very low concentrations of 
the substance to be determined, is a third important advantage of 
radioimmunoassays. These advantages can only be obtained when 
certain conditions are met and certain limitations are accepted. In 
developing an assay, it is necessary that it be thoroughly validated 
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according to established principles. Especially, there is a need for 
extensive characterization of the antibody. It must be recognized that 
the radioimmunoassay does not necessarily measure the active principle 
as the case in a bioassay, since the antibody may also react with a 
biologically inactive precursor or metabolic derivative of the compound 
to be measured. Moreover, production of antibodies is a time-
consuming and laborious technique, a supply of properly prepared and 
characterized antibody, once obtained, can be used for many years of 
work. It is not uncommon to be able to do millions of determinations 
from a single bleeding of a rabbit (Berson & Yalow, 1976). 
2.3 Basic principles of the radioimmunoassay 
A radiolabeled antigen was first used to study the interactions 
of an antigen and its antibody in vitro. This eventually led to the 
demonstration of circulating antibodies to insulin in humans who were 
treated with insulin derived from other species (Berson et al. 1956). 
Berson & Yalow (1958) were the first to point out the remarkable 
sensitivity obtained when unlabeled antigens are measured by their 
ability to inhibit competitively the binding of radiolabeled antigens by 
antibodies. At approximately the same time Ekins studied the binding 
of radiolabeled vitamin B12 to intrinsic factor. These studies led to 
the development of the first radioimmunoassays by Yalow & Berson 
(1959 and 1960) and Ekins (1960). The basis for the radioimmunoassay 
is shown in the following reaction scheme: 
free 
labeled + 
antigen 
anti-
body 
unlabeled 
+ antigen <-> 
labeled 
antigen-
antibody 
complex 
unlabeled 
+ antigen-
antibody 
complex 
Ag* + Ab + Ag Ag"Ab Ag-Ab 
In performing the assay, labeled antigen and the specific anti-
body, are incubated in the presence and absence of a sample, con-
taining the unknown amount of (unlabeled) antigen. After equilibrium 
has been reached or approached, free and antibody bound antigen are 
separated by a suitable physico-chemical method. The radioactivity of 
one or both (usually one) of these fractions is measured. The antigen 
concentration in unknown samples is calculated by comparing the 
decrease in binding of labeled antigen produced by the unlabeled 
antigen in the sample, with that of a standard curve obtained by 
adding known amounts of unlabeled antigen to the assay system. 
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2.4 Requirements for radioimmunoassays 
The requirements for any radioimmunoassay are: a purified 
antigen, a standard preparation of the antigen, a specific antibody and 
a method for separating the bound and free antigen fractions. In 
addition, extraction and chromatographical steps may be required, 
depending on the nature of the sample and the possibility of inter-
ference by closely related compounds or by non-specific factors. 
A supply of purified antigen is an essential prerequisite for the 
development of a radioimmunoassay. Thus the application of a radio· 
immunological technique is limited to substances, where this criterion 
can be met. If the pure substance is available, as is often the case 
with steroid and peptide hormones, this substance is used for antibody 
induction, preparation of radiolabeled antigen and for standards. If the 
substance itself not immunogenic, it can usually be made so by a 
suitable conjugation. 
It should be noted, however, that a pure preparation is not 
absolutely required for use as a standard. A partially purified 
antigen, or even a biological material with a high content of the 
substance that is to be determined, can be utilized. E.g. it is pos-
sible to use a pool plasma standard in a radioimmunoassay (Berson & 
Yalow, 1966). Obviously, in this case, the results will not give molar 
concentrations. It is then necessary, in addition to standard validation 
procedures, to calibrate the method against an International Reference 
Preparation or similarly characterized and accepted material. 
Partially pure antigen preparations can also be used for immuni-
zation, since the resulting antibodies must in any case be selected by 
means of extensive characterization. Experience shows that a specific 
antibody may result after immunization with a very pure antigen as 
well as with a mixture of substances (Yalow, 1973). Given a choice, it 
might be better to use the pure antigen. 
For the preparation of the labeled antigen it is vital to use a 
highly purified substance. The immunological integrity of the labeled 
antigen is of crucial importance, since the performance of the assay 
will greatly depend on its purity and its identity with the substance 
to be measured. Since labeling of the antigen usually involves its 
chemical alteration, it is necessary to purifiy the reaction product, 
e.g. with chromatography, and then check the purified substance for 
its binding capacity to the antibody. For the same reasons, a labeling 
method, causing minimal damage to the antigen, should be selected. It 
might be possible to purify the labeled material after completion of 
the reaction, but this is not always feasible. Chapter 3 supplies 
details of the preparation of radioiodinated LRH. 
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In addition to its dependence on tracer quality, the performance 
and reliability of a radioimmunoassay will depend above all else on the 
properties of the antibodies. Three aspects are of importance: avidity, 
specificity, and availability. The avidity of the antibody will largely 
determine the maximal sensitivity of the assay, which may be of 
crucial importance. The necessity of employing an antibody with the 
highest possible specificity is obvious. Availability of the antibody 
involves the ease or difficulty of raising the antibody, the reproduci­
bility of its characteristics in successive bleedings, and the stability 
of the antibody during storage. Production of anti-LRH sera is discus­
sed in Chapter 3, the determination of their specificity in Chapter 5. 
In order to measure the fraction of labeled antigen that at α 
given time is in the free and the bound form, ft is necessary to 
physically separate the two fractions. This can be achieved by any of 
several methods, which utilize a physico-chemical difference between 
the two fractions. E.g. the addition of an organic solvent to the 
incubation medium may often precipitate the antibody-bound antigen 
but not the free antigen. The main criteria for the separation methods 
are efficiency and practicality. The choice of a separation method for 
the LRH-RIA is discussed in Chapter 4. 
2.5 Optimization and validation of radioimmunoassays 
Optimizing of the assay conditions usually has to be accomplish­
ed in an empirical fashion, but the problem can also be approached in 
a mathematical way. Several investigators have attempted to mathema­
tically define optimum conditions for radioimmunoassay (Ekins & 
Newman, 1970; Ekins, Newman & O'Riordan, 1971; Berson & Yalow, 
1971 and 1976; Rodbard & Lewald, 1970; Rodbard. 1971; Ekins, 1974). 
They have reached somewhat different conclusions, especially with 
regards to the optimal concentration of reactants. Nevertheless, it 
seems safe to state that in order to obtain maximal sensitivity of the 
assay, low concentrations of the antibody must be chosen while still 
maintaining practical assay conditions. The limiting factor here is that 
by lowering antibody concentration, we increase the relative amount of 
non-specific binding in the measured radioactivity, thus burying the 
gain in sensitivity at the expense of the precision. Preincubation of 
the unknown sample with antibody prior to addition of the labeled 
antigen might be advantageous for high sensitivity. In the case of the 
LRH-RIA these factors are discussed in Chapter 4. 
In order to ensure optimal sensitivity, the antigen must be 
maximally labeled so as to yield a high specific activity. The reason 
for this is that the labeled antigen should be present in minimal 
concentration, while still giving the highest possible counting rate 
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(Yalow & Berson, 1969 and 1971). The limiting factor here is the 
decreasing level of precision as the level of radioactivity decreases 
(Ekins, 1974). In developing a radioimmunoassay it is advisable to 
check out these effects. More important is that the integrity of the 
antigen be preserved during labeling procedure. See also Chapter 3 for 
the preparation of 1-125 labeled LRH and Chapter 4 for the influence 
of the tracer concentration on the behaviour of the LRH-RIA. 
The choice of the incubation temperature may also be of impor-
tance, since the sensititvity of the assay will be maximal by incuba-
ting at the temperature at which the association constant of the 
reaction is highest. Should this be at a low temperature, then a longer 
incubation time is required in order to achieve sufficient binding of 
antigen to antibody. The volume of the incubation mixture also plays a 
role in that elimination of unnecessary water has an effect similar to 
that of changing to a more avid antibody, which means that the assay 
becomes more cost-effective. These factors are investigated in 
Chapter 4. 
As pointed out in section 2.2, the nature of the radioimmuno-
assay technique makes it imperative to investigate exactly what is 
being measured. One obvious point to consider is the question of 
antibody specificity. Antibodies are usually directed to only a part of 
a molecule, and thus depending on the circumstances, degradation 
products, precursors, and other structurally related molecules may be 
measured as the original molecule. The immunological specificity can 
be investigated by testing analogues of the antigen for their ability to 
displace labeled antigen from binding to the antibody. Chapter 5 
present our data on the specificity of anti-LRH sera. 
One should also ascertain the immunological identity of the 
standard preparation and the sample material. One way of doing this is 
to check whether they give parallel dose-response curves. This implies 
that it is desirable to assay on at least two, and preferably more 
levels of sample dilution. For the LRH-RIA this is presented in 
Chapter 7. It is also desirable to compare the radioimmunoassay with 
another, completely different, type of assay which has been estab-
lished and validated, e.g. a bioassay or, if possible, a reliable 
analytical technique such as mass-spectrometry-gas-chromatography. For 
the LRH-RIA we have done this by comparing with a standardized 
bioassay, which is reported in Chapter 5. 
2.6 Antibodies 
Antibodies are the key components of all radioimmunoassays. 
The specificity and, to a large degree, the maximally possible sensi-
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tivity of the assay will depend on the quality of this reagent. Their 
production must be provoked in such a manner, that the resulting 
antibodies are of the required standard. The likelihood of obtaining 
suitable antibodies is dictated largely by chance, but a number of 
factors influence the success rate. This includes the choice of proper 
immunization schedules, antigen and injection technique. 
2.6.1 Immunogenicity of proteins and small peptides 
All proteins are immunogenic, although not to the same extent 
and usually not in the species in which they arise. The factors that 
confer immunogenicity are complex and incompletely understood. 
However, it is known that certain criteria must be satisfied. In 
general, the immunogenicity of a molecule is directly related to its 
size. A molecule with a molecular mass above 10,000 usually provides 
a relatively easy production of antibodies, whereas molecules with a 
mass of less then 1000 are poor immunogens. Obtaining antibodies to 
molecules between these two limits meets with variable succes. 
However, size is not the only factor playing a role. For a protein 
to elicit an antibody reaction it must normally be recognized by the 
organism as foreign. It has been observed by Fleischer et al. (1965 & 
1966) that in the case of phylogenetically related molecules the 
antibody will be directed to those parts of the molecule that are 
different. It also seems that greater chemical complexity will make 
the molecule more strongly immunogenic. The method of administration 
of the antigen is also of great importance. Intravenous injection of a 
compound may, for instance, not lead to any antibody production, 
whereas subcutaneous injection with an adjuvant may lead to copious 
antibody production (Orth, 1975). 
Finally, it is possible to enhance, or indeed induce, the immuno-
genicity of a molecule by chemically altering it. Virtually any chemical 
entity may serve as an antigenic determinant if it is coupled to a 
suitable carrier. In fact, by means of chemical alteration it is possible 
to produce antibodies even against metal ions (Goodman, 1976). 
Because of the uncertainty whether a peptide with a molecular 
mass between 1 - 10 kD, such as LRH (molecular mass - 1128), will 
produce antibodies, it is advisable to conjugate it to a protein before 
immunization. Many investigators, who started out using unconjugated 
peptides, have subsequently switched to the use of conjugates. E.g. 
Orth (1975), who had to use more than 200 animals to obtain a single 
antiserum from unconjugated ACTH, could obtain antibodies almost 
immediately when using an albumin conjugate. 
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2.6.2 Conjugation of a small molecule to a carrier protein. 
In a case, as in the present (LRH), when the immunogenicity of 
the compound is thought to be insufficient, it is common practice to 
bind the small molecule covalently to a carrier, usually a protein. The 
carrier protein can be a homologous polyaminoacid (Vunakis, 1971) or 
a naturally occurring protein such as serum albumin (Niswender & 
Midgley, 1970), thyreoglobulin (Bauminger, Kohen & Lindner, 1974) or 
haemocyanin (Doerr & Crambach, 1971). The characteristics of the 
resulting antisera will depend on the nature of the small molecule, the 
nature of the carrier protein, and the way in which they are coupled. 
A number of reactions are available for the conjugation proce­
dure. The most common one is the carbodiimide reaction (Khorana, 
1953; Goodfriend, Levine & Paisman, 1964). In this reaction a carboxyl 
group of the small or large one molecule is linked to an aminogroup of 
the other molecule to form a peptide link. Either the small molecule 
or the carrier molecule can provide the carboxyl group and vice versa 
the aminogroup. Another procedure is the mixed anhydride reaction 
according to Boissonas (1951) and Erlanger et al. (1957). In this case 
a carboxylic function on the small molecule is activated to form an 
anhydride, which can then be aminated by a free amino group of the 
carrier protein. The glutaraldehyde reaction can be used to couple two 
amino groups, present on the small molecule and the carrier protein 
respectively (Reichlin et al. 1968, Richards & Knowles, 1968). When no 
carboxyl groups are available, as in the case of steroids, a hydroxy! 
group can be esterified with succinic anhydride (Mikhail et al. 1970), 
or an oxime derivative formed by the reaction with o-carboxylmethyl 
hydroxylamine. In both cases the modified molecule can then be linked 
to an amino group of a carrier protein, e.g. bovine serum albumin 
(Erlanger, 1973; Liebeman et al. 1959). The classical diazo reaction 
can be used to bind either a histidine or a tyrosine moiety of the 
carrier protein to a diazo salt of the small molecule (Kopitar & 
Kompa, 1975; Paral et al. 1975). Finally it is possible to use the bis-
diazotized benzidine method for the same purpose. This method has 
been used extensively for small peptides like thyrotrophin releasing 
hormone (Likhit & Sehon. 1967; Bassiri & Utiger, 1972). 
2.7 Labeling of the antigen 
An essential aspect of any radioimmunoassay is the determination 
of the distribution between bound and free fractions of antigen. For 
this purpose a fixed amount of α labeled ligand (here: antigen) is 
added to the reaction mixture. The label may be any substance with a 
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characteristic property that can be measured reliably and simply. In a 
radioimmunoassay this is a radioactive isotope. The label can be 
introduced by a variety of methods, depending on its physical and 
chemical nature. 
Basically we can distinguish between two types of radiolabeling: 
internal and external.In the case of internal labeling, an existing atom 
in the antigen molecule is replaced by a radioactive isotope e.g. 
carbon-14 or tritium. The great advantage of the internal labeling 
method is that the labeled antigen is chemically identical to the 
unlabeled one present in samples and standards. External labeling 
involves the introduction of a radioactive isotope by covalent linkage 
to an existing structure in the antigen molecule. Although such a 
molecule is per definition not identical to the unlabeled antigen, in 
practice its immunological characteristics are often indistinguishable 
from those of the unlabeled antigen. 
Tracers with internal label are often commercially obtainable 
and are usually prepared by one of four basic techniques: neutron 
irradiation, chemical synthesis, biological synthesis or exchange reac-
tions. Neutron irradiation is rather unselective and can lead to damage 
of the molecule being labeled. Chemical synthesis involves the use of 
straight forward synthesis but using a labeled component. Biological 
synthesis follows the same principle, but using a biological system 
such as an intact (micro-) organism or an enzyme system rather than a 
chemical system. Exchange reactions are commonly used for tritium 
labeling. The material to be labeled is kept in contact with tritium for 
a prolonged period of time, during which an exchange between hydro-
gen and tritium will take place. 
External labeling of peptide antigens is most commonly carried 
out with radioactive iodine, since iodine substitutes relatively easily 
into the aromatic side-chain of tyrosine. Histidine also reacts with 
iodine, but much slower than tyrosine. While in the early days of 
radioimmunoassay 131-iodine was used. The present availability of 
125-iodine with high specific activity has made it the isotope of 
choice because of its longer half- life. 
2.7.1 Methods of radioiodination 
A number of methods have been described for introducing iodine 
into peptides. They all have in common that the relatively unreactive 
iodide is converted into the more reactive iodine, which can then be 
incorporated into tyrosine residues of the peptide to be labeled 
(Ramachandran, 1956). The older techniques, viz. the iodine mono-
chloride method according to MacFarlane (1958) and the electrolytic 
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method (Rosall, 1964), are hardly used anymore. A more common tech­
nique uses Chloramine T, an oxidizing agent which converts iodide to 
iodine simply by mixing the two substances (Hunter & Greenwood, 
1962; Greenwood, Hunter & Glover, 1963). The reaction is stopped by 
adding the reducing agent sodium metabisulphite. A hazard of the 
method is the possibility of damage to the peptide by the oxidative 
process. The level of iodinalion can be controlled by varying the 
concentration of the oxidant and the length of exposure. Both should 
be kept to a minimum consistent with a sufficiently high radioiodin-
ation level in order to avoid nonspecific damage by Chloramine Τ 
(Yalow & Berson, 1971). The simplicity of the method explains its 
almost universal acceptance. Purification is carried out immediately in 
order to remove unreacted iodine and unwanted reaction products. 
Standard biochemical methods, such as chromatography on molecular 
sieves (e.g. Sephadex gels) are used for this purpose. 
Enzymatic oxidation has the advantage of not exposing the 
peptide to relatively high concentrations of a chemical oxidizing agent. 
Lactoperoxidase in the presence of traces of hydrogen peroxide is 
used to introduce the radioiodine into the peptide (Marchalonis, 1969, 
Thorell & Johansson, 1971). A reducing agent is not required, since 
simple dilution of the reaction mixture will stop the reaction. The 
iodination mostly occurs in tyrosine residues, although as with 
Chloramine Τ iodination of histidyl groups is also possible. It has been 
claimed that this procedure will result in less damage to the labeled 
substance than other methods (Thorell & Johansson, 1971; Karonen et 
al. 1975). 
Conjugation labeling, as described by Bolton & Hunter (1973), 
offers several advantages. With this technique the radioiodine is first 
coupled to a phenol or imidazole group of an appropriate carrier 
containing an amine group for coupling to the antigen. Radioiodination 
of the carrier molecule can be executed with any of the previously 
described methods, whereupon the labeled carrier is coupled to the 
antigen by means of a standard conjugation reaction. This way of 
labeling has the advantage of not exposing the peptide to any possible 
chemical damage of the oxidizing reaction, it can be applied to 
peptides without tyrosyl or histidyl residues. A disadvantage of the 
method is that the label is much larger and may thus lead to alter­
ation of the immunological behavior of the labeled antigen. 
2.7.2 Non-radioactive labels 
Radioactive decay is, by definition, α singular event and only а 
small fraction of all radioactive atoms in a sample are in fact emit­
ting radiation during a typical observation period. On the other hand, 
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other probes such as discussed below, can be used in such a manner 
that virtually all molecules will undergo reaction in a limited time and 
thus provide a far more efficient system. Consequently, such methods 
might yield more sensitive assays, especially if used in techniques such 
as immunoradiometric assays. 
A common non-radioactive labeling method is the use of enzymes 
instead of radioactive substances (van Weenen and Schuurs, 1972; 
Wisdom, 1976; Schuurs and van Weenen, 1977: Engvall, 1980). Because 
of the catalytic nature of enzymes a small quantity of label can be 
measured relatively easily by means of conventional and well estab-
lished laboratory methods. The advantages of enzyroe-immunoassays are 
a prolonged shelf-life of the labeled antigen, absence of radiation 
damage to the labeled antigen, absence of radiation hazards in the 
laboratory and that expensive counting equipment is not needed. A 
possible source of error with this technique is noise due to endoge-
nous enzyme activity in the samples. The sensitivity of the assay will 
depend on the source of the label, ultimately on the number of mole-
cules being catalytically converted and the method employed to detect 
this conversion. Standard fixed-time spectrophotometric determination 
method are commonly used. The more rapid kinetic type of assay is 
less commonly used since most enzyme immunoassays are employing a 
solid phase separation of free and bound antigen, which leads to 
turbid solutions and hence to difficulties in reading initial reaction 
rates. In such cases the use of specific electrodes capable of detec-
ting e.g. ammonia or oxygen can be used to determine the reaction 
rate (Meyerhoff & Rechnitz, 1980). 
A variant of the use of enzyme labels is the prosthetic group 
label immunoassay (Morris et al. 1981). This is in fact a sort of 
homogeneous immunoassay (see also section 2.8) where advantage is 
taken of the fact that an antigen-prosthetic group (FAD) conjugate is 
able to activate (apo-)glucose oxidase, but is strongly inhibited when 
the conjugate is bound to the specific antibody. A conventional 
detection system for the oxygen consumed or the hydrogen peroxide 
liberated by the oxidase is used to quantify the reaction rate. This 
could be the classical Trinder colour generating system (Barham & 
Trinder, 1972) or any other convenient system available such as an 
oxygen sensitive electrode. 
Another approach for the immunoassay is the use of electron 
spin resonance (Leute et al. 1972). The antigen is then coupled with a 
spin label like nitroxide, which has a characteristic sharp-banded 
electron spin resonance spectrum. The change in the spectrum upon 
reaction of the antigen with its antibody is observed. The method is 
simple and rapid, but requires expensive equipment and with the 
present instrumentation the lower detection limit is unfortunately 
several orders of magnitude higher than that of the radioimmunoassay 
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technique. 
Yet another possible labeling method is the use of a fluorescent 
molecule such as fluorescein (Aalbers, 1973; Bryce, 1974). These 
assays share a disadvantage with the enzyme immunoassay, viz. inter-
ference by endogenous (here: fluorescent) compounds in samples, also 
the fluorescence arising from plastic or glass containers. When an 
antigen conjugated to fluorescin is reacted with its antibody, a change 
in fluorescence polarization can occur (Parker, 1973). Alternatively, 
fluorescence quenching can be induced by the binding and the reduc-
tion in fluorescence used as a parameter for the detection (Dandliker. 
Hsu & Vanderlaan, 1980). It is also possible to use techniques such as 
the fluorescence fluctuation method for the same purpose (Elings. 
Nicoli & Briggs, 1983). The search for superior fluorophores led to the 
use of chelated compounds of rare earth elements, e.g. europium. 
These materials display very characteristic fluorescence, including a 
prolonged decay fluorescence, which permit discrimination between 
label-induced photons and background fluorescence (Ekins, 1983). 
The above mentioned europium chelates is but one example of 
the use of metal labels in immunoassay. In fact, metals can general-
ly be used as labels in place of radioactive isotopes. The detection of 
the metal may be carried out by any of a number of more or less 
conventional methods such as emission, absorption and fluorescence 
spectrometry as well as microwave excitation emission spectrometry, 
anodic stripping voltammetry and neutron activation (Cais, 1983). The 
metals are either incorporated directly in the antigen forming organo-
metallics or are introduced as part of a molecule that is attached to 
the antigen. 
A chemiluminescent label offer potentially very high effective 
specific activities (Ekins, 1983). This involves the use of compounds 
capable of emitting light as a result of chemical reactions. A special 
case Is the use of bioluminescence, which allows for a very sensitive 
assay (Wannlund & DeLuca, 1983). The measured parameter in this 
system is light emitted from a reaction catalyzed either by firefly 
luciferase or bacterial luciferase. In the first example the luciferase 
is coupled to the antigen In a manner allowing It to retain its 
enzymatic activity and then this label is used in a conventional 
immunoassay. Alternatively the antigen is coupled to glucose-6-phos-
phate dehydrogenase and the NADH produced is detected by adding a 
bacterial luciferase NADH-dependent light emitting enzyme system. 
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2.В Variants of radioimmunoassay 
Many proteins have been identified, which have an affinity for 
molecules such as steroids (Korenman, 1968), vitamins (Brumbaugh et 
al. 1974), hormones (Catt et al. 1971) and other biologically important 
compounds. These proteins can be used for competitive binding assays 
in a manner resembling the radioimmunoassay. Many binding proteins 
are found in blood, where they serve for transport or storage of 
molecules such as corticoid steroids (Murphy, 1971) or sex steroids 
(Mayers & Nugent, 1968; Johansson, 1969). Other binding proteins 
occur in cells, either in the plasma membrane serving as a receptor 
for hormones regulating events inside the cell via a second messenger 
system, or in cytoplasm or nucleus and having affinity for molecules 
acting within the cell like e.g. cyclic AMP (Gilman, 1970). Although 
immunoassays and binding protein receptor assays may vary consider­
ably in sensitivity and specificity, the one system is not always 
superior to the other. The two types of methods suffer indeed from 
the same pitfalls and, by and large, have the same precision and 
reproducibility. 
A very common variant of the radioimmunoassay is the enzyme-
immunoassay. This can be an assay where the radioactive label on the 
antigen or antibody is replaced by an enzyme (van Weenen & Schuurs, 
1972). The rest of the assay, e.g. the separation of bound and free 
antigen, is executed in the same manner as for the radioimmunoassay. 
Like the radioactive label, the enzyme marker can be attached to 
either the antigen or the antibody. However, there is a fundamentally 
different type of immunoassay employing enzymes: the so called homo­
logous enzymeimmunoassay (Rubinstein, Schneider & Ullman, 1972). Here 
the enzyme activity of the label is inhibited upon binding to the anti­
body and so the remaining activity will reflect the amount of compe­
ting antigen in the sample. As the technique does not require a 
separation of bound and free fractions and is therefore less laborious 
and can easily be subjected to automation with common clinical 
chemistry analyzers. 
An important variant of the radioimmunoassay is the immuno-
radiometric assay. In this system one labels the antibody rather than 
the antigen (Miles & Hales, 1968). As the principal antibody protein, 
immunoglobulin G; contains many tyrosine residues, it can be iodinated 
relatively easily without loss of antibody activity. The radioimmuno-
metric assay is advantageous where it is difficult to produce a labeled 
antigen, e.g. due to the lack of tyrosine residues in a peptide. Alter­
natively, in some cases one might wish to avoid handling the antigen, 
as in the case of hepatitis В antigen. It has the additional advantage 
that a standard procedure can be set up for all labelings in a labora­
tory. A perhaps more important aspect is that this type of assay can 
be made more sensitive than any other immunoassays (Ekins, 1983). 
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This presupposes the use of labels with a higher intrinsic maximal 
specific activity than radioisotopes. This can be done by using e.g. 
chemiluminescent or fluorescent probes. The immunoradiometric type of 
assay requires relatively large amounts of antibodies. It might there-
fore be of advantage to use monoclonal antibodies, which can be 
produced in almost unlimited amounts of uniform and relatively pure 
product. Hence, this type of assay may find a multitude of applica-
tions in the future. 
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CHAPTER 3 
Production of reagents for the radioimmunoassay 
3.1 Antibodies 
When our studies were initiated, LRH was available only in very 
limited quantities and only to specially invited research groups. The 
author was privileged to receive generous supplies of the LRH deca-
peptide from Dr. F. Enzman of Hoechst AG, Frankfurt, W.Germany. 
However, although at one time we received half of the entire supply 
present in Europe at that moment, only milligram amounts of the 
compound was available to us. This had, of course, a decisive 
influence on the choice of immunization techniques and immunogens. 
The Hoechst company was interested in having radioimmunoassays for 
LRH established and hence prepared LRH conjugates for us and for 
other investigators use. Consequently, the immunization schedules 
were made to fit the available synthetic materials. This meant that 
at times when only the unconjugated LRH was available, the pure 
LRH was used as immunogen. 
This was done on the, perhaps dubious, theory that antibodies 
might develop upon challenge with the pure substance in an animal 
that had already been exposed to the more immunogenic conjugate. 
The alternative would have been to undertake the conjugation of the 
scarce LRH ourselves. We choose not to do this, as we were aware 
of the poor results obtained by many laboratories in several 
countries, where considerable experience and sophisticated techniques 
were available. 
As it turned out, we had perhaps been unnecessarily pessi-
mistic. At that time a graduate student in Scotland attempted to 
prepare a LRH-BSA conjugate with the carbodiimide method of 
Goodfriend et al. (1964). According to theoretical considerations, 
discussed in section 3.3. this should not be possible. However, 
apparently he was unaware of this and succeeded! The resulting 
conjugate was injected into two rabbits and he could harvest, 
apparently almost effortlessly, an antiserum well suited for the 
radioimmunoassay of LRH (Fraser & Gunn, 1972). Because of its 
simplicity and high rate of success, the method was adopted by us 
and others and led to the production of antibodies to LRH 
(Seppaelae, Ranta &, Leppaeluoto, 1974; Burger & Franchmont, 1974; 
Root et al. 1975; Kizer et al. 1976; Dahlen et al. 1976). 
We used as immunogens three conjugates of LRH, viz. to poly-
lysin, cellulose and bovine serum albumin, in three separate attempts. 
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All conjugates, and synthetic LRH, were prepared and purified in the 
Hoechst AG laboratories and were made available to us at different 
times. The substances were dissolved in saline and homogenized in an 
equal volume of Freund s complete adjuvant. The suspensions were 
injected in volumes of 50 - 100 μΙ per site in the quantities stated in 
the following three paragraphs. Injections were done intradermally at 
60 - 100 sites on the shaved backs of six male New Zealand white 
rabbits for each conjugate. Initially we gave the booster injections 
subcutaneously in Freunds' incomplete adjuvant. • In later studies we 
have also used the complete adjuvant and intradermal multiple site 
injections for the booster injections. Blood was withdrawn by 
puncturing one ear vein and placing the ear in a partly evacuated 
container. In this manner 30 - 50 ml blood could be collected in a 
few minutes with a minimum of discomfort for the animal. Serum was 
collected by allowing the blood to clot at 4*C for IB - 24 hours and 
centrifuging it to remove the clotted material. The serum was collec­
ted and divided into 0.1 - 1.0 ml aliquota that were snap-frozen by 
immersion in an ethanol bath at -40*0. 
Polylysin-conjugated LRH was given to a first group of six 
rabbits. Two animals received 4 mg of the conjugate, two others 3 
mg, and the remaing two 2 mg. Seven weeks after the preliminary 
injections 1 mg unconjugated LRH was administered (at this time no 
conjugated LRH was available) in an attempt to boost the effect of 
the initial injections. Serum was collected on five occasions at 
monthly or bimonthly intervals. No anti-LRH activity could be detec­
ted in any of the sera. 
Cellulose-conjugated LRH was given to another group of six 
rabbits. The primary injection of 0.8 mg conjugate per rabbit was 
followed by a booster injection of 1 mg unconjugated LRH on the 
9th week of the injection schedule for the same reasons as above. 
No anti-LRH activity could be found in any of the sera obtained over 
a 6-months period after immunization. 
A succesful induction of LRH antibodies was achieved with LRH 
coupled to bovine serum albumin according to Frazer & Gunn (1973). 
Each of the six rabbits received 3 mg conjugate and a booster 
schedule was initiated after 4 months consisting of biweekly 
administration of 0.2 mg conjugate over a two-month period. Three 
rabbits developed antibodies to LRH in response to this treatment, 
but only one produced concentrations suitable for radioimmunoassay. 
All three rabbits received further booster injections, but only the 
rabbit with the high titre continued to produce suitable antiserum. 
Specificity studies indicated that the antibodies were of high quality, 
so no further attempts were made to produce antibodies. 
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Figure 3.1 : Antiserum dilution curves for three LRH 
antisera produced by incubation with a fixed amount 
125-I-LRH and separation of bound and free antigen by 
means of solvent precipitation. 
We tested for the presence of anti-LRH activity in the rabbit 
sera by incubating serial dilutions of the sera with a fixed amount 
(approx. 10,000 cpm) of radio-iodinated LRH (for its preparation, see 
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Figure 3.2 : Antibody titre and assay sensitivity for 
different bleedings from an anti-LRU producing rabbit 
section 3.2). The incubation lasted 3 - 4 hours at 4*0, which is 
enough to reach near-equilibrium conditions (see section 4.2). Bound 
and free antigen were then separated by means of ethanol precipi­
tation of the bound fraction. This was the method of choice for the 
LRH radioimmunoassay (see also section 4.3). Centrifugation and 
measurement of radioactivity in the precipitate in a LKB-Wallac 
gamma-counter 8000 completed the test. 
Figure 3.1 shows typical dilution curves for serum obtained from 
the three antibody producing animals. The uppermost curve represents 
the only antiserum suitable for radioimmunoassay. This rabbit produ­
ced good antisera for an extended period of time. The booster and 
bleeding schedules are presented in figure 3.2. This figure Illustrates 
how the antibody titre varied in response to the booster injections. 
The antibody titre is defined as the dilution at which half of a 
standard amount of radioiodinated LRH (see section 3.2) is bound to 
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the antibody. Also shown in the figure is how the sensitivity of the 
assay varied when sera from different bleedings were used. The lower 
detection limit was defined as the amount of LRH needed to produce 
a significant reduction in the amount of radio-iodinated LRH bound to 
antibody in the absence of added standard LRH (see section 4.4 for 
details). 
3.2 Preparation of the radioiodinated hormone 
LRH contains a tyrosine residue in position 5, hence we chose 
radioiodination by means of the Chloramine Τ method. Through a trial 
and error approach the following method was established: To 5 Ug 
pure synthetic LRH in 10 |il bidistilled water (predispensed in 1 ml 
serum vials and kept at -30*0 we add 25 μΐ 0.5 M phosphate buffer 
(pH 7.5) and 1 raCi 125-iodine in 5 |il aqueous solution as sodium 
Iodide. The radioiodine was purchased from New England Nuclear in 
volumes varying between 5 - 10 yl, in 5 mCi lots. Each lot was 
diluted to 25 ul to facilitate handling. The reaction is initiated by 
the addition of 20 ug Chloramine Τ dissolved in 10 ul 0.05 M 
phosphate buffer (pH 7.5). The content of the vial is mixed for 15 
seconds on a Whirlmix. and the reaction is then stopped by the 
addition of 125 UK sodium metabisulphite dissolved in 50 ul phosphate 
buffer (0.05 M. pH 7.5). Then 500 ul carrier protein solution (5% egg 
albumin in phosphate buffered saline) is added to minimize losses from 
non-specific absorbtion on glass and other materials. The reaction 
products are separated by means of gel chromatography over a 15 χ 
300 mm Sephadex G-25 column, equilibrated with 0.01 M acetic acid, 
which also was used for elution. Fractions of 40 drops each are 
obtained on a fraction collector. The radioactivity of each fraction is 
measured on a gamma counter. We regularly find that 3 or 4 peaks 
of radioactivity are present, and that the last of these contains the 
material with the highest immunoreactivity. For routine use we pool 
the 3 · 5 tubes with the highest radioactivity in the last eluting 
component. The radiolabeled LRH is stored at -30*C in 0.1 ml 
aliquots. Radioiodinated LRH prepared in this way is stable for about 
4 • 6 weeks. The immunological integrity as determined by binding to 
excess antibody was good to excellent: binding was never below 80 % 
and usually between 90 - 95%. Under standard assay conditions (see 
section 5.2.2) the non-specific binding of the tracer never exceeded 
5% of the total radioactivity. 
A more detailed characterization of the reaction mixture has 
been obtained by applying it to a longer Sephadex G-25 column. 
Fractions of 100 drops are collected and three consecutive fractions 
are pooled. The pooled fractions are diluted with phosphate buffered 
•aline (0.01 M phosphate, 0.14 M sodium chloride, pH 7.0 with 0.1% 
egg albumin) so as to contain 100 cpm/μΐ. The immunoreactivity of 
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Figure 3.3 : Purification of 125 I labeled LR H on a 
Sephadex G-50 column, χ—χ denotes radioactivity and 
о—о denotes immunoreactivity expressed as % bound to 
antiserum under optimized conditions, the black bar 
represents immunoassayed LRH in the experiment with 
labeled LRU. 
each fraction is tested by incubating 100 ul of the above dilution 
with 200 μΙ antiserum, appropriately diluted with the above phosphate 
buffered saline but containing 0.05 M EDTA and 0.25% normal rabbit 
serum. After incubation over night at 4*C bound and free antigen are 
separated by the addition of 5 volumes of cold ethanol and subse­
quent centrifugatlon at 1000 χ g for 5 minutes. The behaviour of the 
radiolabeled LRU on the Sephadex column was further investigated by 
chromatography of 1 ng of pure synthetic LRH on the same column. 
Fractions collected es described for the radioiodination reaction 
mixture have a pH far too low for the antigen-antibody reaction. 
Hence, in order to determine LRH content of the fractions, we 
extract with ethanol before the radioimmunoassay. The extraction 
procedure is described in section 6.3 and the immunoassay procedure 
in section 5.2.2. 
The results of the two experiments are summarized in figure 
3.3. Surprisingly 125-iodine-LRH elutes after the unreacted iodine, 
rather than before as would be expected. Furthermore, the unlabeled 
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LRH élûtes before or together with the iodide. This suggests that 
radioiodinated LRH is retained on the Sephadex G-25 material by a 
mechanism not related to difference in molecular size but rather to 
the presence of iodine in the molecule. 
3.3 Discussion 
Experience with the production of antibodies against small 
peptides was first obtained in work with the neurohypophyseal 
peptides and thyrotrophin releasing hormone. It was found that 
antibody production could be enhanced by rather elaborate techiques 
such as injection of the immunogen into the spleen or the lymph 
nodes (Boyd. Landon & Peart, 1967; Chard. Kitan & Landon. 1970). 
These methods were, however, soon replaced by the conjugation 
techniques and, above all, the very effective intradermal multiple site 
injection method of Vaitukaitis et al. (1971). The first report on the 
successful generation of anti-LRH sera by a group of French inves-
tigators (Kerdelhue et al. 1973a and 1973b) described the injection of 
pure synthetic LRH in guinea pigs for prolonged periods of time. The 
hormone was prepared in Freunds complete adjuvant and injected in 
or near the lymph nodes. At the end of the injection schedule the 
LRH was adsorbed to aluminium oxide before injection. 
A conjugation method was used by Nett et al. (1973). who 
coupled the LRH-analogue pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-
COOH to lysine residues of bovine serum albumin by means of the 
mixed anhydride reaction (Boissonas, 1951). They also used LRH 
coupled to bovine serum albumin by means of the bis-diazotized 
benzidine technique. Intradermal multiple site injections were made in 
rabbits. Booster injections of the same type were administered at 
monthly intervals. 
Anti-LRH sera were also produced by adsorbing LRH on poly-
vinylpyrrolidone followed by emulsification in Freund's complete 
adjuvant before multiple site injection in rabbits with monthly booster 
injections as reported by Arimura et al. (1973). Shin and Kraicer 
(1974) immunized rabbits intradermally with LRH coupled to bovine 
serum albumin by means of the bis-diazotized benzidine reaction and 
employing Freund's complete adjuvant. Booster immunizations with the 
same LRH-conjugate were given every 3 weeks. 
A rather different approach was used by Koch and collabora-
tors (1973), who attached p-diazonium phenylacetic acid to synthetic 
LRH and then coupled the resulting azo derivative to bovine serum 
albumin by means of the carbodiimide reaction. This resulted in a 
mixture of azo-tyrosyl and azo-histidyl linkages between LRH and 
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albumin. Rabbits were immunized by multiple site intradermal 
injections in Freund's complete adjuvant, supplemented with vaccine 
against Haemophilus pertussis. 
As mentioned above, Frazer & Gunn (1973) managed to couple 
LRH to bovine serum albumin in a rather simple but obscure manner. 
They simply mixed 2 mg bovine serum albumin with 2 mg LRH and 75 
mg l-ethyl-3-(3-methyl aminopropyl) carbodiimide and dialysed the 
mixture overnight against phosphate buffered saline. The product was 
then used for immunization of two rabbits in Freund's complete 
adjuvant using multiple site injections. It is not clear how the 
carbodiimide could affect the conjugation, since LRH has both the 
C-terminal and the N-terminal blocked and is therefore unable to 
participate in peptide bond formation. One terminal of the deca-
peptide is blocked by internal ring formation of the glutamic acid and 
the other by amidation. The site on the LRH molecule for conjugation 
is thus not immediately apparent. Possibly, conjugation takes place 
via the hydroxyl group of the tyrosine or serine residue. 
This method was also successful in our hands. After overcoming 
the initial difficulties with the administration of the conjugate, 
antibodies suitable for radioimmunoassay of LRH were obtained. The 
quality of the antibody, especially its specificity, was high enough to 
keep one rabbit for further antiserum production. Both titre and 
sensitivity were improved to some extent by the booster injections, 
but they varied quite independently of each other and no particular 
pattern was observed. 
Most investigators, developing radioimmunoassays for LRH, chose 
to label with radioiodine by means of the chloramine Τ method. The 
method is simple, and as LRH contains a tyrosine residue the 
reaction is easy to perform. Others, e.g. Miyachi et al. (1973) and 
Nett & Adams (1977), preferred to use enzymatic methods, but the 
proof of the superiority of this method has yet to be supplied. In 
order to improve the quality of the tracer, it is probably better to 
use a purification step after labeling. Sarda, Barnes & Nalr, (1980) 
could show improved purity, specific activity and immunological 
behaviour after purifying the labeled hormone by means of batch 
ion-exchange resin chromatography. In our studies we did not purify 
beyond the molecular sieve step, as our quality control data indicated 
that the assay was performing well. 
Many different techniques have been used to separate the reac­
tion products from each other after the oxidative iodination. Most 
investigators used, as we did, Sephadex G-25. Our observation that 
radioiodinated LRH is retained on Sephadex has been confirmed by 
other investigators. Nett et al. (1973), who also used Chloramine Τ 
radiodination and Sephadex G-25 separation, found two peaks of 
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radioactivity. The first elution peak could be identified as unreacted 
iodine and the second as radioiodinated LRH. 
Kerdelhue et al. (1973a and 1973b). who also purified the 
reaction products of a Chloramine Τ reaction on Sephadex G-25. 
observed like we did that unlabeled LRH elutes before the radio­
iodinated LRH. The in vitro biological activity of their labeled 
preparation comprised 30 · 50% of that of the original preparation. 
Jeffcoate et al. (1974) showed that the first peak eluting from 
Sephadex G-25 contains,in addition to unreacted iodine, LRH with 
diminished immunoreactivity and with enhanced capability of non­
specific binding to serum components. This probably represents 
damaged peptide. 
Hichins et al. (1974), when employing another molecular sieve 
Biogel P2 concluded that the first peak emerging from the column 
contained the radioiodinated LRH. However, studies by others (Sarda, 
Barnes & Nair, 1980) indicated that also on this type of column the 
free iodine and damaged LRH elute before the good quality tracer. 
By comparing the separation of the reaction mixture on different 
Sephadex columns. Sorrentino & Sundberg (1975) could show that the 
best separation of iodinated LRH from the other reaction products 
can be obtained on G-25 Sephadex. The mechanism responsible for 
the retention of iodinated LRH on Sephadex G-25 has not been 
identified. It is presumably due to adsorption induced by the presence 
of iodine. A similar chromatographical behaviour has been observed 
for oxytocin (Chard, Kitan & Landon, 1970). This peptide can also be 
separated from Its iodinated form by molecular sieve chromatography 
on Sephadex G-25. 
3.4 Summary 
A method was found for the preparation of antibody by injec­
ting LRH coupled to bovine serum albumin in rabbits. Radioiodinated 
LRH could be prepared by the Chloramine Τ method. A subsequent 
Sephadex purification step yielded a suitable tracer for the radio­
immunoassay of LRH. In the next chapter we shall describe the 
radioimmunoassay for LRH with this material and the optimal condi­
tions the assay. 
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CHAPTER 4 
Radioimmunoassay of the hormone 
4.1 Introduction 
Although all radioimmunoassays are based on the same principle 
and essentially the same methods are employed to produce the rea­
gents, it is always necessary to establish the optimum incubation 
conditions for a particular assay. This typically involves the following 
items. A search for the optimal incubation temperature and reagent 
concentrations must be made. A separation method for bound and free 
antigen must be found. A standardized and reproducible method for 
preparing standard curves must be established. Finally, the assay 
must be set up in a manner ensuring the highest possible sensitivity 
and precision. In these studies we used bleedings КЗ and H6 from 
rabbit K14, the one rabbit which produced antiserum with a reason­
ably high titre. The two bleedings showed similar or identical charac­
teristics in terms of sensitivity, specificity and general performance. 
In addition we tested two donated anti-LRH sera for specificity and 
sensitivity. ' 
4.2 Optimum incubation temperature and reagent concentrations 
The reaction between antigen and antibody Is generally temper­
ature dependent, as are all biochemical reactions. Furthermore, the 
highest sensitivity of the assay will be achieved when incubating at 
the temperature, at which the affinity constant is maximal. Many, but 
not all, radioimmunoassays are enthalpy driven reactions. This means 
that the binding between antibody and antigen will be maximal and 
also that the radioimmunoassay will be most sensitive at low temper­
atures. However, the rate of biological reactions Is also temperature 
dependent. All other things being equal, the rate of approach to the 
equilibrium will be decreased upon lowering the temperature, so that 
a longer incubation will be required. Association rates between 
molecules will generally be smaller for large proteins than for small 
peptides. Factors which play a role are diffusion rates and probability 
of collision in the proper orientation. This means that we also have 
to establish the time required to reach equilibrium. These parameters 
can be established by incubating labeled antigen with antiserum at 
different temperatures, removing aliquots at various times and then 
separate bound and free antigen by means of a suitable method. 
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A personal communication from Dr. S.L. Jeffcoate indicated that 
relatively short incubation times suffice for the radioimmunoassay of 
LRH. Consequently, we have used short term incubations for these 
studies. The optimum incubation temperature was determined as 
follows: 125-1 labeled LRH is mixed with appropriately diluted 
antiserum and kept at 0, 5, 9, 14, 25 and 37*C for 2, 4 and 6 hours, 
respectively. After each incubation period 5 volumes of cold ethanol 
are added to precipitate the antibody-bound fraction (see section 
4.3.3 and 4.5 for choice of phase-separation method). After centri-
fugation and removal of the supernatant containing the free antigen, 
the remaining radioactivity is measured in the precipitate. Figure 4.1 
(right) shows that maximal binding under these conditions is obtained 
when the incubation is carried out between 5 and 10*C. The results 
also show that binding is much reduced at and above room temper-
ature. 
Such reduced binding could be due to the tracer or antibody 
being temperature sensitive and breaking down at even slightly 
elevated temperatures. Consequently, we investigated whether the 
reduced binding was due to damage or some other mechanism. Timed 
incubations at 5, 23 and 37*C were carried out (figure 4.1, left). 
After 4 hours incubation at 23 and 37*C samples were removed and 
placed at 5"C for another two hours (figure 4.1, dotted lines). Since 
the binding in these tubes reached the same levels as in the samples 
kept at 5*C all the time, it follows that the lower binding at the 
higher temperature is not due to damage of the antibody or the 125-1 
labeled LRH. This has been confirmed by reversing the experiment: 
preincubation at 5*C to achieve a preliminary binding, then bringing 
the tubes to 23 or 37*C for 2 hours and a final incubation for 2 
hours at 5*C (figure 4.2). Control tubes were kept at the three 
temperatures for 30 hours. 
The results of these experiments show that binding is dependent 
on the temperature, and that the processes of binding and release of 
LRH from the antibody are reversible over relatively short periods of 
time. The results also show that an incubation time of 4 - 6 hours is 
sufficient to reach near-equilibrium conditions, since there was over 
the next 24 hours an increase of only 5 - 10 %. 
The reaction between LRH and its antibodies can be assumed to 
follow the law of mass action. This implies with increasing reactant 
concentrations the reaction will proceed more to completion during a 
given time. It means that more tracer will be bound to antibody and 
hence the measurement of bound antigen will be more precise. The 
effects of the reagent concentrations on the behaviour of the 
LRH-radioimmunoassay were determined in a simple experiment by 
adding different amounts of buffer to fixed amounts of antiserum and 
labeled LRH. The mixture was incubated at 5*C for 5 hours to ensure 
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Figure 4.1: Influence of temperature and incubation time 
on binding of 1-125 labeled LRH to antibody. Bound and 
free antigen were separated by solvent precipitation. 
near-maximal binding of antigen to antibody (see above). After phase 
separation by solvent precipitation the radioactivity of the bound 
fraction 'was measured. The results are shown in Table IV.1. 
Table IV.l Dependence of antibody binding on reactant concentration 
total volume % bound 
0.3 ml 
0.4 ml 
0.5 ml 
0.6 ml 
0.7 ml 
47.4 
43.0 
39.7 
36.3 
34.3 
As expected, higher binding Is achieved at higher reagent concen­
trations. So the highest possible reagent concentrations should be 
employed in order to achieve maximal yield in terms of radioactivity. 
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Figure 4.2: Reversibility of 1-125 labeled LRH binding to 
antibody by temperature changes. See text for description 
of experiment. Phase separation was achieved by solvent 
precipitation. 
Final incubation volumes in the radioimmunoassays arc largely 
established on the basis of very practical considerations, such as 
availability of precise dispensing equipment and size of disposable 
reaction vessels. Commonly volumes between 0.5 and 2 ml are used 
for a typical radioimmunoassay. However, when an extraction proce-
dure is employed in order to, among other things, increase the sensi-
tivity, it is advisable to use the smallest possible volume. Under 
these conditions a reduction of the final incubation volume from 1.0 
ml to 0.1 ml would bring a net increase in sensitivity by a factor of 
10. Another reason fur using the smallest possible volume is to 
economize on precious antiserum. On the basis of these 
considerations, we chose to use 0 1 ml sample or standard, 0.2 ml 
diluted antiserum and 0.1 ml labeled LRH. 
As a general rule, the amount of labeled antigen used in a radio-
immunoassay should be approximately equal to the smallest amount of 
antigen to be measured. Using less tracer allows theoretically for a 
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more sensitive radioimmunoassay (Rodbard & Lewald, 1970: Rodbard, 
1970; Yalow & Berson. 1971). However, in practice there is a limit 
below which further reduction of the tracer will not produce any 
improvement in sensitivity (Chard, 1971b; Ekins, 1974). The limiting 
factor is the increasing level of imprecision as the level of radio-
activity decreases. This can be compensated, to a limited extent 
only, by increasing the counting time. The effect of reducing the 
tracer concentrations was investigated for the present LRH radio-
immunoassay by running standard curves with doubling dilutions of 
tracer (figure 4.7, see also section 4.4). Radiolabeled LRH, produced 
as described in section 3.2, was routinely diluted to contain 200,000 
cpm/ml, corresponding to 10,000 cpm measured in the zero standard 
incubation after phase-separation (0.1 ml tracer/tube and approx. 50% 
tracer bound). This limits the counting error to between 1 and 3 % 
when counting for 1 minute, which was a desirable time in view of 
the availability of gamma-counters. The sensitivity of the radio-
immunoassay was also acceptable when using tracer prepared in this 
way. 
The concentration of antibody in a radioimmunoassay is often 
chosen such that approximately 50 % of the tracer is bound to anti-
body in the absence of competing unlabeled antigen. It has been 
claimed by Yalow & Berson (1971) that generally the lower the anti-
body concentration the greater the sensitivity of the radioimmuno-
assay. However, there is an obvious practical limit here as well, set 
by the error in the measurement of the bound radioactivity (Ekins, 
1974). This is due to an increased fraction of non-specific binding of 
tracer and any increase in sensitivity is lost to an increase in 
imprecision. In actual practice binding cannot usually be reduced to 
much less than 25 %. In our study conditions were chosen such that 
close to 50 % of the antigen was bound. 
4.3 Separation of bound and free antigen 
4.3.1 Introduction 
Every radioimmunoassay ends with the measurement of the radio-
activity of either free or bound antigen. Mostly this involves a 
physical separation of the two fractions. In rare instances, a 
spontaneous precipitation of the antigen-antibody complex will allow 
phase separation by simple centrifugation. This was accomplished by 
Walsh et al. 1970 in an assay for Australia antigen. In this case the 
relatively large size of the antigen and the rather high concentrations 
of the antigen and antibody made such separation possible. However, 
in most cases the antibody-antigen complex remains soluble and one 
of a wide variety of separation methods has to be applied. Table IV. 
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2 lists the commonly used separation methods. 
We chose two of the methods of category 3 for further study: 
solvent precipitation and double antibody precipitation of the antigen-
antibody complex. The double antibody technique has the advantage 
of an almost universal applicability and the solvent precipitation 
method is a simple but reliable method utilizing a specific property 
(difference in molecular mass) of the reagents. 
Table IV.2 Methods for the separation of bound and free 
antigen. 
1. Electrophoresis 3. Antigen-antiboby complex 
- starch precipitation 
- cellulose acetate - double antibody technique 
- Polyacrylamide - salting out 
2. Adsorption of free - solvent precipitation 
antigen on a solid phase - trichloroacetic acid 
- cellulose 4. Solid phase antibody 
• charcoal - adsorption on tube walls 
- coated charcoal - adsorption on disks 
- talcum powder - polymerized antibody 
- QUSO 5. Gel filtration 
• ion exchange resins 
4.3.2 Double antibody precipitation 
The double antibody precipitation method is perhaps the most 
widely used of all phase separation techniques. It was introduced for 
radioimmunoassay by Utiger, Parker & Daughaday (1962). It depends 
on the ability of immunoglobulin antibodies to bind to the soluble 
antigen-antibody complexes and so render it insoluble. The insoluble 
complex will precipitate and can be centrifuged down, thus effecting 
a separation of any bound radiolabeled antigen from free labeled 
antigen present In the incubation mixture. The method is very 
versatile and it can be used for a large number of radioimmunoassays 
without changing the incubation conditions. 
The anti-immunoglobulins are obtained by immunizing a second 
animal species with purified gamma globulins derived from the species 
serving as source for the first antibody. As we were producing anti-
LRH in rabbits, the first step was to isolate and partially purify 
rabbit gamma-globulin. This was done according to the classical 
method of Cohn (1946) for the separation of plasma proteins by 
means of cryoprecipitation with various concentrations of ethanol at 
temperatures below 0*C. Cohn fraction II, which contains gamma-
globulins in a very high percentage, could be prepared from rabbit 
% bound 
¿CL 
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Figure 4.3: Determination of antibody titre for a "second 
antibody" viz. anti-gamma-globulin. Antiserum to LRU and 
labeled LRH were incubated under standard assay 
conditions and this was followed by the addition of 
serial dilutions of anti-gamma-globulin serum. After 24 
hours at 4*C bound and free fractions separated 
by centrifugation and the radioactivity of the bound 
fraction was measured. 
serum in large quantities and with relative ease. The resulting 
protein preparation was lyophilized and could be stored at 4'C for 
very long periods of time. A sheep was injected with the rabbit 
gamma-globulin fraction in Freunds complete adjuvant and at multiple 
sites according to Vaitukaitus et al. (1971). The sheep was subjected 
to jugular phlebotomy at regular intervals. The blood was left to clot 
at room temperature, rimmed and stored overnight at 4'C for clot 
retraction. It was then centrifugea to recover the anti-rabbit-
gamma-globulin (ARGG) serum. The serum was stored frozen in ali-
quote at -20*C or as a lyophilized preparation at 4*C. 
'When setting up a double antibody system for phase separation, 
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it is necessary to determine the optimal concentration at which the 
anti-gamma globulin is to be used. The concentration required for 
maximum precipitation will vary with each antiserum. In the presence 
of an excess of the first antibody (here: anti-LRH) nearly complete 
precipitation should occur. On the other hand, as excessive amounts 
of the second antibody (antiimmunoglobulin) can lead to diminished 
immunoprecipitation. Hence it is desirable to prepare a dose-response 
curve for the second antibody. An example of testing a batch of 
ARGG for use in the LRH radioimmunoassay Is shown in figure 4.3. 
LRH antiserum and radioiodine-labeled LRH in phosphate buffered 
saline (PBS, see section 3.2) were incubated for 24 hours at 5*C to 
achieve near-maximal binding of antibody to antigen. This was 
followed by the addition of sheep ARGG at various -dilutions and a 
further 24 hour incubation at 5*C. At this point 1.5 ml PBS was 
added and the tubes were centrifuged for 20 minutes at 5000 χ g. 
After removing the supernatant the radioactivity in the precipitate 
was measured. When the inverse ARGG dilution is plotted against 
percent bound antigen, a maximum appears at a dilution between 1: 
20 and 1:30. Hence, this concentration is preferably used in the LRH 
radioimmunoassay. Higher concentrations lead to a decreased amount 
of bound antigen 
4.3.3 Solvent precipitation of antibody 
In the immunoassay of small peptides, as in our case, the 
separation of bound and free antigen is usually easier than in assays 
of large proteins. Because of the large differences in molecular mass 
between the immunoglobulin-antigen complex and the LRH molecule, 
relatively simple methods of separation can be used. Solvent preci­
pitation is such a technique, where the method depends on the 
relative ease with which gamma globulins and thus antibody-antigen 
complexes can be precipitated from aqueous solution by organic 
solvents. The much smaller LRH molecule can be expected to remain 
in solution at solvent concentrations precipitating gamma-globulins and 
their antigen-antibody complexes. This type of separation offers 
advantages of speed, reproducibility, economy and constancy of 
reagents. 
We have investigated the suitability of this type of phase 
separation for the LRH radioimmunoassay. Volumes of 100 μΐ each of 
radioiodine-labeled LRH, anti-LRH serum or normal rabbit serum and 
PBS are incubated for 6 hours at 4*C. Then 3 · 10 volumes (0.9 - 3.0 
ml) cold ethanol are added, the tubes are centrifuged at 5000 χ g for 
5 minutes, the supernatant is removed and the radioactivity of the 
precipitate is measured. The results can be seen in figure 4.4. There 
is an effective separation of the bound and free LRH fractions over 
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Figure 4.4: Ethanol precipitation separation of bound and 
free antigen. Labeled LRH was incubated in the presence 
and absence of anti-LRU serum under standard assay 
conditions. Ethanol was added, the incubation tubes were 
centrifuged and the supernatant decanted. The percentage 
radioactivity in the precipitate without added antiserum 
is denoted о—о and with anti-LRH serum present is 
represented by x—x. 
the whole range of ethanol additions tested. We conclude that this 
method also seems to give satisfactory results. Its performance in 
the LRH assay is described below in section 4.4. We have also 
investigated whether methanol can be used in place of ethanol. 
Virtually Identical results are obtained, but we have chosen the less 
toxic ethanol for further assays. 
4.4 Preparation of standard curves 
Many different media can be used in performing radioimmuno-
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assays. However, the assay medium must satify the following require­
ments: 
1) The pH and molarity must be close to optimal for the 
reaction to proceed without interference. In our studies we chose 
near-physiological molarity (0.14 M NaCl and 0.01 M phosphate) and 
the pH was kept at 7.0. 
2) The assay medium must contain protein in quantities suffi­
cient to prevent loss of reactants on container walls due to non­
specific adsorption. Egg albumin in a concentration of 0.1 % provides 
a cheap and effective means of carrier protection for most appli­
cations. 
3) In order to provide uniform serum concentrations in all experi­
ments, normal rabbit serum must be added as a carrier to all anti-
serum-containing solutions at a final concentration of e.g. 1:400. 
4) Interference by factors such as complement should be reduced 
by including 0.05 M EDTA in the incubation mixture. 
5) A bacteriostatic agent should be used. Merthiolate at a conc­
entration of 0.01 % provides adequate protection against bacterial 
growth without interfering with the RIA. 
Pure synthetic LRH (Hoechst, Frankfurt) has been used for the 
preparation of standard curves. Aliquots of 50 μΐ of a stock solution 
containing 12.8 ng/ml in the phosphate buffered saline (PBS) are kept 
at -20"C. Immediately before use aerial dilutions are prepared to 
contain 12.5. 25. 50. 100. 200. 400. 800. 1600. 3200. 6400 and 12800 
pg LRH/ml. This provides doubling concentrations (very convenient 
for plotting standard curves) over the useful range of the LRH radio­
immunoassay: 1.25 pg/tube to 1.28 ng/tube when dispensing 100 gl 
per tube. Standard curves are always prepared in triplicate. Samples 
were run in duplicate or triplicate, depending on availability. Tubes 
containing normal rabbit serum instead of anti-LRH serum as well as 
tubes lacking unlabeled hormone were always included to determine 
"non-specific binding" and "zero standard value". 
There are numerous ways for plotting standard curves obtained 
from radioimmunoassay data, e.g. the measured radioactivity may be 
expressed in cpm, % bound, bound/free ratio or free/bound ratio. The 
constant component (amount of antigen in the standard) may be 
plotted in an arithmetic or logarithmic manner. A number of loga­
rithmic and logit transformation combinations for both axes have also 
been employed. Since these methods fail to linearize all types of in­
hibition curves, there is no single preferable method. For each new 
radioimmunoassay the best way has to be found by trial and error. A 
straightforward and readily understood way, which ia commonly used, 
is to plot % bound on the vertical axis against log standard concen­
tration on the horizontal axis. Deviations from normal, such as 
damaged tracer or antiserum and other binding irregularities, are 
immediately detectable. It also permits easy comparison of the be-
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Figure 4.5: Effect of delayed addition of tracer on Lltll 
standard curves. Antiserum and samples were incubated 
over night under standard assay conditions with (о-o) or 
without (x-x) labeled LR Η present. After 16 hours at 
4*C tracer was added to the rest of the incubations. 
After a further 5-hour incubation bound and free antigen 
was separated by means of ethanol precipitation. 
haviour of individual antisera from assay to assay. If the % bound in 
the "zero standard" sample is low this suggests deterioration of 
tracer or antiserum. When this is combined with "non-specific binding" 
samples and a quality control preparation in every assay, the beha­
vior of the radioimmunoassay sufficiently characterized for daily use. 
The method of plotting % bound against log standard has been 
used throughout this study. In practice we obtained the data from 
the gamma-counter in the form of triplicate measurements, which 
were corrected for non-specific binding and averaged. The results 
were then used for freehand drawing of the standard curves on semi-
logarithmic paper, allowing for a best f it with the use of the 
individual cpm of the triplicates when in doubt. However, for 
comparisons of different standard curves, as frequently shown in this 
study, we re-calculate the results. After the usual quality control 
procedure, we converted to % bound in terms of the cpm of the 
"zero- standard". This permits a comparison between different antisera 
or between assay schedules, but it can only be done on pre-screened 
data as this method of plotting may conceal assay problems. 
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Figure 4.6: Comparison between solvent precipitation and 
double antibody phase-separation in the LRH radioimmuno­
assay. Antiserum and tracer were incubated under standard 
assay conditions over night after which the bound and 
'free fractions were separated by the addition of either 
ethanol (χ—χ) or ARGG (о—о). 
The order in which reagents are added in a radioimmunoassay is 
usually: sample - tracer - antiserum. This means that both labeled and 
unlabeled antigen have equal access to the binding sites. However, 
preincubation of unlabeled antigen with antiserum, i.e. delayed 
addition of tracer, increases the sensitivity of the radioimmunoassay 
(Samols & Bilkus, 1963). This effect is not always found, and thus its 
applicability to a given system must be established by trial and error. 
Figure 4.5 shows this effect in the LRH-radioimmunoassay. Standards 
were incubated with antiserum at 5*C for 16 - 20 hours, followed by 
the addition of tracer and a further incubation for 4 - 6 hours at 
5*C. Separation of bound and free antigen was carried out by means 
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Figure 4.7: Influence of reagent concentrations on the 
standard curves in LRH-radioimmunoassay. Antiserum and 
tracer incubated under standard assay conditions but with 
varying reagent concentrations (see text and table IV.3). 
Phase separation was done with the solvent precipitation 
technique, χ—χ high concentrations, о—о lowest 
concentrations. 
of solvent precipitation. The radioactivity of the bound fraction was 
measured in a gammacounter. We can see that in this radioimmuno­
assay preincubation doos seem to lead to a more sensitive assay, as 
suggested by the steeper slope of the inhibition curve is steeper. 
Whether the difference is really significant and always present was 
not Investigated. However, this method of incubation offers a 
convenient incubation schedule (overnight and the morning of the 
following day) and was, therefore used for all subsequent radio­
immunoassays in this study. 
The method of phase separation may have an influence on the 
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sensitivity of the radioimmunoassay. Figure 4.6 shows standard curves 
with the same standard dilutions, the same antiserum solutions and 
the same 125-1 labeled LRH preparation, but using two different 
separation methods. The inhibition curves are very similar although 
the double-antibody method yields a slightly steeper slope and could 
be said to give a slightly higher assay sensitivity. 
As pointed out before the sensitivity of a radioimmunoassay can 
theoretically be improved by employing less concentrated tracer and 
antibody solutions. This was investigated by running standard curves 
with different dilutions of the same tracer and antiserum prepa­
rations. In order to maintain comparability between the results, 
reagent solutions were prepared so that the percentage bound antigen 
remained between approximately 45 % and 55 %. The dilutions and 
resulting % bound values are presented in table Г .З. 
Table IV.3 Effects of tracer and antibody concentrations 
on % bound to antibody 
cpm / tube antiserum dilution % bound 
10,000 1 : 900 47.4 
5.000 1 : 1050 52.7 
2,500 1 : 1200 56.0 
1,250 1 : 1350 56.7 
1,250 1 : 1500 51.3 
In figure 4.7 the standard curves obtained with the highest and 
lowest concentrations are shown. A slightly higher sensitivity, as 
indicated by the slope of the inhibition curve, is found with the 
lower reagent concentrations. However, this requires a 10-fold longer 
counting time. Considering the marginal improvement that could be 
achieved in this way, it was decided to employ conditions as before 
(10,000 cpm and a 1:900 dilution for this antiserum). 
Figure 4.8 shows composite standard curves for three different 
antisera, two of which were obtained from other investigators: 
ASI - our own production, bleeding 0 3 
AS2 - antiserum supplied by Dr. S.L. Jeffcoate, London, England 
AS3 - antiserum supplied by Dr. G.D. Niswender, Ft Collins, 
Colorado, USA 
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Figure 4.8: Comparison of three different anti-LRH sera. 
The points and vertical bars represent ptean and standard 
deviations for six assays using six different tracer 
preparations. The results are expressed as % bound in 
terms of the "zero-standard". 
The points and vertical bars represent averages and standard 
deviations for six assays using six different preparations of 125-1 
labeled LRU. The sensitivity of a radioimmunoassay is often defined 
in terms of the variability of the binding to antibody in the absence 
of standard or sample antigen. Furthermore a value of 2 standard 
deviations is often used as the limit of statistical significance. 
Combining the two criteria we can say that the value read from a 
standard curve that Is 2 standard deviations below the amount 
binding at zero standard provide an estimate of the sensitivity of the 
assay. For these three antisera we found a sensitivity of 5.7 pg/tube 
for ASI, 1.9 pg/tube for AS2 and 1.7 pg/tube for AS3, respectively. 
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Figure 4.9: Comparison of twenty LRU radioimmunoassays. 
The points and vertical bars represent means and standard 
deviation for the standard curve. The results are 
expressed as % bound in terms of the "zero-standard". 
The precision of a radioimmunoassay is evaluated either as the 
within-assay variance determined by multiple measurements of the 
seme sample in a given assay, or by the between-assay 'variance 
determined by multiple measurements in several assays. For the LRH-
radioimmunoassay we did this by analyzing the results of 20 assays 
using the same standard LRH preparation, the same antiserum 
(bleeding tt 6) and different 1-125 labeled LRH preparations over an 
extended period of time. The standards were made up by serial 
dilutions in the assay buffer, dispensed in assay tubes and kept 
frozen at -20*0 until used. The results from the standard curves were 
converted into % bound of the "zero-standard" (%B/Bo) and then re-
calculated as average and the coefficient of variation, I.e. the 
standard deviation in % of the average (figure 4.9). The within-assay 
variation for all the standard points was on average 4.7 % for the 20 
assays. When comparing the % B/Bo for the individual standard 
points between assays we see an average variation (cv) of 7.7 %. 
Both values are quite acceptable, indicating that our radioimmuno-
assay is reliable and reproducible. 
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4.5 Discussion 
The LRH radioimmunoassay presented in this thesis has its 
optimal incubation temperature at approximately 5*C. Preliminary ex-
periments showed that for the LRH radioimmunoassay the time re-
quired to reach equilibrium is relatively short compared to that for 
larger molecules such as luteinizing hormone. For the latter compound 
days are needed, whereas binding of LRH. to its antibody is complete 
after 6 hours of incubation. This means that incubation times of 4 -
6 hours are sufficient for our LRH radioimmunoassay. The reversi-
bility of the binding at hieher temperatures indicates decreased 
binding at higher temperatures is due to kinetics rather than to 
denaturation of the reactants. These observations have the following 
practical consequences for the design of the LRH radioimmunoassay: 
1) The incubation time in the LRH radioimmunoassay need not 
exceed 6 hours. 
2) Normal refrigerator temperatures provide optimum binding 
conditions. 
3) Temperature during the assay should never exceed 10"C 
Other investigators, such as Jonas et al. (1975) used longer in-
cubation times (24 hours), while some investigators employed only 2 
hours (Jeffcoate et al. 1972 and 1974a). It seems that incubation 
time is either not very critical or depends on the individual antisera. 
Of the two methods for phase-separation studied by us is the 
solvent precipitation technique clearly the better choice because of 
its simplicity and speed and its satisfactory performance. The more 
elaborate double antibody technique provides a slightly more sensitive 
radioimmunoassay, but the difference hardly justifies employing this 
more elaborate and expensive method. In addition, the solvent preci-
pitation method is easier to perform inasmuch as no precision pipet-
ting is required. Consequently, we consider the solvent precipitation 
method to be the method of choice and have used it in all subse-
quent experiments. The major disadvantage of precipitation tech-
niques, the relatively high non-specific binding, did not seem to play 
a role in our assay. These techniques usually yield blanks with values 
between 5 and 15 % (Chard, 1980), smaller molecules giving lower 
blanks. In our case 5 % was the normal value, which at a "zero 
standard" binding of 50 % can be considered as quite acceptable. 
Jeffcoate et al. (1972 and 1974a) have also used the method of 
solvent precipitation. Several other methods have been used for 
phase-separation in LRH-radioimmunoassays. Dextran-coated charcoal 
was used by Arimura et al. (1973) and others, while Nett et al. 
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(1973) and others employed double antibody separation. All these 
methods work satisfactorily, and thus the choice of method can 
apparently be made on the basis of personal preference, locally 
available equipment and other rather pragmatic reasons. 
Due to the nature of the LRH producing system and its method 
of delivering the releasing hormone to the site of action, i.e. 
secretion into the portal system, we can expect only minute amounts 
in the general circulation. A lower detection limit in the order of a 
few pg/ml seems to be a requirement (see also section 6.7). Actually 
we observe this level of sensitivity in the routine assay. When 
applying the rather stringent sensitivity definitions described in 
section 4.4 (figure 4.8), we see statistically significant results at the 
standard dose levels of 1.7 - 5.7 pg/tube. This sensitivity together 
with an efficient extraction method (see section 6.3) could be 
expected to yield physiologically meaningful results in biological 
fluids. The variability of the assay is at a level where we can hope 
to be able to make reliable measurements at these concentrations. 
4.6 Summary 
In this chapter we have established optimal conditions for the 
performance of the LRH-radioimmunoassay, viz. incubation time (4-6 
hours), incubation temperature (5*C), concentration of antiserum and 
radiolabeled LRH. Two different methods for the separation of bound 
and free antigen have been examined, the double antibody technique 
and solvent precipitation of the antibody. The latter technique has 
been chosen for routine use. The preparation of standard curves has 
been discussed in detail. The type of incubation schedule with the 
best performance was selected. Three different antisera were com-
pared and the variability of the assay method was established. In the 
next chapter we shall describe the determination of the immunological 
and biological specificity of the LRH radioimmunoassay. 
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CHAPTER 5 
Specificity of the radioimmunoassay 
5.1 Immunological specificity 
5.1.1 Introduction 
One of the main advantages of radioimmunoassays is their poten-
tially very high specificity. Whether this potential is achieved in a 
given assay depends to a large degree on the nature and quality of 
the antibodies used. Consequently, the most important single factor in 
establishing a successful radioimmunoassay is the production of a 
suitable antiserum. It is often stated that production of antisera with 
high avidity and specificity is an art rather than a science and that 
success is determined largely by chance. Be that as it may. it is of 
paramount importance to assess the specificity of the antisera pre-
parations in order to select the most suitable one. This assessment 
should also permit the determination of the limitations of the radio-
immunoassay in terms of possible interference by other substances. 
5.1.2 Definitions and principles 
An antigen is a substance that induces antibody formation 
(ANTIbody GENerator) when introduced parenteraly into an animal (or 
man for that matter). The term antigen is also used in radioimmuno-
assay terminology to mean the substance present In a body fluid that 
we wish to measure. This rather ambiguous terminology has developed 
over the years and is difficult to avoid. In order to. identify the 
substance used for antibody induction which is frequently another 
molecular entity than the "antigen", the term immunogen was coined. 
The Immunogen is the substance actually entering the antibody-
producing animal. In the case of a small molecule, such as LRH, that 
must be coupled to a large carrier to become immunogenic, the sub-
stance is referred to as a hapten. Injection of the hapten by itself is 
not inducing antibody formation, but it is capable of reacting with 
the antibodies induced by the injection of the antigen produced by 
its coupling to a carrier. 
The part of a molecule that is actually combining with the anti-
body is known as the antigenic determinant, which comprises in the 
case of a peptides a few amino acids. These amino acids have a 
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unique three-dimensional arrangement. A change of one amino acid 
e.g. by addition of a methyl group, or replacement by its stereo-
isomer, may impair its binding to the antibody (Berson & Yalow, 1961 
and 1966). The area of the hapten that is farthest away from the 
point where it is attached to its carrier, is often seen to be the 
antigenic determinant (Parker et al. 1976; Crumpton 1974). Con-
sequently, different conjugation methods may lead to quite consider-
able differences in specificity. 
The part of a molecule that is recognized by an antibody may 
also be influenced by the type of adjuvant or vehicle that is used 
when immunizing the animal. For example, an ACTH preparation in 
gelatin yielded antibodies directed against the C-terminal part of 
ACTH (Landon. Friedman & Greenwood, 1967), while a zinc complex 
of ACTH produced antibodies directed against the N-terminal end 
(Fleischer et al. 1967). 
The specificity of an antiserum will depend on the structure of 
the antibodies involved. Not all antibodies will have the same struc-
ture and the serum obtained from an immunized animal may show con-
siderable heterogeneity in its antibody population. Antibodies produced 
in response to a given antigen may, as a consequence, show different 
avidities to the antigen, i.e. the strength of the bond between the 
molecules varies. This explains in part so called cross-reactivity, this 
means that antibodies with a very low avidity may react with some 
other molecule. On the other hand, cross-reactivity may result from 
the inability of an antibody to distinguish between different molecules 
due to similarities in their structure. 
5.1.3 Analysis of cross-reactivity 
The immunological specificity of antisera can be assessed by 
running standard curves with a variety of related labeled compounds. 
The binding characteristics and. more specifically, the displacement 
from the antibody by the standard substance, can be used to cal-
culate cross-reactivity. A simpler and better method is to run, in the 
same radioimmunoassay, inhibition curves with as many structurally 
related materials as possible. Analogues with varying degrees sub-
stitution in their amino acid sequence should be employed to obtain a 
picture of the cross-reactivity. The percentage cross-reactivity is 
defined as the dose of standard antigen required to displace 50 % of 
the radiolabeled antigen from the antibody, divided by the dose of 
analogue required to cause the same 50 % displacement, multiplied by 
100 (Abraham. 1974). 
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Figure 5.1: Inhibition curves obtained with antiserum ASI 
and twelve LRU-analogues, fixed amounts of antiserum and 
tracer were incubated with varying amounts of the 
analogues under standard assay conditions. Phase separation 
was achieved by means of ethanol precipitation. 
Numbers refer to table V I .1 . 
In order to establish the immunological specificity of the LRH 
radioimmunoassay, antisera were incubated with the same series of 
LRH-analogues as described in the preceding paragraph. These ana-
logues included C-terminal as well as N-terminal fragments and deca-
peptides with one amino acid of the LRH molecule substituted, kindly 
supplied by Dr. J. Sandow of Hoechst, Frankfurt. The ability of the 
analogues to displace 125-1 labeled LRH from the antibody was 
estimated by incubating them with labeled LRH and antiserum as in a 
radioimmunoassay (described in detail below in section 5.2.2.1. Serial 
dilutions ranging from 1 pg to 1 V8 were prepared in the standard 
assay buffer (PBS with 1 % egg albumin) and were used as unknowns 
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in the radioimmunoassay. In order to give an impression of the type 
of inhibition curves that were obtained, the results for one of the 
tested antisera (ASI) are depicted in figure 5.1. It can be seen that 
the analogues are giving rise to a wide variety of displacement 
curves, indicating cross-reactions varying from very close (A3 and Ив) 
to almost non-existent (tt2, ttl9 and Й6), parallel and non-parallel. 
The results of the specificity studies with the three antisera 
compared in section 4.4 (in terms of sensitivity and inhibition curves 
with synthetic LRH) are summarized in Table V.l. 
Table V.l Crossreactivity of three antisera to LRH. 
Results were obtained by incubating fixed amounts of anti­
serum and tracer with varying amounts of the displayed 
LRH-analogues. 
nr. structure ASI AS2 AS3 
0 pGluHisTrpSerTyrGlyLeuArgProGlyNH2 
1 HisTrpSerTyrGlyLeuArgProGlyNHZ 
19 TrpSerTyrGlyLeuArgProGlyNH2 
18 SerTyrGlyLeuArgProGlyNHZ 
2 TyrGlyLeuArgProGlyNH2 
17 ArgProGlyNH2 
12 ZSerTyrGlyLeu 
13 pGluHieTrpSerTyrGly 
14 pGluHlsTrp 
15 pGluHis 
6 pGluHieTrpSerTyrGlyLeuArgProETHYL 
9 pGluHisTrpSerTyrGlyLeuArgProPICOL 
11 ZSerHisTrpSerTyrGlyLeuArgProGlyNHZ 
5 pGluHieTrpAlaTyrGlyLeuArgProGlyNH2 
3 pGluHieTrpSerTyrGlyLeuLeuProGlyNH2 
4 pGluHisTrpSerTyrGlyLeuOrnProGlyNH2 
10 pGluHlBTrpSerTyrGlyLeuhArProGlyNH2 
n.d,- not detectable, Ζ is a protective group used in peptide 
synthesis, ETHYL - ethyl amide, PICOL - picolyl amide. hAr 
homo arginine. 
Antiserum ASI, (our own antiserum) and antiserum AS3 (supplied 
by Dr. Niswender) are specific for both the C-terminal and the N-
terminal end of the decapeptide, whereas aniserum AS2 (supplied by 
Dr. Jeffcoate) seems to be specific for the C-terminal only. This can 
be concluded from the fact that removal of the N-terminal pyro-
glutamic acid (01) reduces cross-reaction of antisera ASI and AS3 to 
1 0 0 
3 . 7 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
0 . 0 3 
0 . 8 
1 4 . 0 
5 4 . 6 
5 8 . 5 
5 6 . 5 
1 0 0 
5 4 . 4 
7 4 . 7 
5 1 . 1 
4 8 . 6 
0 . 2 
n . d . 
n . d . 
n . d . 
n . d . 
0 . 0 2 
0 . 0 3 
5 5 . 7 
9 7 . 9 
0 . 1 1 
0 . 1 2 
0 . 1 2 
1 0 0 
3 . 8 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
n . d . 
0 . 7 
7 1 . 0 
6 9 . 0 
5 3 . 3 
5 0 . 7 
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less than 4%, whilst this reduces the cross-reaction of antiserum AS2 
only to 54%. Furthermore, it appears that after replacement of the 
C-terminal glycinamide with either ethyl- or picolyl-amide (06 and ЙЭ) 
none of the three antisera are cross-reacting. Antiserum AS2 
crossreacts with the C-terminal hexapeptide Tyr-Gly-Leu-Arg-Pro-Gly-
amide (02) to almost 50 %, indicating that this antiserum ignores a 
large part of the N-terminus. On the other hand, antiserum AS2 
shows a high degree of dependency on the arginine in position 8. 
When this amino acid is replaced by leucine (ИЗ), ornithine (H4) or 
homo-arginine (ttlO) the cross-reaction is substantially reduced for 
antiserum AS2 but to a much lower degree with the other two anti-
sera. For antiserum AS] we see a higher dependency on the alanine 
residue in position 4 (US). 
We have also investigated whether the high specificity obtained 
in one of the rabbits changed during the course of immunization. The 
first six bleedings from this rabbit were checked as described above 
with one difference. Only des-pGlu-LRH (Hl). LRH, and des-Gly-amide-
ethyl-amide-LRH (416) were used. These two peptides lack either the 
C-terminal or the N-terminal end of the LRH molecule, and thus their 
degree of cross-reactivity will provide the essential information · the 
C- terminal and N-terminal specificity of the antisera. The results, 
shown in Table V.2, indicate that the antisera from this rabbit are 
consistently of the same high specificity. 
Table V.2 Specificity of LRH antisera obtained from 
sequential bleedings of the same rabbit. 
Bleeding '4 croee-reaction 
number C-termlnal N-terminal 
lacking lacking 
1 n.d. 4.7 
2 n.d. 3.9 
3 n.d. 4.4 
4 n.d. 3.9 
Ь n.d. 1.5 
6 n.d. 2.9 
n.d. - not detectable 
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5.2 Biological specificity 
5.2.1 Introduction 
It is known that many hormones may be present in the organism 
in several forms, in addition to the actual biologically active form, 
e.g. as precursors or metabolic breakdown products. Any of these 
forms may contain the immunologically recognized structure(s) for a 
certain antibody. Precursors have been identified for LRU (Millar et 
al. 1977; Galton, Pattou & Kordon, 1981; Seeburg & Adelman, 1984) 
and metabolic breakdown products have also been reported (Jeffcoate 
& Holland. 1975; Marks & Stern, 1974) 
The accuracy of a radioimmunoassay depends on the identity or 
association between the structural components determining the bio­
logical activity and the components responsible for the immunological 
binding. A comparison of measurements based on biological assay prin­
ciples with those based on radioimmunoassay is therefore an essen­
tial part of the validation of a radioimmunoassay. Even though our 
LRH radioimmunoassay has been shown in section 5.1 to possess ex­
cellent immunological specificity we still deemed it necessary to 
compare with an established bioassay, the Ramirez-McCann in vivo 
assay for LH-releasing activity. 
5.2.2 Radioimmunoassay of the hormone 
Based on the results of the experiments described in chapter 4 
we set up a standard method for the radioimmunoassay of LRH. 
Sample size for unknowns and standards was set at 100 μΐ. Standards 
and unknowns in the cases where extractions were done, were dis­
solved in PBS-0.1% egg albumin (see section 3.2). The samples, in 10 
χ 75 mm tubes, were put on ice. Appropriately diluted antiserum (200 
pi) was added, and the content of the tubes was mixed on a Whirl-
mix. The antiserum hád been diluted in PBS-0.1% egg albumin con-
taining normal rabbit serum to give a final dilution of 1:400 with 
EDTA added to yield a final assay concentration of 0.05 M. The mix-
ture was incubated at 4*C over-night, after which 100 μΐ of 125-1 
labeled LRH was added in PBS- 0.1% egg albumin. The tubes were 
kept on ice at all times and never allowed to reach room tempera­
ture. After mixing the tubes were incubated for a further 5 - 6 hours 
at 4*C. The bound and free fractions were separated by the addition 
of 5 volumes cold ethanol followed by centrifugation. After decanting 
the supernatant, the radioactivity of the precipitate was measured. 
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5.2.3 Bioassay of the hormone 
The first attempts to assay LH-releasing activity were made by 
measuring the ovarian depletion of ascorbic acid in immature rats, 
pretreated with gonadotrophins. Since this test animal is highly 
sensitive to LH. the only way to distinguish between LH and LR H in 
this system was to treat the samples by heat, as LH is heat labile 
and LRH is not. 
A much better method was later developed by Ramirez & McCann 
(1963). They took advantage of the fact that ovariectomy will lead to 
removal of ovarian steroid feed-back. This results in an open-loop 
system which is highly sensitive to LRH stimulation. However, this 
treatment has the disadvantage that the pituitary is already stimu-
lated to a very high degree by endogenous LRH. This leads to very 
high LH levels in the blood, making it difficult to detect any 
increases. Furthermore, the high stimulation level may result in a 
decreased capacity to respond to any further stimulation. In experi-
ments designed to block LH releasing activity Ramirez and McCann 
pretreated the ovariectomized rats with large doses of oestrogen and 
progesterone. To their surprise they found that the rats had an in-
creased sensitivity to LRH rather than a block. Apparently this 
treatment lowers LH blood levels, while at the same time main-
taining the high sensitivity to LRH stimulation presumably due to the 
highly elevated pituitary LH stores. This method became the standard 
in vivo bioassay for LRH activity. 
In the original LRH bioassay, another bioassay, the ovarian 
ascorbic acid depletion method was used to determine changes in 
plasma LH levels after injection of the test substances. The advent 
of radioimmunoassays for rat LH led to improvements in the sensi-
tivity of the bioassay and to its simplification. In these experiments 
we have employed a radioimmunoassay for plasma LH developed by 
Niswender et al. (1968). It uses anti-ovine LH serum and radiolabeled 
ovine LH and a rat standard preparation. The specificity of this 
assay was established by measuring LH content of several pituitary 
preparations with widely varying LH/FSH and LH/TSH ratios. The 
observed behaviour of serum LH levels was consistent with known 
physiological processes. 
The LH antiserum used in these studies was GDNttlS. supplied by 
Dr. Niswender. Ovine LH for radioiodination by the method of Green-
wood et al. (1963) and the standard preparation (rat LH-RP1) were 
supplied by the National Institute of Arthritis and Metabolic Dis-
eases, NIAMD, Bethesda, MD, USA. The assay was carried out by 
placing samples or standards in a total volume of 0.5 ml phosphate 
buffered saline (PBS, see section 3.2) containing 1 % egg albumin. 
This was followed by addition of 0.2 ml appropriately diluted anti-
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ovine LH serum. The antiserum was diluted 1:20,000 in a buffer con­
sisting of normal rabbit serum diluted 1 : 400 in PBS-1% albumin. 
The content of the tubes was then mixed and incubated at 4*C for 
24 hours, whereupon 0.1 ml 125-1 labeled ovine LH was added. The 
radiolabeled LH had previously been purified on a Sephadex G-50 
column and was then diluted with PBS-0.1 % egg albumin to contain 
approximately 10,000 cpm/incubation tube. After a further 24 hours 
at 4*C 0.2 ml anti-rabbit-gamma-globulin (see section 4.3) was added 
to each tube to precipitate the antigen-antibody complex. After 72 
hours at 4*C bound and free antigen could be separated by adding 3 
ml cold PBS and centrifuging at 1000 χ g for 30 minutes. The 
supernatant was decanted and the radioactivity of the precipitate 
was measured in a gamma counter. 
The performance of the LH-radioimmunoassay was checked by 
evaluating between-assay-variation as well as within-assay-variation. 
This was done by including a quality control preparation made from 
pooled rat serum from normal rats eacrified for other experiments. 
The preparation was measured 3 to 5 times in every radioimmuno­
assay and the coefficient of variation (cv) calculated from the 
results. From 12 radioimmunoassays we obtained an average within-
assay variation of 3.4% with a range of 0.82 to 11.61%. The 
between-assoy variation, calculated from the same results, amounted 
to 3.4 % (coefficient of variation). 
5.2.4 Comparison of the immunoassay and the bioassay 
For the standard Ramirez-McCann bioassay for LH-releasing 
activity female Sprague-Dawley rats, weighing 120 - 150 grams, were 
bilaterally ovariectomized between 1 and 3 months prior to their use 
in these studies. The rats were prepared for the bioassay by sub­
cutaneous injection of 50\ig oestradiol benzoate (Progynon В oleosum 
dissolved in sesame oil) and 25 mg progesterone (Progesterone "Vitis" 
dissolved in sesame oil). After three days the rats were placed under 
ether anasthesia and the jugular vein was exposed. A 1-ml blood 
sample was taken from each rat, followed by the injection of a LRH 
solution into the jugular vein through the sampling syringe. The blood 
was immediately centrifuged and the plasma was snapfrozen. It was 
kept at -30*C until radioimmunoassay of the LH content. Exactly 10 
minutes after the injection of LRH a second blood sample was taken 
in the same manner. The LRH doses tested in this experiment varied 
between 1 ng and 10 ng, which according to earlier experiments 
covers the range of a linear semilogarithmic plot of the bioassay. 
The releasing hormone preparations were prepared by serial dilution 
in the normal phosphate buffered saline containing 1 % egg albumin 
to minimize losses due to adsorption on tube walls and other 
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Figure 5.2: Comparison between our radioimmunoassay and a 
standard bioassay (Ramirez-McCann assay) for LRU. Results 
of the bioassay are expressed as the increase in plasma LH 
(rat LH RPttl) in response to the LRU administration. 
materials. Five rats were used for each dose of LRH and the 
average results calculated from triplicate determinations in the LH 
radio- immunoassay. The same preparations were also subjected to 
LRH radioimmunoassay as described in section 5.2.2. 
The results of the two assays are displayed in figure 5.3. 
Bioassay results are plotted on the vertical axis as the change in 
radioimmunoassayable plasma LH caused by the releasing hormone 
injection. On the horizontal axis the results of the direct LRH 
radioimmunoassay are shown in logarithmic fashion. The linear 
relationship between the two parameters indicates that there is an 
excellent agreement between the two assay methods under these 
conditions. 
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5.3 Discussion 
Antisera ASI and AS3 were found to be specific for both ends 
of the LRH molecule. The studies of Nett et al (1973) and Jonas et 
al (1975) using antiserum AS3 and a later bleeding from the same 
animal, in analogy to our studies, showed limited or non-detectable 
cross-reaction with LRH analogues having either the C-terminal or the 
N-terminal amino acid removed or substituted. Antiserum AS2 is 
specific for the C-terminal end only, as has previously been reported 
by Jeffcoate et al. (1973). Their studies showed complete cross-
reaction from the 3 - 10 octapeptide and an almost complete lack of 
cross-reactivity from the 1 - 9 nonapeptide. The specificity difference 
between AS2 and ASI is not easy to explain, since the immunization 
procedures were not greatly different and the same coupling 
technique had been used for producing the LRH-BSA conjugate. The 
mechanism of this conjugation method is not clear, as the deca-
peptide LRH has both terminals blocked for peptide bond formation. 
The N-terminus has an internal ring structure and the C-terminus has 
an amide group attached. As mentioned earlier, the conjugation site 
is important for the specificity of the produced antiserum. It is 
conceivable that the conjugation method is not very specific and may 
thus yield different results in different laboratories, giving rise to 
conjugation at different sites of the LRH molecule and leading to 
different spécificités. 
The fact that antisera ASI and AS3 are specific for both ends 
of the LRH molecule should make them immunologically highly speci-
fic, since any LRH metabolite is likely to have at least one terminal 
amino acid missing. In this respect, these antisera should be superior 
to antiserum AS2, which is specific for the C-terminal end only. 
An immunogen may contain several antigenic determinants, some 
strong, some weak. The initial response in the course of immuni-
zations will likely be directed towards the strong determinants. 
However, as the immunization proceeds over a period of perhaps many 
months a diversity of antibodies may develop, as also the weaker 
antigenic determinants may become involved. This has been observed 
in the production of antibodies to collagen by Timple et al. (1972). 
During the early phases of antibody production the antibodies were 
predominantly directed towards the C-terminal ends of the polypeptide 
chains of collagen. In a later phase antibodies against the N-terminals 
appeared and the production of antibodies for the C-terminals 
diminished. Thus, in the course of an immunization over an extended 
period of time it is desirable to investigate whether the initial speci-
ficity is maintained. In our case, the one rabbit producing suitable 
antisera generated for several months an antiserum which had an 
invariably high specificity for both ends of the LRH molecule for 
several months. Hence, all the bleedings could be used and a large 
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amount of antiserum could be stockpiled for later use. 
Since the antigenic determinant need not correspond to the 
amino acid sequence responsible for the biological activity of the 
compound, it is obvious that in this way serious discrepancies can 
arise between the immunological and biological activities. A radio-
immunoassay may thus, in addition to the desired compound, measure 
biologically inactive fragments, denatured antigen retaining the anti-
genic determinant, and other compounds containing elements 
structurally similar to the antigenic determinant. 
The bioassay used for comparison with the radioimmunoassay in 
this study, the Ramirez-McCann assay, is the most sensitive in vivo 
bioassay for LH releasing activity (McCann, 1983b). According to the 
originators of the method it can be used to detect approximately 
1/10 of a rat stalk median eminence equivalent (Ramirez et al. 1975). 
This corresponds to about 0.3 - 1 ng LRH depending on the size of 
the rat (see chapter 7). We found the the same order of magnitude 
for the detection limit as reported by Ramirez et al. (1975), viz. 
basal LH levels of 50 - 150 ng/ml (in terms of the NIAMD RPftl) and 
an increase by 200 - 300 ng/ml after injection of 1.25 ng LRH. The 
bioassay could possibly be made somewhat more sensitive, but is 
unlikely to yield a sensitivity below 0.1 ng. This compares rather un-
favourably with the approximately 1 - 5 pg lower detection limit of 
the radioimmunoassay. The excellent agreement between the bio-
assay and the radioimmunoassay for LRH, also noted by e.g. Ramirez 
et al. (1975), for a different LRH radioimmunoassay confirms that the 
immunoassay can indeed be very specific. Under the conditions used 
by us, it should yield a true measurement of releasing hormone 
activity provided certain precautions are taken to eliminate plasma 
Interference. 
5.4 Summary 
In this chapter we have investigated the specificity of the LRH-
radioimmunoassay. The immunological specificity was established by 
means of measurement of the ability of LRH-analogues to displace 
radiolabeled LRH from binding to the antibodies. Of the three anti-
sera checked, two were found to be highly specific in that they re-
quired both ends of the LRH molecule for binding, the third was 
found to be specific for the C-terminal only. It could also be estab-
lished that the high specificity was maintained during a prolonged 
immunization period. The biological specificity of the radioimmuno-
assay was checked after establishing a bioassay for LRH, which in 
turn required the setting up of a radioimmunoassay for rat LH. We 
found excellent agreement between the two assay methods. Further 
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evidence validating the LRH radioimmunoassay is provided by the 
parallel inhibition curves for hypothalamic extracts and synthetic LRH 
in chapter 7. In chapter 6, we shall describe the radioimmunological 
measurement of LRH in plasma. 
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CHAPTER 6 
Measurement of the hormone in plasma 
6.1 Introduction 
The assay of LRH in plasma encounters various problems. First, 
LRH like other hypothalamic releasing hormones is essentially a local 
hormone, which is primarily secreted into the hypothalamo-pituitary 
portal circulation. This implies that we can expect only minute con-
centrations of hypothalamic LRH to be present in the general circu-
lation. As the sample size in a radioimmunoassay is limited, an 
extraction procedure is needed to increase assay sensitivity suffi-
ciently to permit determination of LRH in plasma samples. A second 
potential problem of a more general nature is the danger of enzym-
atic degradation of LRH in biological fluids. A third potential problem 
is that binding of the releasing hormone to macromolecular compo-
nents of plasma or serum may occur and affect the assay results. 
finally, LRH may be secreted, as is LH in an episodic manner and 
there may be a relatively rapid plasma clearance of LRH. 
The first three of these potential or real problems in the assay 
of LRH in plasma could conceivably be overcome by the use of a 
suitable extraction procedure. Such a method must fulfill several 
requirements (Chard et al. 1971b and 1973). The hormone should, of 
course, be present in a higher concentration after the extraction. 
The extraction procedure must be rapid and simple, not only for the 
sake of efficiency, but also to prevent degradation of LRH by proteo-
lytic enzymes. Non-specific inhibitors and proteolytic enzymes must be 
eliminated. The recovery must be reasonably high and reproducible. 
The chemical identity of the hormone must be preserved during the 
extraction, so that its immunological activity will not be affected. 
6.2 Direct measurements in plasma 
Initial attempts to measure LRH in plasma often showed no 
detectable LRH. In order to investigate whether plasma degradation 
of LRH plays a role in this phenomenon, we prepared a pool of aged 
plasma by combining a number of normal samples which had been 
received for routine gonadotrophin measurements. The plasma pool 
was left at 4*C for 30 days in order to allow for termination of all 
potential reactions. LRH was added at four different levels (160. 320, 
640 and 1280 pg/ml) and the fortified plasma samples were incubated 
at three different temperatures (4, 20 and 37*C). Samples were 
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removed after 4 hours and after 24 hours and they were rapidly 
frozen. The samples were then thawed and simultaneously analyzed 
by means of radioimmunoassay with two different antisera, ASI (our 
own antiserum, bleeding КЗ) and AS2 (Dr Jeffcoate's antiserum). 
Sampling was done in quintuplicate. The results, summarized in Table 
VI.1, represent averages for four dose-levels of LRH added. 
TABLE VI.1 Stability of exogenous LRH in plasma. 
X recovery with ASI У. recovery with AS2 
temperature 4 hours 24 hours 4 hours 24 hours 
b'C 90 57 106 68 
20°C 68 n.d. 72 16 
37,C 47 n.d. 61 12 
n.d.- not detectable 
It is obvious that the plasma samples contain proteolytic activity 
and thus that a countermeasure should be employed. It can also be 
seen that the antiserum with the less specific antiserum AS2 (which 
is specific for the C-terminal of the LRH molecule only) gives higher 
values, probably reflecting the presence of metabolites, i.e. proteo­
lytic fragments. 
Another problem associated with the radioimmunological measure­
ment of LRH is also seen in Table VI. 1, viz. the 106 % recovery 
after 4 hours at 5*C as measured by antiserum AS2. We often 
encountered such effects during the preliminary attempts to measure 
LRH in plasma, frequently with "recoveries" higher than the above 
106% Such non-specific interference by plasma with the binding of 
LRH to antibody has also been reported by others (Arimura et al. 
1973). 
An obvious way to circumvent this problem would be to prepare 
all standard curves in LRH-free plasma, while at the same time 
taking care to prevent enzymatic degradation. This was achieved by 
using aged plasma, obtained as above, and preparing the standard as 
rapidly as possible and keeping all reagents at or below 4*C at all 
times. The feasibility of this approach was tested by preparing ten 
standard curves with serial dilutions of synthetic LRH in ten 
different (aged) plasma pools at ten different occasions. These 
preparations were then subjected to a normal LRH-radioimmunoassay 
as described in section 5.2.2. The results, shown in figure 6.1, are 
represented as average % bound (%B/Bo) with standard deviation for 
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Figure 6.3: Preparation of 
standard curves in plasma 
with prior extraction. 
Averages with SD 
from 10 assays. 
Figure 6.1: Preparation of 
standard curves in plasma 
without prior extraction. 
Averages with SD 
from 10 assays. 
each dose of LRH. The very high variation between the individual 
standard curves shows that direct measurement of LRH in plasma can 
lead to completely misleading results. This is presumably due to that 
plasma from different individuals may contain factors interfering to 
different degrees and in different manners, i.e. plasma compensation 
alone is not sufficient. A falsely negative as well as a falsely 
positive value is equally possible. An overestimate would arise when 
the plasma interference caused a decrease in binding of labeled LRH 
to antibody. Similarly, a reduction of apparent LRH levels would 
result when the plasma caused an increase in binding. Both these 
effects were seen in the above individual plasma standard curves. 
6.3 Extraction procedure for LRH plasma samples 
In view of the above observations we have included an 
extraction procedure preceding the measurement of LRH in plasma 
samples. The procedure consists of adding 10 volumes of cold ethanol 
to the sample, mixing for 10 seconds on a Whirlmix, centrifuging off 
the precipitate and removing the supernatant to another test tube. 
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The sediment was washed to remove any remaining LRH by adding a 
further 5 volumes ethanol followed by mixing, centrifugation and 
decanting of the supernatant. The two supernatants were combined 
and evaporated to dryness under a stream of dry nitrogen in a water 
bath at 50*C. The dry residue was dissolved in assay buffer (PBS 
with 1 % egg albumin) and subjected to a standard LRH radioimmuno-
assay (section 5.2.2). 
The extraction method was checked for performance and 
recovery by preparing a normal series of standards in assay buffer, 
splitting each sample in two parts and subjecting one of them to the 
extraction procedure before assay, while using the other part without 
extraction. The results, shown in figure 6.2, demonstrate an almost 
complete overlap of the two standard curves, indicating a virtually 
complete recovery. It also seems that using this procedure there is a 
neglible loss of LRH due to proteolytic activity. Furthermore, the 
extraction method allows for a plasma sample of up to 1 ml, as the 
standard curves are drawn as pg LRH/determination we acchieve a 
sensitivity of a few pg LRH/ml plasma. This means an approx. 
ten-fold increase above the straight 'sampling method. 
6.4 Measurement of the hormone in plasma extracts 
We investigated whether the above extraction procedure could 
eliminate the spurious results obtained with standard curves prepared 
in plasma as shown in figure 6.1. Experiments analogous to those in 
section 6.2 were carried out, but this time the samples were first 
extracted. Again, ten aged plasma pools were prepared at ten 
different occasions, LRH was added and serial dilutions with the 
appropriate LRH concentrations were prepared. Ethanol was added 
immediately and the extraction procedure carried out as described 
above in section 6.3. The results, shown in figure 6.3, are again 
presented as averages with standard deviations. The resulting varia-
tions that are observed are now well within the normal range for a 
proper LRH-radioimmunoassay, indicating that plasma non-specific 
interference can largely be eliminated by this extraction procedure. 
6.5 Measurement of the hormone in rat plasma 
At a signal from higher brain centres involved in circadian 
rhythm control the hypothalamo-pituitary system responds with a LH 
surge, resulting in ovulation. Thus, the highest plasma LH levels in 
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Figure 6.2: Comparison of standard curves for extracted 
and non-extracted standard mixtures 
the rat are found during the pro-oestrous phase of the reproductive 
cycle. It follows that we have a large probability of finding the 
highest plasma LRH levels at or around the time of ovulation. 
However,' there are quite large variations between individual rats in 
terms of time of ovulation, length of oestrous cycle and maximum LH 
levels. So we decided that relying on the reproductive cycle might 
not be the best experimental design and that more standardized 
conditions would be preferable. 
It is well established that the ovulatory surge of LH in the rat 
is induced by gonadal steroids acting on the preoptic/hypo- thalamic 
regions of the brain (Everett, 1964; Davidson, 1969; McCann, 1974). 
Steroids can act at both the pituitary and hypo- thalamic levels to 
inhibit gonadotrophin release (Bogdanove, 1964; Davidson, 1969; 
McCann, 1974), but also to sensitize the pituitary gland to releasing 
hormone action directly (Kalra et al. 1973; Libertun et al. 1974; 
Debeljuk et al. 1974). The most interesting effect of exogenous 
steroids in this context is a massive gonadotrophin release some 6 
hours after injection of oestrogen-primed, ovariectomizcd female rats 
with progesterone (Caligaris et al. 1968 and 1971; Kalra & McCann, 
1973). This artificial LH-surge seemed to provide conditions with a 
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reasonably high probability of finding elevated LRJI levels in the 
general circulation. 
Twelve mature female rats, which had been ovariectomized not 
less than six months earlier, were injected subcutaneously with 5 ug 
oestradiol benzoate (Progynon В oleosum) in 0.5 ml sesame oil. After 
two days six of these rats were injected with 1.5 mg progesterone 
(Progesterone Vitis) in 0.5 ml sesame oil and the other six rats with 
sesame oil only. A blood sample was collected under ether anesthesia 
from the jugular vein of each animal at the time of the oestradiol 
injection and of the progesterone injection. Further samples were 
collected in the same manner 1 hour and 6 hours after the pro­
gesterone treatment. Plasma was prepared by centrifugation of the 
blood samples in a refrigerated centrifuge and was frozen immedia­
tely, Samples were kept at -30"C until performance of the LRH-
radioimmunoassay with prior extraction as described in section 6.3. 
The results are presented in Table VI.2, expressed as pg LRH / ml 
plasma. 
Table VI.2 Plasma immunoreactive LRH levels in rats before 
and after progesterone injection in oestradiol-primed 
castrates. 
group day 0 day 2, Oh day 2, Ih day 2, 6h 
control 32+/-1 17+/-2 25+/-2 
30+/-6 
treated 20+/-6 28+/-6 33+/-β 
Oestradiol priming took place on day 0, progesterone 
injection on day 2, Oh. Averages with SEM are given 
The results on day 0 were pooled as all rats had been treated in 
an identical manner up to this point. Although the levels of immuno­
logical LRH are above the detection limit of the assay, no statistical 
differences are observed either in time within the groups or between 
the treatment groups. We must therefore conclude that no signifi­
cant increases in immunoassayable plasma LRH in response to the 
steroid treatment have been detected. This could possibly be due to 
the sampling technique, the LRH output responsible for the LH 
release may have been of short duration only. 
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6.6 Continuous recording of the plasma hormone level in man 
When several blood samples are collected at short time intervals 
and estimated for hormone content, one will often find that the 
hormone levels fluctuate from sample to sample. This phenomenon was 
first recorded in the secretion of ACTH by Berson & Yalow (1968). 
Since then similar evidence has accumulated for a number of other 
hormones such as LH (Dierschke et al. 1970: Yen et al. 1972). FSH 
(Naftolin et al. 1972), growth hormone (Takahashi et al. 1968). TSH 
(Vanhaelst et al. 1972). Detailed examination of plasma LH concen-
trations shows sharp oscillations. The periodicity varies, but it is of 
the order of one to several hours. It seems that there is no mainten-
ance of a steady "basal" gonadotrophin level, but rather that there 
are abrupt peaks of episodic pituitary discharge separated by periods 
without secretion. The magnitude of the pulsatile LH release varies 
with the endocrine milieu. The highest release is found under condi-
tions of low steroid feed-back, such as after castration (Yamaji et al. 
1972) or menopause (Yen & Tsai, 1972). The frequency of the LH 
secretory bursts is also variable. Yen et al. (1972a) could show 
differences in frequency over the different stages of the human 
menstrual cycle. 
Consequently, when samples are being collected for hormone 
determination, intermittent sampling techniques can conceivably give 
misleading or even false information about secretory patterns. This is 
particularly true where the sampling interval is greater than the 
half-life of the hormone being investigated. An obvious solution to 
this problem is to employ continuous sampling, which will enable the 
investigator to obtain the mean hormone level for the collection 
period. The collection time required for a given hormone will depend 
on the half-life of the hormone. LRH has a relatively fast disappear-
ance of the order of 3 - 4 minutes half-life (Keye et al 1973; 
Arimura et al. 1974). Hence, in this case a sampling time of the 
order of a few minutes is required. 
This led us to carry out a series of measurements of immuno-
assayable plasma LRH in patients and volunteers, employing a system 
for continuous sampling. A jugular vein catheter was inserted via the 
cubital vein and connected to a peristaltic pump. Blood was 
continuously withdrawn at a rate to yield approx. 5 ml blood per 5-
or 10-minute collection period. The blood samples were collected in 
heparinized tubes kept in an ice-bath. After sampling was completed, 
each individual tube was briefly mixed on a Whirlmix and centrifuged 
in a refrigerated centrifuge to obtain the plasma. Plasma aliquote 
were frozen for LH determinations as described in chapter 8 (Dahlen 
et al. 1974). For the LRH determinations 1 ml aliquote were 
immediately extracted and assayed as described in section 6.3. 
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Figure 6.4 Continuous recording of plasma immunoreactive 
LH and LRH levels in male volunteer (IIGD). 
Results from an experiment with a male volunteer are shown in 
figure 6.4. Immunoassayable LRH levels vary in a pulsatile manner 
between 10 pg/ml and 30 pg/ml. We see several typical LH-episodes 
(spiking) with LRH levels showing a parallel assayable plasma LRH 
pattern in three LH-episodes during the six hour registration time. 
Figure 6.5 shows the results for six female patients, who were being 
seen in the endocrinological out-patient section in ' the course of 
fertility studies. All subjects show more or less typical LH-spikes, and 
in some cases the immunoreactive LRH peaks appear to correlate 
with a LH-episode. but on the whole there is no over-all correlation 
between the two hormones. 
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Figure 6.5 Continuous recording of plasma immunoreactive 
LH and LRH levels in 6 female patients. 
6.7 Discussion 
In studies of the stability of LRH in human plasma Saito et al. 
(1975) obtained almost identical results as in our study: a decrease 
during the first two hours at 20"C and a recovery of 14 % after 24 
hours at this temperature. At 0*C the immunological activity was 
preserved for a few hours and was then gradually lost. In contrast to 
these findings. Jeffcoate et al. (1974) reported that enzymatic degrad­
ation in ovine plasma appeared to be a problem associated with the 
radioimmunoassay of thyrotrophin releasing hormone (TRH) but not 
with that of LRH. Nett & Adams (1977) studied the immunoreactivity 
of LRH in serum from a number of species. Pooled sera showed a 
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disappearance of immunologically active exogenous LRH in a time 
and temperature-dependent manner. The rate of disappearance varied 
from species to species with the half life ranging from 15 minutes in 
equine serum to 240 minutes in ovine serum The kinetics of the dis-
appearance process suggests that it is enzymatic in nature This is 
further supported by the fact that addition to the sample of enzyme 
inhibitors such as Trasylol and Benzamidine results in higher levels of 
LRH (Aksel & Glass. 1979) 
The non-specific inhibition of the binding of radiolabeled LRH to 
antibody has also been noted by other investigators Anmura et al 
(1973) could show that the effect is dose related They also reported 
that upon re-assaying a sample with apparently high LRH levels, while 
compensating for the serum effect by adding serum to all tubes, the 
sample then showed little or no LRH present This type of effect 
could explain the extremely high plasma levels (up to several ng/ml) 
reported by some investigators (e g Kerdclhue et al 1973) who 
neither compensated for the plasma effects nor extracted the plasma 
samples 
Anmura et al (1974) showed that the non-specific inhibitory 
activity of serum or plasma on the binding in the LRH-radio immuno-
assay cannot be extracted in ethanol or aceton-water mixtures but 
that exogenous LRH can be recovered quantitatively in the extract 
They also confirm our findings that the non specific interfering 
material fluctuates from individual to individual and from time to time 
in the same individual (Anmura & Schally 1976) Further evidence for 
the necessity of employing an alcohol extraction prior to radio-
immunological measurement of plasma LRH was presented by Jonas et 
al (1975) These authors showed that overnight storage at 37"C of 
ovine plasma containing high levels of immunoreactive LRH material 
and/or added synthetic LRH destroyed all exogenous LRH, while the 
endogenous activity remained largely intact. This means that the 
endogenous LRH like activity could not be identical to the 
(exogenous) decapeptide as the latter is broken down by enzymes 
present in plasma and the former not. The endogenous LRH could be 
present in a form protected for enzymatic action but this seems 
rather unlikely. More evidence for the dissimilarity of the two 
immuno-activities was given by the fact that methanol extraction of 
the samples removed the exogenous LRH but not the endogenous 
immunoreactive material 
Concentrations of LRH in the peripheral circulation are likely to 
be very low and the background values in the assay due to non-
specific plasma effects may very well hide any LRH that is present 
Elimination of such effects must therefore be considered very 
important. A very high specificity is also extremely important in 
order to obtain meaningful results. Considering our results, presented 
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in this and the preceding chapter 5. both these requirements seem to 
have been met in our LRU radioimmunoassay. 
Failure to find elevated plasma LR H after injecting oestrogen-
primed ovariectomized rats with progesterone may be due to pulsatile 
secretion of endogenous LRH similar to the secretion of LH, resulting 
in maintenence of basal LH levels. A sample may thus reflect only 
one moment in a fluctuating pattern, so that physiologically meaning-
ful measurements cannot be done with this way of sampling. In this 
context it should be noted that the half-life of LRH in general circu-
lation is much shorter then the time between peak levels of LH and 
FSH after stimulation by LRH (see chapter 8). This indicates that the 
presence of unchanged LRH in the circulation may not necessarily 
coincide with the time of maximal gonadotrophin release. 
A number of investigators have reported low or non-detectable 
levels in peripheral plasma. Rosenblum & Schlaff (1975) found levels 
below 5 pg/ml for most normal individuals. Exceptions were noted 
during midcycle and in normo-gonadotrophic patients with amenorrhea, 
where levels up to 40 pg/ml were noted. However, they, and many 
others, used random sampling for these studies, and thus it is quite 
possible that the difference between the patient groups is a result of 
infrequent sampling. This kind of variation of immunoreactive LRH 
levels was also seen in our studies over 6 hours in one subject, 
confirming the need for a different, preferably continuous, sampling 
method when studying hormones such as LRH. 
Our results obtained with continuous sampling indicate that LRH 
is in fact secreted in an episodic manner. Unfortunately, our studies 
offer no proof that the observed patterns are the result of episodic 
hypothalamic activities. However, over the years evidence for the 
hypothalamic origin of the pulsatile LH release, and thus for a 
pulsatile LRH secretory pattern has accumulated and its existence 
can hardly be disputed. Centrally acting drugs such as phenobarbitone 
(Blake, 1974) and nicotine (Blake, Norman & Saywer, 1974) can inhibit 
LH-spiking in ovariectomized rats and this inhibition can be overcome 
by administration of LRH. More direct evidence was obtained with a 
LRH radioimmunoassay by Nett, Akbar & Niswender (1974) who meas-
ured between 15 and 90 pg/ml immunoreactive LRH in ewes. As in 
our studies rhythmic oscillations in LRH were noted, but there was 
no apparent correlation with the LH release patterns. 
Using the same radioimmunoassay (Nett, Akbar & Niswender, 
1974; AS3 in chapters 4 and 5) and a special technique for collecting 
portal blood. Carmel, Araki & Ferin (1976) detected significant fluctu-
ations of LRH in Rhesus monkeys. Peak concentrations of up to BOO 
pg/ml were observed with a peak to peak time of 1 - 3 hours. Bursts 
of immunoreactive LRH in concentrations up to 2000 pg/ml was 
- 88 · 
recorded in human portal plasma (Antunes et al. 1978). Simultaneous 
detection of (portal) LRH and (peripheral) LH surges has been 
achieved (Levine et al. 1982; Clarke & Cummings, 1982) as well as 
simultaneous detection of hypothalamic electrical pulses and LH 
pulses. 
Thus, it seems that there is no doubt that hypothalamic LRH is 
released in a pulsatile manner. Whether our studies in fact picked up 
LRH secreted from the hypothalamus is another matter. Although the 
levels we and others measured are at a level where we could reason-
ably expect to find them, (based on back-calculations from the dose 
exogenous LRH needed to induce LH release: from a few pg/ml up to 
a few tens of pg/ml, chapter 9). more recent measurements in portal 
plasma give rise to estimates sometimes considerably lower. If we 
take the above cited 2000 pg/ml peak levels (Antunes et al. 1978), 
and consider that portal plasma will be diluted approximately 500 
times upon reaching general circulation, the corresponding peripheral 
levels would be around 5 pg/ml. This upper level estimate would then 
correspond to our measured lower level. Other investigators found 
even lower levels immunoreactive LRH in the portal system: 40 · 160 
pg/ml (Sarkar & Fink, 1979); 50 - 150 pg/ml (Ferin, Van Vugt & 
Wardlaw, 1984); 5 · 30 pg/ml (Clarke & Cummings. 1982). 
One reason for the differing values might be found in that 
several different species were used for the measurements. It might 
be significant, in relation to our studies, that the highest values 
were found in humans. If we accept these values, the discrepancy 
between peripheral and portal LRH concentrations are reduced to a 
reasonable but still significant figure. Another factor that should be 
taken into consideration is the extra-hypothalamic occurrences of 
LRH. Although it was originally thought to be a specific hypothalamic 
releasing hormone, several other sources for the hormone have been 
found (Siler-Khodr & Khodr, 1978; Gibbons. Mitnik & Chieffo, 1975, 
Baram et al. 1977; Pauli et al. 1981 and others). The extrahypo-
thalamic functions of LRH are largely unknown although speculations 
are available in quantity. Be that as it may, it is conceivable that 
the peripheral immunoreactive LRH detected, in our studies and those 
of others, may not reflect hypothalamic activity but rather some 
other as yet undefined function(s). Yet, it is of course also possible 
that the peripheral Immunoreactive LRH activity is of a mixed 
hypothalamic and extrahypothalamic origin. The question remains 
unsolved and awaits its solution by other means. 
If we want to really prove that what we measure in plasma is 
the releasing hormone and nothing else, we would have to include 
other assays, relying on other principles such as bioassays or chroma-
tographic motility. This has been done for the thyroid stimulating 
hormone releasing hormone, TRH. The same controversy as regards 
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peripheral hormone levels is also found there. Using immunological, 
chromatographic and enzymatic evidence it was possible to detect 
approximately 80 pg/ml in human peripheral blood (Mallik et al. 1980). 
Although the results seem rather conclusive, even in this case there 
is no proof for a hypothalamic origin of the releasing hormone 
activity. 
6.8 Summary 
In this chapter we have shown that direct measurement of LRH 
by means of radioimmunoassay has many pitfalls. Proteolytic enzymes 
can cause a loss of LRH. Other macromolecular components of can 
interfere and invalidate results. Non-specific interference can largely 
be eliminated by an alcohol extraction procedure that was developed 
and validated in this chapter. Continuous sampling is an essential tool 
when measuring LRH in circulation, as it seems to be secreted in a 
pulsatile manner and has a relatively short half-life. In the next 
chapter we will describe the measurement of LRH in tissues and in 
vitro. 
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CHAPTER 7 
Measurements of the hormone in tissues and incubation media 
7.1 Introduction 
There are three reasons why we decided to extend the radio-
immunological measurement of LRH to tissues. First, measurement of 
tissue concentrations of the hypothalamic releasing hormones is likely 
to be essential for the elucidation of their physiological role. As 
reported in chapter 6, only small amounts of releasing hormone are 
secreted into the hypothalamo-hypophyseal portal system, and these 
are diluted to a great extent upon entering the general circulation. 
This means that we can expect determination of releasing hormone 
content in the hypothalamus to yield more precise information about 
changes in production and release of these hormones. 
Secondly, validation of a radioimmunoassay involves a compari-
son of a standard and its physiological counterpart. Parallelism of 
dose-response curves between unknown and standard is a requirement 
for a valid radioimmunoassay, but is in itself no proof of identity 
(Ekins, 1974). In the case of radioimmunoassays for hypothalamic 
releasing hormones the assay sensitivity is being pushed to the limit 
for measurements in the general circulation, so that parallelism can-
not be investigated, much less be established. The only biological 
material with which we can hope to do this is a hypothalamic ex-
tract. 
Thirdly, the mechanisms regulating hypothalamic LRH synthesis 
and release are not yet fully understood. It was generally accepted 
at the time when these studies were carried out that biogenic amines 
are involved in the processes. Studies of these systems commonly 
employ in vivo and in vitro methods. The latter often involve the 
incubation of hypothalamic fragments and the detection of releasing 
hormone activity by means of bioassays or radioimmunoassays. In the 
course of this study we decided to investigate whether it is possible 
to obtain some information about the involvement of biogenic amines 
in LRH release by means of a simple incubation technique and a more 
elaborate perifusion method. 
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7 2 Determination of LRH in tissues 
7 2 1 LRH content of selected parts of the brain 
Tissue extracts were obtained by means of extraction in hydro 
chloric acid For this purpose 20 male Sprague Dawley rats weighing 
160 - 200 g were decapitated The hypothalamus (stalk median 
minence), posterior pituitary, pineal body and a part of the cerebral 
cortex were immediately excised and homogemred in 0 1 M HCl After 
centrifugation at 30,000 χ g for 30 minutes in a refrigerated centri 
fuge, the extracts were neutralized with 1 N NaOH and recentnfuged 
The supernatants were subjected to LRH radioimmunoassay in tn 
plicate on five or more dose levels In addition, we assayed porcine 
posterior pituitary extracts, prepared m the same manner during 
earlier experiments and kept frozen ever since The LRH contents of 
the tissue extracts were calculated from the average of these data 
and expressed as ng LRH / tissue fragment 
The median eminence extract was found to contain 7 10 ng (SE 
0 9 ng) Figure 7 1 shows the inhibition curves obtained with the 
various extracts in the radioimmunoassay The inhibition curves 
obtained with synthetic LRH and median eminence extract are paral 
lel indicating that the median eminence contains large amounts of a 
material that is immunologically identical to the decapeptide Cerebral 
cortex and the porcine posterior pituitary extracts contained small 
but measurable amounts of radioimmunoassayable LRH activity, 0 07 
and 0 45 ng respectively, whereas the pineal extracts and the rat 
posterior pituitary extract contained less then 0 005 ng per gland 
7 2 2 Effects of gonadal steroid feed back on hypothalamic LRH 
content in male rats 
Steroid feed back mechanisms are generally complex In gonadal 
feed back mechanisms there are inhibitory as well as stimulatory 
effects on the pituitary, and feed back signals may also involve the 
hypothalamus In addition to gonadal feed back signals we must also 
consider the existence of short feed-back route from the pituitary In 
order to cast some light on this, we investigated in a pilot experi­
ment, the effect of castration and hypophysectomy on hypothalamic 
LRH content Castration reduced the LRH level to about half of that 
in the control untreated group The same was true for the hypophys-
ectomized rats These rats, deprived of essential growth factors such 
as growth hormone, failed to develop normally and weighed at the 
end of the experiment only half as much as the other animals 
Therefore, we decided to investigate whether hypothalamic LRH 
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Figure 7.1: Inhibition curves obtained in the LRIl-
radioimmunoassay by synthetic LRH (x-x), median eminence 
extract (o--o) and extracts of posterior pituitary, 
cerebral cortex and pineal body (·--·). Tissue extracts 
are expressed as decimal fraction of gland or hypothalamus. 
content is related to body weight. Male Wistar rats (FW95) were 
obtained at different ages with body weights ranging from 120 to 400 
g. Groups of 10 rats were decapitated and the median eminences 
removed, extracted and assayed for LRH content as described above 
in section 7.2.1 The results shown in figure 7.2 indicate a positive 
correlation between body weight and hypothalamic LRH content. 
In order to investigate the effect of gonadal steroid feed-back 
we divided 50 male Wistar rats were divided into five groups of 10 
rats each: 1. an untreated control group, 2. animals subjected to 
transaurical hypophysectomy by means of suction through a capillary, 
3. animals that were orchidectomlzed, 4. animals given a subcutaneous 
injection of 50 mg testosterone, 5. orchidectomlzed animals receiving 
50 mg testosterone. All animals were decapitated 5 weeks after these 
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Figure 7.2: Correlation between body weight and 
hypothalamic LRH content in male rats of various ages. 
treatments and the hypothalamic LRH content was determined as 
before. The results are shown in table VII.l 
Table VII.l Hypothalamic LRH content in male rats with 
different states of gonadal steroid feed-back. 
treatment 
group 
control 
hypophysectomy 
orchldectomy 
testosterone 
orchldectomy + 
teatosterone 
ng LRH per 
med. emln. 
7.7 +/- 1.« 
3.6 +/- 0.8 
3.7 +/- 1.0 
8.4 ·»•/- 1.1 
6.9 +/- 1.1 
ng LRH per 
100 g BW 
2.3 +/- 0.4 
2.3 +/- 0.5 
1.0 +/- 0.3 
2.8 47- 0.4 
2.2 +/- 0.4 
averages with SD 
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Figure 7.3: Inhibition curves obtained in the LRH· 
radioimmunoassay with synthetic LRH (x--x) and median 
eminence extracts from rats subjected to orchidectomy 
(o--o), hypophysectomy (open triangles), testosterone replacement 
(filled triangles) and control animals (a--·). 
It is obvious that the testosterone treatment alone had no effect 
on hypothalamic LRH content, whether calculated per rat or per 100 
g body weight. In the case of castration and hypophysectomy there is 
a significant reduction to about half in both these cases when 
considered per rat. However, the effect in the hypophysectomized 
group disappears when considered per 100 g body weight. The testo-
sterone substituted orchidectomized rats had a hypothalamic LRH 
content comparable to the control group. Indicating that the reduc-
tion was due to the absence of testosterone feed-back in these rats. 
The data from the LRH radioimmunoassay in the above experi-
ments are also plotted in figure 7.3. The paralell lines obtained by 
plotting radiotmmunologically measured LRH against the dilution factor 
shows that there is a high degree of immunological identity between 
the different hypothalamic extracts. 
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7.3 Determination of LRH in tissue incubation media 
7.3.1 Incubation of rat hypothalami 
We investigated the possibility of modifying the LRH release 
from hypothalami in a simple incubation system, by addition of 
steroids and biogenic amines in order to obtain information about the 
involvement of these compounds in the release process. Such a tech­
nique would then enable further investigations of the regulatory 
mechanisms of LRH release Female Wistar rats (300 g body weight) 
were decapitated The hypothalami were immediately excised and five 
each placed in 2 ml Krebs Ringer bicarbonate glucose solution 
(KRBG) This solution contained 3% bovine serum albumin, was 
adjusted to pH 7.4 and then gassed carbogen (95% carbondioxide/ 5% 
oxygen). In these studies the hypothalamus was defined as the tissue 
lying between the optic chiasm on the anterior side, the hypo­
thalamic sulci on the lateral sides, the mammilarv bodies on the 
posterior side, and the third ventricle on the superior side There 
were four treatment groups 1. controls. 2 addition of 5 ug dop­
amine, 3. addition of 100 vg oestradiol. 4 addition of both dop­
amine and oestradiol The oestradiol was dissolved in 5 ui ethanol. 
which amount of solvent was also added to the control incubations 
For each treatment five incubations were carried out After 15 nuns 
preincubation the medium was discarded and replaced with 2 ml fresh 
medium The hypothalami were then incubated for 2 hours at 37*C 
under gassing with carbogen Incubation was stopped by deprotein-
ization through the addition of 8 volumes of ethanol After centn-
fugation the supernatants were extracted as described in section 6 3. 
The results of the subsequent LRH radioimmunoassay are presented in 
Table VII.2. 
Table VII.2 LRH released in incubation media in the 
presence and absence of dopamine and oestradiol 
Treatment LRH pg/tnl medium 
control 176 +/- 19 
dopamine 204 •*•/- 24 
oestradiol 185 +/- 14 
dopamine + 227 +/- 14 
oestradiol 
Averages with SE from 5 incubations with 5 hypothalami each 
The average LRH levels are higher in the presence of both dop­
amine and oestradiol, but the difference is not statistically significant 
(0.05 < Ρ < 0.1). 
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Another experiment along these lines was carried out to test the 
effects of norepinephrine and dopamine on LRH release. Hypothalami 
were obtained from male rats weighing about 150 grams. The experi-
mental details were identical to the above experiments with the only 
exception that the final incubation time was only 5 minutes. The 
short incubation time was chosen on the assumption that proteolytic 
enzymes might be present and degrade part of the released LRH. A 
wide range of concentrations of the two biogenic amines was used in 
the absence of any reliable information of the possible effects. 
Considering the wide range of amine concentrations that was em-
ployed, we did not include a "zero concentration". The results are 
shown in Table VII.3 
Table VII.3 LRH content of incubation media in the 
presence of dopamine and norepinephrine. 
catecholamine concentration (pg/ml) LRH (pg/ml) 
0.001 
0.01 
0.1 
1.0 
10.0 
0.001 
0.01 
0.1 
1.0 
10.0 
57 +/-
108 +/-
59 +/-
40 +/-
53 +/-
24 +/-
78 +/-
39 +/-
n.d. 
n.d. 
29 
46 
32 
16 
15 
7 
33 
15 
Averages with SE from 5 incubations per dose-level 
with 5 hypothalami each, n.d. - not detectable. 
Both catecholamines seem to increase the LRH release at an 
intermediate concentration of 0.01 Mg/ml. Unfortunately, the 
variations within the groups were again too large to obtain statisti-
cally significant effects. 
Several attempts were made to improve the reproducibility and 
stabilize the system. This included lowering the incubation tempera-
ture from 37*C to room temperature (20*C), and varying the pre-
incubation and incubation times. None of these changes gave better 
reproducibility than the above experiments. We concluded that static 
incubation of hypothalami as described above does not yield suffi-
ciently reproducible data to permit studying the regulation of LRH 
release from the hypothalamus. 
norepinephrine 
dopamine 
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7.3.2 Perifusion of rat hypothalami 
As static incubation of hypothalami did not seem to be a suitable 
technique for studying the regulation of LRH release, we decided to 
set up a perifusion system. This would continuously provide the hypo­
thalami with fresh incubation medium, thus removing waste products, 
offering fresh nutrients and allowing frequent sampling. Carbogen 
gassed KRGB • 3 % BSA is passed through a heat exchanger and 
oxygenator by means of a peristaltic pump. The whole system is kept 
at 37*C in a thermostated water bath. After removing gas bubbles in 
a debubbling device, the medium is passed through a 10 pm membrane 
into a perifusion chamber. After leaving the chamber through another 
membrane the medium is collected on a fraction collector. The 
collection tubes are kept on ice and contain the ethanol required for 
the extraction procedure as described in section 6.3. As soon as a 
tube has recieved the desired amount of medium, it is mixed on a 
Whirlmix for 15 seconds and centrifuged. This is followed by deter­
mination of radioimmunoassayable LRH as described earlier. Plow 
rates are kept between 0.10 and 0.25 ml/minute and the collection 
time for each sample is between 3 and 12 minutes. Before each 
experiment the whole apparatus is rinsed with the perifusion medium 
to coat it with albumin and bring it to the desired temperature. 
Standard curves for the subsequent radioimmunoassay are prepared in 
the same medium and the standard samples are extracted simul­
taneously with the experimental samples as described in section 6.3. 
In initial experiments we investigated whether LRH can be recovered 
from the perifusion medium. LRH was injected as a pulse into the 
tubing entering the perifusion chamber, which contained one hypo­
thalamus. About 2/3 of the injected quantity (120 pg) could be 
recovered from the perifusate. In a second experiment medium 
containing 10 pg LRH / ml was prepared and samples were collected 
in three different ways: the first sample- was kept on ice without 
extraction, the second sample was extracted with ethanol (section 
6.3) and the third sample was extracted in the same manner with 
methanol. After passage of the medium through the perifusion 
chamber with a hypothalamus we could detect 8.6 +/- 0.8 pg / ml 
without extraction, 13.8 +/- 1.7 pg / ml in the ethanol extracted 
samples and 14.0 +/- 1.2 pg / ml in the methanol extracted samples 
(5 samples each, assayed in triplicate, mean +/- SD). Without extrac­
tion we find · as expected - about 60 % of the LRH obtained in the 
extracted samples. Furthermore, the results from the extracted 
medium samples indicate that a «mall amount of LRH (ca. 6 pg/ml) is 
added to the medium during its passage through the perifusion 
chamber, presumably due to release by the hypothalamus. 
Basal LRH release into the perifusate was further investigated 
by α perifusion of two hypothalami for 6 hours. The hypothalami in 
this and the following experiments were obtained from male rats 
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Figure 7.4: Basal release of immunoassayable LRH from 
two perifused rat hypothalami. 
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Figure 7.5: Basal release of immunoassayable LRH from 
two perifused rat hypothalami. 
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Figure 7.6: ImmunoreacUve LRH in perifusate from 2 
hypothalami subjected to norepinephrine pulses. 
weighing between 150 and 250 g. The rats were decapitated after 
stunning without anesthesia, incubation temperature was 37"C and the 
collection time for each medium fraction was 6 minutes. Figure 7.4 
shows that LRH release can be detected in this way. There is a 
steady increase from 10 · 15 pg/ml to a level of 50 · 60 pg/ml at 
the end of the 6-hour perifusion period. A slightly different picture is 
seen in figure 7.5. In this experiment there is a steady release of ca 
50 pg/ml 4 hours, after which tissue decay sets in and larger 
amounts of LRH are liberated into the medium. 
Numerous attempts were made to stimulate the release of LRH 
into the medium by means of catechol administration. A few typical 
examples are shown above. In the experiment shown in figure 7.6 
(left), pulses of norepinephrine were injected into the perifusion 
medium just prior to where the tubing is entering the perifusion 
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Figure 7.7: Immunoassayable LRH in perfusate from 2 
hypothalami subjected to continuous exposure to nor­
epinephrine. 
chamber. The first pulse consisted of 0.5 Ρ в norepinephrine in 100 μΐ 
KRGB, injected slowly over a 3 minute time period. Ten minutes later 
this was followed by a 5 |ig injection, and thereafter by a 50 lig 
injection. A sharp increase in perifusate LRH levels can be seen 
after the first pulse of norepinephrine, while smaller increments in 
immunoassayable LRH were detected after the second and third 
pulses. The experiment was repeated, but this time with a pulse of 
KRBG followed by three 0.5 ve norepinephrine pulses. The results, 
shown in figure 7.6 (right), suggest that the LRH increases detected 
in this and the previous experiment are more likely due to an in­
jection artifact, rather than by a drug-induced release. 
In view of these results we decided to avoid such disturbances 
in the medium flow and to administer the norepinephrine continuously. 
This also permitted maximal stimulation of the system. This was 
achieved by switching to a medium containing 10 pg/ml catecholamine 
after a 15-minute pre-perifusion period with normal KRGB. Results are 
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shown in figure 7.7. In this experiment the initially high LRH levels 
are followed by a drop to 10 - 25 pg / ml. No significant reaction to 
norepinephrine treatment during 1 hour is observed. The experiment 
was repeated three times with virtually identical results were 
obtained. Norepinephrine doses of 5 and 100 pg/ml were also em-
ployed in this manner, but again the results did not show any 
response to the treatment. 
7.4 Discussion 
7.4.1 Tissue LRH content 
As expected,the hypothalamus was found to be an excellent 
source of LRH. The extraction method yielded LRH in amounts that 
are comparable to those found by other investigators. The importance 
of using a proper extraction method is emphasized by the results of 
Shin & Howitt (19741. They found that using a buffer extraction and 
omitting a boiling step reduced the recovery to 10 %. This suggests 
that the LRH is stored in a inaccessible form to simple buffer ex-
traction. The use of acid, organic solvents or boiling is essential. 
Ramirez et al. (1975) found 5.5 +/- 0.9 ng per rat hypothalamus 
with a bioassay (Ramirez & McCann 1963) and 5.1 +/- 0.3 ng (mean 
+/- SE) with a radioimmunoassay. These values (for 200 g male rats) 
are very similar to our data (4.5 ng). As in our studies, these investi-
gators could show a parallelism between standard and tissue sample 
in the radioimmunoassay system. This could also be established for 
human hypothalamic extracts by Mortimer et al. (1976). Jeffcoate et 
al. (1974b) reported hypothalamic LRH contents between 0.7 and 5.8 
ng LRH in the rat, 8 - 12 ng in the rabbit and 0.030 - 1.0 ng in the 
chicken. All extracts exhibited dilution curves that are parallel to 
those for synthetic LRH. These values appear to confirm the relation-
ship between animal size and hypothalamic LRH content, which we 
have demonstrated for hypothalami from rats of different weights. 
Araki et al. (1975) presented almost identical results. However, they 
used only rats up to the lowest weight investigated by us. The 
dependence of hypothalamic LRH content on body weight needs to be 
taken into account when comparing results from experiment with rats 
of different sizes. It is obvious that the results of the hypophys-
ectomy treatment can only be interpreted correctly when body weight 
Is taken into consideration. 
There is no doubt that the regulation of gonadotrophin secretory 
patterns is under some type of steroid feed-back control. After 
gonadectomy, both sexes in many species will show elevated gonado-
trophin levels (Gay & Midgley, 1969; Yamamoto, Diebel & Bogdanov, 
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1970; Blackwell & Amoss, 1971). Treatment of ovariectomized monkeys 
with physiological levels of oestradiol rapidly depresses plasma LH 
levels and interrupts the pulsatile release pattern (Yamaji et al. 
1972). Similar results have been obtained in man (Yen et al. 1972). In 
early experiments Piacsek & Meites (1966) found an increased bio-
assayable LRH content of the rat hypothalamus after castration, 
which could be restored to normal by administration of testosterone 
propionate. Consequently, we were slightly surprised when the effect 
of castration in our studies turned out to be a decrease in hypo-
thalamic LRH content by approximately 50 %, which change could be 
reversed by testosterone treatment. Similar reductions were also 
observed by Shin & Howitt (1975), who showed that hypothalamic 
LRH initially increases for the first 48 hours after castration, 
followed by a gradual decrease to approx. 50 % of the normal levels 
after about one week. This was also observed by Baker & Dermody 
(1976), Rotztein et al. (1977) and Martini (1983). All these investi-
gators used rats and radioimmunoassays. However, similar results were 
obtained in mice by Hegeman et al. (1983). In women reduced hypo-
thalamic LRH levels are found after ovariectomy and in the meno-
pause Parker, Parker & Porter, (1984). This indicates that such 
mechanisms are operative in various species. 
Mouguilevsky et al. (1975a). measuring the incorporation rate of 
tritiated tyrosine into peptides with LRU-activity, found a higher 
rate in castrated rats than in untreated rats. This indicates that 
removal of the gonadal steroid feed-back leads to an increased 
synthesis of LRH, which is in apparent contrast to our studies and 
those of others. However, we must recognize that when hypothalamic 
LRH content is measured, the results do not necessarily reflect the 
rate of synthesis of the releasing hormone. It is more likely that in 
fact the difference between synthesis and release into the portal 
system is measured. Thus, it is conceivable that the decrease 
observed by us is the result of an increased release that is not 
paralleled by the same increase in the synthesis of the peptide. This 
suggestion is supported by the results of Mouguilevsky et al. (1975b), 
who by means of the Ramirez-McCann bioassay showed that hypo-
thalami from castrated rats have a higher rate of synthesis and a 
lower LRH content. 
White et al. (1974) reported very large amounts of LRH in ovine, 
bovine and porcine pineal glands. These studies were carried out with 
a radioimmunoassay as well as a bioassay. The pineal gland was 
found to contain 4 · 10 times more releasing hormone than the hypo-
thalamus from the corresponding species. These unexpected findings 
prompted us to measure the LRH content of the rat pineal gland, 
which we found to contain less than 0.005 ng LRH. It seems unlikely 
that this would merely be due to species differences. Indeed, other 
investigators using the same methods as we did (Gradwell, Millar & 
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Symington, 1976; Duraiswami et al. 1976) could not confirm the high 
values of White and collaborators for bovine pineal glands. 
7.4.2 Incubation studies 
The results of the incubation experiments suggest that there 
are factors interfering with the assay. One obvious source of 
trouble is proteolytic degradation of LRH by hypothalamic peptidases. 
The existence of such enzymes have been demonstrated in the soluble 
fraction of hypothalamic tissues (Griffiths & Hooper, 1973; Griffiths 
et al. 1975, Koch et al. 1974). The levels seem to be inversely 
correlated with the LH levels and possibly with the LRH activity. 
The peptidase activity was shown to be able to degrade LRH, 
resulting in a loss of both immunological and biological activity. This 
was the rationale for trying shorter incubation times. The use of 
enzyme inhibitors was rejected, since these compounds are often very 
unspecific. 
The later findings of Negro-Vilar. Ojeda & McCann (1979) offer 
another explanation for the absence of a response in our incubation 
studies. Their results indicate that the choice of the hypothalamic 
region is quite critical when incubating hypothalamic tissue. They 
only found dose-dependent stimulation by norepinephrine and dopamine 
when incubating the median eminence alone, but not when surrounding 
tissue was present. They suggest that LRH release from the median 
eminence is inhibited by neurons with cell bodies in the surrounding 
structures. This has been confirmed by other recent studies where 
the median eminence was also responding much better than the medial 
basal hypothalamus (Gambacciani, Yen & Rasmussen. 1986). This 
speaks in favour of a neural system, present in the intact hypo­
thalamus only, which is capable of inhibiting LRH release. It thus 
appears that in our desire to include the complete hypothalamic 
structure for LRH release studies so as to have a system resembling 
the in vivo situation as closely as possible, we may have in fact 
included inhibiting functions. 
Other investigators were equally unsuccessful in provoking a 
change in LRH release in vitro by means of biogenic amine stimu­
lation. Kao et al. (1977) testing the effects of acetylcholine, 
norepinephrine, dopamine and serotonin in a perifusion system, were 
also unable to find any effects. The levels of immunoassayable LRH 
in the medium were close to those in our experiments. Yet other 
Investigators could show dose-dependent stimulation of LRH release 
from hypothalami in vitro with very low doses of catecholamines (less 
than ΙμΜ), whereas higher doses did not lead to LRH release (Ojeda, 
Negro-Vilar & McCann, 1979). The doses used in our perifusion ex­
periments were according to their results, too high to be effective: a 
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0 5 microgram pulse the lowest concentration used by us, would lead 
to nearly millimolar levels The same is true for the experiments of 
Kao et al (1977) In our static incubation experiments, we observed 
elevated LRH levels, albeit not statistically significant, at the lower 
catecholamine concentrations In other words, it is quite possible that 
the doses employed in many of our experiments did not permit physio-
logical LRH release It is probably fair to state in the seventies 
when we carried out our experiments, there was a tendency to aim 
for maximal stimulation Since then the scientific community has come 
to realize that the use of "pharmacological' concentrations and even 
the higher ranges of physiological concentrations can lead to mis-
leading results 
Although there is solid evidence for a stimulatory role of nor-
epinephrine in the release of LRH from the hypothalamus (Ranee et 
al 1981. Ojeda et al. 1982, McCann et al 1979, McCann. 1983a and 
b), evidence for suppression have also accumulated (Leung et al. 
1982, Parvizi & Ellendorf. 1982, Donoso et al 1971. Gallo & Drouva, 
1979, Gallo, 1981) The same is true for the other putative synaptic 
transmitter, dopamine, where stimulatory effects (Schneider & Mc-
Cann, 1969, 1970a, 19870b and 1970c) as well as suppressive effects 
(Fuxe & Hoekfelt, 1969, Gnodde & Schuiling, 1976) have been seen 
Later studies have shown that both effects are equally possible and 
that this probably depends on the steroid environment (McCann, 
1983a & 1983b, Vijayan & McCann, 1978a and 1978b) In our studies 
the steroid enviroment (with one exception) was not controlled beyond 
the selection of animals, and it is thus conceivable that this factor 
contributed to the results In the one instance where oestradiol 
levels were altered, we unfortunatly used again a dose that was far 
beyond physiological. 
The importance of selecting the correct steroid environment for 
LRH release studies is demonstrated by the following experiments. 
The response to dopamine stimulation of hypothalamic tissue in vitro 
is one order of magnitude lower for an ovariectomized rat, which is 
has not been primed with an oestrogen injection (Negro-Vilar et al. 
1979) There is a higher 'basal" LRH release by eu perfused rat hypo-
thalami from oestrogen-primed ovariectomized rats that were treated 
with progesterone prior to the experiment (Ramirez et al 1980) 
Furthermore, progesterone can induce LRH release from such prepa-
rations in vitro, but only If the rats are primed with oestrogen 
(Miyake et al. 1982. Kim & Ramirez. 1985) 
Another factor that might determine whether the action of the 
neurotransmitters will be stimulatory or not is the mode of adminis 
tration Continuous infusion of norepinephrine into the third ventricle 
of rats can suppress LH output after an initial peak (Gallo, 1982) In 
contrast, when the amine was given at spaced intervals, large LH-
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responses were noted for each norepinephrine pulse. Similar results 
are seen when stimulating the LRH output in vitro by means of pro-
gesterone administration to hypothalami derived from ovariectomized. 
oestrogen primed rats. Only a pulsatile but not a continuous mode of 
infusion was effective in stimulating LRH release. There was a 
latency period of approximately 1 hour (Kim & Ramirez, 1982). 
The lack of effect with high doses and prolonged exposures can 
be explained by phenomenon of desensitization or refractoriness, i.e. 
a decreased response to repeated or continuous stimulation. This has 
been noted for a large number of cellular processes and it can either 
be acute or chronic. The acute desensitization is developing rapidly 
and Is also rapidly reversible, the chronic one is slow both in onset 
and reversal. The acute effects possibly involves a decreased 
receptor function, whereas the chronic change often involves a loss 
of receptors or down regulation (Chang & Cuatrecasas. 1983). This 
altered response to stimulation appears to play an important role 
in the regulation of hormone action. 
There are other ways of stimulating the release of LRH from 
hypothalamic tissue in vitro. Using a static incubation system, Brideli 
& Snyder (1978) measured approximately 10 pg LRH / ml medium, 
which value was increased by 200 • 500 % upon depolarizing the cell 
membranes by increasing the potassium concentrations to 60 mM or 
adding ouabain to the medium. Exclusion of calcium from the media 
prevented this increase. The isolated median eminence from ovari-
ectomized rats, primed with oestrogen, responded to superfusion of 30 
mM potassium enriched medium with reproducible, rapid and reliable 
LRH outputs (Kim & Ramirez. 1982). This potassium-evoked release 
depends on the temperature and calcium levels (Hartter & Ramirez, 
1980). Furthermore, LRH release evoked in this manner can be 
altered by pretreatment with progesterone (Drouva et al. 1983). 
Thus, it seems that LRH release from the hypothalamus depends 
on membrane depolarization and a resulting calcium influx into the 
cells. This mechanism is found for a growing number of hormones in 
many tissues, and has been substantiated by many -investigators. 
Recently, Drouva et al. (1984) have shown the involvement of cal-
modulin and a calcium/calmodulin dependent protein kinase in the 
calcium dependent, potassium evoked LRH release from hypothalami in 
vitro. 
In view of the experiments carried out in recent years, it is 
obvious that simple in vitro experiments in the manner described here 
can only yield meaningful information when a number of conditions 
are fulfilled. Most of them were not known at the time we did our in 
vitro experiments and thus the results are a consequence of, and 
demonstrating the need for employing the correct mode of agonist 
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introduction and experimental model. With the wisdom of hindsight 
we can visualize a number of approaches that could have yielded 
better information about the regulation of LRH release from the 
hypothalamus. However, we had to use the available information at 
that time and the results were as presented here. 
7.5 Summary 
In this chapter we have investigated the distribution of LRH in 
various parts of the rat brain. The highest concentrations were 
measured in the stalk median eminence. Low or non-detectable levels 
of immunoassayable LRH were found in the posterior pituitary, pineal 
gland and cerebral cortex. We could achieve one important aspect of 
radioimmunoassay validation by establishing parallel dose-response 
curves for standard and experimental samples. A relationship between 
body weight and hypothalamic LRH content was established. Removal 
of gonadal steroid feed-back led to a reduction in LRH content, 
probably as a result of a change in the ratio of biosynthesis and 
release of the releasing hormone. Two in vitro systems for possible 
use in investigations of regulation of LRH release were investigated: 
a simple static incubation system and a perifusion method. Basal 
release of LRH could be measured, but no significant responses to 
biogenic amines could be detected, probably because the entire hypo-
thalamus and too high levels of biogenic amines were used. 
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CHAPTER θ 
Studies with LRH in human subjects 
8.1 Introduction 
The availability of synthetic LRH (Matsuo et al. 1971. Geiger 
et al. 1971) provided the means to develop a rapid and efficient test 
of the capacity of the pituitary gland to respond to hypothalamic 
stimulation. In this manner, it became possible to detect degrees of 
functional capacity ranging from absolutely insufficient via adequate 
to overresponsive reactions. This technique could be very useful for 
evaluating the pituitary-hypothalamic axis in endocrine disorders of 
the gonadal-pituttary-hypothalamic system. Our research group was 
fortunate in receiving as one of the first in Europe samples of 
synthetic LRH. However, this meant that we had to carry out all 
experiments without any knowledge of how to use this new hormone 
in practice. Consequently, when we conducted the clinical studies 
with LRH, we had to determine first the time required for the 
pituitary to respond to LRH by measuring plasma LH and FSH levels 
in women and men. We also had to establish the minimum effective 
dose of LRH before we could carry out investigations of the pituitary 
capacity in a variety of endocrine disorders affecting the human 
reproductive system. 
Early studies indicated that LRH can be used to induce release 
not only of LH but also of FSH in a number of species, including 
man (Schally et al. 1971; Schneider & Dahlen, 1972a, 1972b,; Yen et 
al. 1972). It is also possible to induce follicular growth and ovulation 
by employing LRH to elevate the circulating LH and FSH levels 
(Zarate et al. 1972; Schneider & Dahlen. 1973c; Keller. 1973; Bohnet 
et al. 1974). As these studies indicated that relatively long treatment 
schedules are necessary, it seemed desirable to find an easy and 
reliable way for self-administration. Intravenous, intramuscular and 
subcutaneous injection as well as oral and nasal administration lead 
to release of LH and FSH (Amoss et al. 1972. Mortimer et al. 1974, 
London et al 1973). Hoechst AG developed a spray for self-adminis­
tering peptides or other similar materials into the nasal cavity. When 
reasonable amounts of synthetic LRH became available, we were 
given the oppurtunity to test the spray and evaluate the possibility 
of using it for chronic LRH therapy. 
Considerable variation has been observed in sensitivity to a test 
dose of LRH. Steroid pretreatment can alter the pituitary sensitivity 
(Matsuo et al. 1971). During the human menstrual cycle and the rat 
oestrous cycle, responsiveness varies according to the steroid environ­
ment (Yen, 1977; Goodman. 1978; Fink,1979). A pulsatile fluctuation of 
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basal LH release of variable frequency and amplitude has been 
related to the different phases of the menstrual cycle (Schelly et al. 
1971: Yen et al. 1972; Santen & Bardin. 1973: Brody et al. 1982; 
Bachstrom et al. 1982; Liu & Yen. 1983; Veldhuis et al. 1984: 
Crowley et al. 1985). Both frequency and amplitude seem to be modu­
lated by ovarian steroids. However, changes in sensitivity to LRH of 
the gonadotropjiic cells could also be due to limitations in reserve 
capacity or a refractory period of the pituitary. In this context we 
investigated the behaviour of the human pituitary in response to re­
peated LRH stimulation. Our results led us to postulate the existence 
of a refractory period of the anterior pituitary to LRH stimulation. 
8.2 Materials and methods 
Eugonadal volunteers and patients with a variety of endocrine 
disorders were fitted with a jugular vein catheter. Blood was with­
drawn by a peristaltic pump at 3-7 minute intervals in heparinized 
centrifuge tubes kept on ice. Samples were centrifuged immediately 
and the plasma snap-frozen and stored at -30*C. Plasma LH and FSH 
were measured by radioimmunoassay employing a double antibody tech­
nique (Dahlen, Keller & Schneider, 1974). LH was iodinated according 
to the method of Greenwood, Hunter & Glover (1963). utilizing highly 
purified material of human origin (LER-960 and a similar preparation 
from Dr Schams. University of Munich, Weihenstephan). LH antiserum 
nr. 391 was a gift from Dr. A.R. Midgley, University of Michigan, 
Ann Arbor, USA. The materials for the FSH radioimmunoassay were 
supplied by the National Institute of Arthritis and Metabolic 
Diseases, Bethesda, Md, USA. In both assays 2nd International 
'Reference Preparation of Human Menopausal Gonadotrophin (2nd IRP-
HMG) was used as a standard. Anti-rabbit-gamma-globulin was obtained 
by immunization of sheep with Cohn fraction II of normal rabbit 
serum in Freunds complete adjuvant (see also section 4.3.2). The pre­
cipitated radioactivity was measured in a LKB-Wallac Gamma Scintil­
lation Counter using a 3" χ 3" Be-coated crystal. The Inter-assay 
error (coefficient of variation) was 11.7% for the LH-assay and 9.4 % 
for the FSH-assay as determined by replicate determinations of a 
control plasma (average binding percentages 35 and 20%, respective­
ly). The intra-assay variations as determined by the variation of the 
points on the standard curve for the LH-assay was 2.4% at 100% 
binding and 11.5% at 10-15% bound with a mid-slope value of 4.1%. 
For the FSH-assay the corresponding values were 2.1% at 100% 
bound, 13.5% at 10% bound and 3.7% at midslope. Synthetic LRH. a 
gift from Farbwerke Hoechst AG. Frankfurt, was injected via the 
indwelling catheter. The nasal spray, also a gift from Farbwerke 
Hoechst, was designed to deliver 100 μΐ containing 0.1, 0.5. 1.0 or 2 
mg LRH in saline per application with an accuracy of about 10%. 
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Figure 8.1: Continuous recording of plasma LH and FSH of 
two eugonadal female volunteers after intravenous 
injection of low doses of LRH. 
Figure 8.2: Effects of increasing doses of LRH on 
continuously recorded plasma LH and FSH levels of 
increasing doses of LRH in a eugonadal woman 
8.3 Results 
8.3.1 Response to intravenous LRH in eugonadal women 
In order to detect small and short-lived changes we elected 
to establish the minimum effective dose and the time for maximum 
response by continuously monitoring the plasma LH and FSH levels. 
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LRH given at doses of 0.1, 0.2, 0.4. 0.5, 0.6 ug i.v. did not alter the 
basal plasma levels of LH and FSH. As seen in figure 8.1, 3.0 vg 
LRH was the minimum effective dose for the release of LH and FSH 
in two eugonadal female volunteers.Doses from 3 - 24 ug LRH re-
sulted in LH release in the first 14 individuals tested. In 10 of these 
normogonadotrophic women FSH release was also noticed. Net in-
creases in LH ranged from 9 to 110 mIU/ml. net increases in plasma 
FSH from 3 to 16 mIU/ml. These LRH doses caused the LH to reach 
a peak level after an average time interval of about 20 minutes 
(Table VIII.I). 
Table VIII.I Time interval for LH peak levels 
following i.v. injection of low doses of LRH 
LRH d o s e t i n e I n t e r v a l number of 
( p g ) min ( r a n g e ) s u b j e c t s 
3 18 ( 1 6 - 2 0 ) 3 
6 16 ( 1 4 - 2 0 ) 4 
12 21 ( 1 4 - 2 7 ) 6 
24 24 ( 1 0 - 3 1 ) 10 
In an attempt to induce a dose-dependent LH release LRH was 
injected in doses of 12.5 - 25 - 50 vg into a 26-year old eu-
menorrheal woman on day 9 of the menstrual cycle. As judged by 
laparoscopy, this individual had macroscopically normal ovaries. The 
time interval selected between the first and the second injection was 
56 minutes and between the second and the third injection 59 
minutes. THe net increases in plasma LH concentrations resulting 
from these 3 doses were 38, 100 and 156 mIU/ml respectively (fig 
B.2). The time interval between injections did not allow circulating 
LH to return to resting levels. A linear relationship is evident when 
plotting LH increment versus log LRH dose. FSH concentrations were 
not altered after administration of 12.5 and 25 ug LRH. but injection 
of 50 jig LRH resulted in a 6 - 7 fold elevation of plasma FSH. 
Dose-related FSH release was noted in a 40 year old eu-
menorreal subject when LRH was administered in doses of 6. 12 and 
24 pg. Plasma FSH increments of 7. 11.5 and 17 mIU/ml were deter-
mined (fig 8.3). In a semilogaritmic plot of FSH increments versus 
LRH dose, a linear log dose response was found again. 8.3.2 Response 
to i.v. LRH in endocrinopathies. 
Among 150 individuals tested with LRH in doses of 25 or 50 Mg, 
8 did not respond with a detectable gonadotrophin release. Figure 8.4 
•hows 3 typical examples. The upper recording was from a 22-year 
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Figure 8.3 : Effect of 6, 12 and 24 Me LR H on continuously 
recorded plasma FSH in a eumenorrheal women. 
old woman with a monophasic menstrual cycle and a history of no 
pregnancy after 4 years of marriage and continuing attempts at con­
ception. Urinary ketosteroids were found to be subnormal at 3.6 
mg/24 hours and urinary gonadotrophin activity was reduced to 10 
Ш/1. No reaction in plasma LH and FSH levels to 25 and 50 pg LR H 
was evident. The next recording shows the findings in a 15-year old 
girl with retardation of growth and puberty (height 146 cm. genital 
hypoplasia, infantilism, karyotype XX regular, normal plasma growth 
hormone levels). No reaction to repeated injections of 25 |ig LRH was 
observed. The lower recording pertains to a patient with a typical 
Sheehan syndrome and a history of four pregnancies, hypothyroid with 
TBI of 1.48 and PBI of 1.7 Mg/100ml, urinary ketosteroids 1.7 mg/24 
hours. Here again, 25 μ в LRH did not alter basal gonadotrophin 
levels. The inverted LH/FSH ratio in the last two cases should be 
noted. 
We also found cases of over-responsiveness of the pituitary to 
LRH. In figure 8.5 4 cases are compared to a normal LH release 
pattern. In a 55 year old menopausal woman, basal LH concentrations 
ranging from 79 to 88 mlU/ml rose to a peak level of 210 mlU/ml 32 
minutes after injection of the 25 |ig test dose. 
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Figure 8.4 : Failure of synthetic LRH to induce LH and 
FSH release in three subjects with different endocrine 
disorders. 
Similarly, in a peripubertal girl.aged 9.5 years (bone age 12.5 years. 
menarche at 8.9 years, total urinary oestrogens 11.8-20& 6g/24h). The 
LRH responses showed a peak LH concentration of 326 mlU/ml after 
27 minutes, starting from basal levels 4 - 6 mlU/ml. 
Such overresposiveness was also apparent in hypogonadal and 
hypergonadotrophic men. For example, in a cryptorchid patient with 
aspermia and a subnormal urinary testosterone value of 6.3 ug/24h, 
the corresponding pattern was a basal LH level of 40 · 60 mlU/ml. 
rising to a peak of 223 mlU/ml after 19 minutes. Similarly, a patient 
with Klinefelter syndrome and basal LH levels of 42 - 48 mlU/ml 
exhibited a peak LH concentration of 147 mlU/ml after 21 minutes. 
8.3.3 Response to intranasal LRH 
The nasal spray was tested on five apparently healthy male 
volunteers, aged 2 1 - 3 7 years. Thçy administered 0.1 · 2.0 mg LRH 
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Figure 8.5 : Overresponsiveness of human pituitary to a 
test dose of 25 Mg synthetic LRH as compared to normal 
reaction pattern. 
to themselves. The average basal plasma LII valuó was 5.7 +/- 2.9 
mlU/ml (mean +/- SD). This means that plasma LH values of up to 
11.5 mlU/ml would have to be considered as falling within the normal 
variation (2SD). A spray of saline with no or with 0.1 mg LRH did 
not produce changes outside this normal variation. Application of 0.5 
mg LRH led to detectable LH increases in all 5 cases. The average 
LH value 45 minutes after application of the spray was 13.9 +/- 7.4 
mlU/ml and thus outside the above mentioned limit. We must there-
fore consider that a true LH release had in .fact taken place in 
response to the intranasally sprayed LRH (figure 8.6). After adminis-
tration of 1.0-and 2.0 mg LRH a readily apparent LH release was 
observed in all cases. For the 1 mg spray the average LH peaks 
was 18.4 +/-6.9 and for the 2 mg spray 30.2 +/- 7.3 mlU/ml. Basal 
FSH values were found to be 5.3 +/- 2.0 mlU/ml, which leads to a 
2SD limit of 9.3 mlU/ml. The average FSH levels in this experiment 
remained below this limit (data not shown) and we must therefore 
conclude that even the highest LRH dose was insufficient to cause a 
clear FSH release. 
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Figure 8.6 : LH release in normal men after ¡ntranasally 
sprayed LRH in doses from 0.1 to 2.0 mg (averages from 
five individuals). 
Of the five female volunteers, three were given 0.5 mg LRU and 
two were given 2.0 mg on days 9, 10 and 11 of their menstrual 
cycles. In figure 8.7 it can be seen that after 0.5 mg LRH a sig-
nificant LH-release is seen only on one day out of three in all sub-
jects and that the net LH increase never exceeded 15 mlU/ml. In 
two cases the LH-release was seen on day 11 and in one on day 10. 
The administration of 2.0 mg to the remaining volunteers, however. 
resulted in a significant LH-release in both cases (figure 8.7). One of 
these women (K.G.) must have been close to the ovulatory LH-surge, 
as Judged by the high basal values and high gonadotrophin response. 
Also, only in this case increased FSH release was noted. 
8.3.4 Response to repeated intravenous LRH injections 
Continuous monitoring of plasma hormone concentrations does not 
allow more than a few hours recording time in order to avoid 
excessive blood loss. Consequently, we always kept the recording 
time as short as possible. When using multiple LRH injections in 
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Figure В.7 : LH- and FSH-release in normal females on 
days 9. 10 and 11 of the menstrual cycle after intranasally 
sprayed 0.5 mg or 2 mg LRH. 
one recording session, this often led to the rather disturbing result 
that a dose-dependent LH-release could not be obtained. When 
however, the time interval between LRH injections was increased to 
about one hour, the expected LH dose-dependency could indeed be 
observed. It was also apparent that with repeated injections of the 
same LRH dose, the LH release was not reproducible at time 
intervals in the range of 30 - 40 minutes. Therefore, the time 
interval was considered to be of significance for the pituitary 
response and we set out to investigate this phenomenon further. 
Figure 8.8 depicts three typical unsuccessful attempts of inducing a 
dose-dependent LH release following intravenous injection of synthetic 
LRH in women. In the upper recording 6.25, 12.5 and 25 tig LRH 
gave rise to a rather disproportional LH release, when injected at 43 
and 36 minute intervals in this 28-year old subject on day 26 of her 
regular menstrual cycle. The same pattern was observed in subjects 
with chronic anovulatory cycles, when larger LRH doses were chosen 
(12.5, 25 and 50 pg or 25, 50 and 100 pg LRH at 40 and 57 min. or 
25 and 25 min. intervals in the two middle recordings). However, the 
administration of 12.5, 25 and 50 Mg LRH at 56 and 60 minutes 
intervals respectively resulted in a dose-dependent response (the 
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Figure 8.8: Attempts to induce a dose dependent 
LH-release with synthetic LRH monitored by continuous 
recording of immunoprecipitable LH. 
lowest recording). When the net LH increments recorded in these four 
subjects are plotted against the logarithm of the LRH dose, linearity 
is only apparent in the lower recording. 
In a group of seven patients the same LRH dose (12.5, 25 or 50 
tig) was repeatedly injected at 30 minute intervals (figure 8.9). With 
one exception the second and third doses were less effective. This 
reduction in LH release was found to be significant at the 1% level 
for the second and at the 2% level for the third response. 
In a different approach 25 ug LRU was injected at 30 min. 
intervals and this was repeated after a resting period of one 
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Figure 8.9: THe effect of repealed injections of the same 
dose LRH on immunoprecipitable LH in 7 subjects. 
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Figure В. 10: LH-release following two LRH injections 
30 minutes apart, repeated once after a 65 minute resting 
period. 
hour (figure 8.10). Again a typical LH release after the first injection 
was followed by a diminished response 30 minutes later. The one-hour 
interval allowed the LH-response to be fully restored, but 30 minutes 
later the fourth injection was as ineffective as the second injections. 
Net increments of LH in four subjects with anovulation, following two 
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Figure 8.11: LH increments in 4 subjects following two 
pairs of LRH injections spaced 30 minutes with a one-hour 
resting period between the pairs. 
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Figure 8.12: Net LH increments in response to paired LRH 
injections spaced 30. 45 and 60 minutes. The opposing 
open and solid bars represent the initial and subsequent 
LH increments resulting from the 25 |ig LRH test dose. 
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pairs of 25 /»g injections spaced as described above, are 
presented in figure 8.11. The maximum LH increase detected after 
the first releasing hormone stimulation (left bars) ranged from 55 -
191 mlU/ml, whereas the second response of the pairs (right bars) 
was lowered to a range of 3 - 35 mlU/ml (p<0.05). The corresponding 
results for the second paired stimuli 60 minutes later were 63 - 167 
mlU/ml for the primary and 21 - 50 mlU/ml for the secondary 
respons (p<0.05). The primary as well as the secondary responses in 
the first versus the second pairs do not differ significantly. 
Paired injections spaced at 30. 45 and 60 minutes were 
performed in the same subjects (female volunteers) at 0, +6 and +24 
hours. Again. LH maxima were found by continouos recording of 
plasma LH concentrations. These 10 normal individuals at various 
days of the menstrual cycle revealed a considerable variation of the 
pituitary responsiveness to LRH. Nevertheless, a significant loss of 
responsiveness occurs when the paired injections followed within 30 
minutes (P<0.01), but not at 45- and 60-minute intervals. When the 
initial or subsequent responses of the three treatment schedules were 
compared with each other (figure 8.12, opposing solid and open bars). 
a significant difference in the LH release pattern was evident only 
between the secondary injections in the experiments with 30- and 
60-minute intervals (P<0.02). If the subsequent response is expressed 
in percent of the initial response, a significant decrease in LH 
release was detected after the 30-minute interval as compared to the 
45-minute and 60-minute intervals approach (P<0.01 and P<0.02. 
respectively). No significant difference was detected between the 
responses to the 45- and 60-minute injection intervals. 
8.4 Discussion 
8.4.1 Initial studies 
One would assume that the observed increases in plasma the LH 
and FSH levels would be due to an increased release of these 
anterior pituitary hormones. The possibility that their inactivation or 
removal is being blocked can be discounted on the basis of the 
following calculations. Assuming that the calculation of the daily 
removal rates for LH in the rat (Gay. Niswender & Midgley, 1970) 
also apply to man, we can assume that: 
mlU/day - body weight In grams χ mlU/ml plasma 
In a 60 kg human with maximum LH levels of 20 mlU/ml the daily 
removal rate would be 1.20 million mlU/day or 833 mlU/minute. If 
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the blood volume is 1/13 of the body weight and the haematocrit 
is 45 %. then the total plasma volume is 2.07 litres. This results in a 
removal rate of 0.40 mill/ml plasma per minute. With maximal 
responses occurring at 21 minutes after injection of LRH. a total 
block of LH degradation and removal from systemic circulation would 
account for an increase of no more then 8 mIU/ml. This rate of 
increase cannot account for the observed increases (40 - 120 
mIU/ml). 
Continuous recording of plasma hormone concentrations in man 
is limited by the total blood volume that can be withdrawn. There-
fore. our experimental protocol did not allow for more then a few 
hours of recording time. Consequently, when several LRH injections 
were administered in one session, it was not possible to wait for the 
gonadotrophins to return to their baseline values. Nevertheless, 
linearity in the LH and FSH release was observed. This must be due 
to the relatively slow disappearance rate of gonadotrophins after LRH 
relative to normal plasma elimination. If the expected continuation of 
the gonadotrophin removal is extrapolated, linearity of the log-dose 
response still persists for both gonadotrophins (data not shown). A 
comprehensive study on this subject was done by Wollesen et al. 
(1976) who found a dose-response relationship with LRH doses 
between 1.5 and 3000 pg. This linearity seen in the release of LH 
and FSH suggests that synthetic LRH acts via a physiological 
mechanism and thus behaves like a natural hormone, as one would 
expect from natural human LRH. Furthermore, it supports the view of 
Schelly et al. (1971) that LRH is a releasing hormone for FSH as 
well. However, in approx. 150 recording sessions conducted in 120 
individuals, we did not regularly observe a significant FSH release. 
8.4.2 The LRH test 
One of the the aims of these studies was to obtain a better 
classification of certain infertility disorders in women on the 
basis of plasma LH and FSH levels and the results of LRH stimu-
lation. Several publications were written in the seventies on the 
subject of the usefulness of LRH as a diagnostic tool to differentiate 
between different types of hypogonadism. After the initial euphoria of 
having a new hormone to work with, a number of investigatitors 
became rather disappointed when the use of LRH did not revolu-
tionize diagnosis of infertility disorders. E.g. Mortimer et al. 1973, 
stated that the variation within groups is so large that gross 
characteristics of an individual's LH response is of little diagnostic 
value. It has also been reported that the response is related to basal 
values and does not distinguish between different pathologies and is 
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thus of questionable clinical value (Nilius & Wide. 1972: Mortimer et 
al. 1976; Coscia et al. 1974; Mortimer et al. 1973). It seemed to us 
that in order to obtain satisfactory differentiation, the methodology 
of the test would have to be standardized and expanded. This we 
attempted to do. 
In our experience, 25 micrograms of synthetic LRH seems to be 
the most appropriate dose for evaluating pituitary function, as 
it gives rise to net LH increases ranging from 40 to 120 mIU/ml 
in eumenorrheal women. This increase parallels the physiological 
response of the anterior pituitary around the time of ovulation 
and leaves an assayable range for insufficient and overresponsive 
reactions to releasing hormone stimulation of the gland. Other 
investigators have suggested a dose of 100 vg (Mortimer et al. 
1973, Patton et al. 1974; Taymor et al. 1974) but others favour lower 
doses in the order of a few tens of Mgs. Schally et al. 1976; Crowley 
et al. 1985). 
Our initial efforts (Schneider & Dahlen. 1972a. 1972b, 1973a, 
1973b, 1973c, also reported here) led to a cooperative study at 
the Universities of Ulm, Tuebingen and Basel. This in turn led to the 
development of the so-called Human Pituitary Gonadotrophin Index 
(Keller et al. 1976), which is based on the statistical evaluation of 
339 carefully standardized LRH tests with 25 tig LRH and a sampling 
of LH and FSH before and after stimulation. The index classifies 
patients into several categories according to basal LH levels and LH 
responses. Combination of this index with a clomiphene test 
(clomiphene is thought to be acting on the hypothalamus) and an 
investigation of the pulsatile LH patterns (Bohnet et al. 1975), may 
be provide a useful evaluation of patients before, during and after 
therapy for fertility disturbances (Bohnet et al. 1976). 
Although LRH has now been available to clinicians for several 
years, there are still publications appearing, which report new 
results from using the LRH test in the diagnosis of hypothalamic 
- pituitary - gonadal dysfunctions. It has been reported that the 
relationship between basal LH and LRH response differs in men with 
or without hypothalamic - pituitary dysfunction and this phenomenon 
can be used to improve the diagnosis of pituitary hypogonadism 
(Herman et al. 1982). In elderly men there seems to be a delayed 
response (Winters & Troen, 1982; Herman et al. 1982) and a 
diminished response in diabetic patients with amenorrhea (Ojursing et 
al. 1983). 
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8.4.3 Abnormal responses 
In the first 150 LRH tests we observed eight instances 
without detectable increase in plasma LH concentrations. Such 
lack of pituitary responsiveness to synthetic LRH could be due to 
either primary or secondary pituitary failure. Primary failure is 
commonly seen in patients with pituitary necrosis, tumour, trauma 
or empty sella syndrome. However, it must be born in mind that 
pituitary function may remain normal even when large amounts of 
pituitary parenchyma have been destroyed (van Buren & Bergenstal. 
1960). This type of pituitary failure is illustrated in the present 
study by the recording from a patient presenting a typical Sheehan 
syndrome. The low but still detectable LH and FSH levels should be 
noted. As pointed out by Ross (1972), the mere presence in plasma of 
immunoassayable gonadotrophins does not necessarily imply continu­
ation of their trophic function. Maqueo et al (1972) demonstrated a 
lack of antral follicles in 92% of a large group of women using oral 
contraceptives, although this treatment is known to leave seemingly 
sufficient plasma gonadotrophins. The other two instances of no 
response, demonstrated here, represent a group of patients with 
clinically suspected secondary pituitary failure i.e. with a lack of 
proper endogenous LRH stimulation, resulting in insufficient gonado-
trophin release, which is also noticoble after exogenous LRH admini­
stration. 
In contrast to an insufficient response, the other extreme, an 
overresponsiveness, is regularly observed in patients presenting such 
endocrine states as menopause, castration, cryptorchidism, Kline-
felter's syndrome and onset of puberty. All these endocrine disorders 
have in common a hypogonadal and hypergonadotrophic status and 
thus an open-loop condition in terms of gonadal feedback control. The 
open-loop is associated with high endogenous LRH activity, as 
suggested by the results of in vivo studies in basic reproductive 
endocrinology. In the primate and human menstrual cycles, the highest 
sensitivity to LRH is found during mid-cycle (Knobil, 1974; Saito et 
al. 1972; Crowley et al. 19Θ5). 
The chief criticism of the LRH test has been that it does not 
always distinguish between hypothalamic and pituitary causes of 
amenorrhea. A normal response to LRH does not always indicate 
hypothalamic dysfunction, since even a diseased pituitary can release 
LH (Schelly et al. 1976) and the absence of a response does not 
always indicate a pituitary disease. A normal pituitary deprived of 
(prolonged) LRH stimulation caused by a hypothalamic lesion may lose 
its capacity to respond. Patients with anorexia nervosa show a poor 
response to LRH, although the cause of the problem undoubtedly 
originates above the pituitary (Van der Kerckhoeve. Dhont & van 
Eyck, 1975; Nillius & Wide. 1972; Schneider & Dahlen, 1973a). It is 
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also important to note in this context that anovulation could also be 
caused by dysfuntion of a brain centre responsible for cyclical 
functions. Not only must LRH signals be present to induce LH 
release, they must also take place at the right time and with the 
right frequency in order to lead to a proper ovulatory cycle (Crowley 
et al. 1985). Such considerations lead to the conclusion that the LRH 
test alone does not suffice in all cases and must be supplemented by 
other tests. A clomiphene test can give useful information about the 
functional capability of the hypothalamus (Bohnet et al. 1976). 
Estimates of endogenous LRH release can be obtained by measuring 
the pulsatile LH release patterns (Bohnet et al. 1975; Crowley et 
al. 1985). State of the art diagnosis of hypogonadism today is 
employing a combination of LH pulse recording, either in response 
to endogenous or exogenous LRH in a pulsatile manner, and in 
addition is the response recorded to LRH replacement therapy based 
on physiological doses and time intervals. (Crowley et al. 1985). 
Our data support the concept that pituitary sensitivity to 
exogenous LRH depends on the degree of endogenous gonadotrophin 
releasing hormone stimulation. Thus, varying degrees of gonado-
trophin release to a standard stimulus can occur. The extreme 
sensitivity to LRH seen in a girl at the onset of puberty (figure 
8.5) can also be explained in terms of high levels of endogenous 
releasing hormone. Animal experiments indicate that this phenomenon 
can be explained by the fact that LRH can induce its own receptor. 
Pituitary LRH-receptors increases late in dioestrous during the rat 
oestrous cycle and remain high until late pro-oestrous (Clayton et al. 
1980). Furthermore, low doses of LRH can increase receptor the 
content in rats and the treatment also leads to increased LH 
responses (Frager et al. 1981). Gonadectomy has also been shown to 
increase the receptor levels (Marion, Cooper & Conn, 1981; Clayton 
& Catt, 1980). This can be interpreted to mean that the rate of 
hypothalamic LRH secretion will determine the number of pituitary 
receptors, which then provides a means of modifying gonadotrophin 
secretion. 
8.4.4 Intranasal LRH 
The results from the nasal spray experiments confirm that 
synthetic LRH is indeed capable of releasing LH when applied intra· 
nasally. A significant LH-release is seen only when doses of 0.5 mg 
or more are used. The release after 2 mg is in the same range as 
seen after i.v. injection of 25 (g LRH, indicating that about 1 % of 
the applied LRH reaches the circulatory system in a biologically 
active state and can thus act on the pituitary. Studies with a LRH-
radioimmunoassay suggest that Indeed about 1 % of the intranasally 
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applied LRH is detected in the plasma (P. Franchimont, personal 
communication), which suggests that there is a considerable intranasal 
loss of LRH. 
The time-course for the LH-release reveals a retarded release 
(peak at 45-60 minutes) compared to the response after i.v. injection 
(peak at 20-25 minutes). This was to be expected as the LRH must 
first reach the circulatory system in appreciable quantities before it 
can act on the pituitary. This retardation in the maximum response is 
probably due to slow absorption of LRH. London et al. (1973) have 
reported peak LH-values at 30 minutes rather then the 45 minutes 
reported by us. The discrepancy may be due to the fact that these 
authors did not include sampling at 45 minutes but only at 30 and 60 
minutes and so they may have missed the true peak. 
Although this mode of administration employs relatively large 
amounts of LRH, this disadvantage is more then outweighed by the 
ease of application. The fact that little or no FSH is released 
may limit the use of the spray method. Nevertheless, the chronic 
mode of LRH therapy has more aspects than gonadotrophin release 
alone. E.g. the anovulatory female, not responding to clomiphene due 
to hypothalamic dysfunction, can be converted into a clomiphene 
responder by chronic LRH therapy (Bohnet et al. 1976). In the rodent 
this kind of treatment exerts a stimulatory effect on endogenous 
releasing hormone activity, when subcutaneous injections are used 
(Sandow & Heptner, 1974). Furthermore, in monkeys with lesions in 
the hypothalamus, continuous infusion of the releasing hormone did 
not support the gonadotrophin secretion. After initial increases the 
pituitary became refractory and the levels fell. However, the 
administration of LRH in a pulsatile manner once per hour resulted in 
a normal secretory pattern of the gonadotrophins (Knobil, 1980 fit 
1981). This mode of application was sucessful in the induction of 
ovulation in women with amenorrhea (Leyendecker, Struve & Plotz, 
1980). The LRH spray is ideal for this kind of replacement therapy 
as has been shown by several investigators (Hagberg & Westphal, 
1982. Cacciari, Frejaville & Becaa, 1982). The opposite effect, 
inhibition of ovulation, can also be induced by means of the LRH 
spray (Bergquist, Nillius & Wide. 1979 & 1982). This, initially rather 
surprising, contraceptive effect might depend on overstimulation and a 
resulting down-regulation of pituitary and/or ovarian receptors. 
8.4.5 Refractoriness of the pituitary 
Our studies with different time ' intervals for sequential paired 
LRH injections present evidence for the existence of a partial 
refractory period of the pituitary gonadotroph amounting to least 30 
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minutes. It is also evident that these phenomena are independent of 
a possible diurnal rhythm, since the response pattern remains 
unchanged when the experiments were carried out at different times 
of the day. Furthermore, there are no changes in the refractory 
pattern during the various stages of the menstrual or an anovulatory 
cycle. 
A look at the relative LH responses reveals that the second 
response is on the average about 30, 60 and 75 % of the initial one 
after intervals of 30, 45 and 60 minutes respectively. In other words 
there is a gradually diminishing response by the pituitary lasting for 
about one hour. Under physiological conditions the maximal frequency 
for the pulsatile pattern of basal LH release is also about one hour 
(Yen et al. 1972b). Thus, it could be that the pituitary gonadotroph 
responds with a similar refractory pattern to endogenous LRH 
stimulation and does not allow for unlimited transmission of the 
neurohormonal stimulus. 
Similar results were obtained by Crowley et al. (1985) when 
they investigated the effects of changes in frequency of LRH 
administration to hypogonadal men. When gradually increasing the 
frequency from a pulse every 2 hours to one every 15 minutes, there 
was a progressive loss of response and they noted non-transmitted 
pulses of exogenous LRH. Throughout the experiments the serum 
testosterone level remained unchanged. 
An explanation for this phenomenom can be found in modulation 
of the numbers of cell surface receptors in response to hormone 
concentration. As discussed above in section 8.4.2 LRH can induce its 
own receptors. However, there is another aspect to LRH - receptor 
interactions. Once LRH is bound to the receptor, a sequence of 
events starts, leading to a disappearance of the receptor from the 
cell surface. After 20 minutes the LRH-receptor complex forms 
clusters, which after 30 minutes are internalized (Hazum et al. 1980). 
This means that there is a transient loss of receptors available on 
the cell surface. Working with cultured rat anterior pituitary cells, 
Loumayer & Catt (1982) could show an initial loss of receptors, which 
reaches a maximum after 1 hour. This down-regulation was followed 
by a recovery and sub- sequently an increased number of receptors. 
These findings may be relevant for clinical pituitary function 
tests. A negative result would suggest either pituitary insufficiency 
or hypothalamic failure. However, the possibility that a normally 
integrated hypothalamo-pituitary system was stimulated during a 
refractory period must be eliminated by repeating the test at a later 
time. 
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There are also obvious consequences for the chronic use of LR H 
e.g. to stimulate secondary gonadal immaturity. For a number of 
years chronic LRH therapy was not giving the expected results. 
Infusions failed to sustain gonadotrophin secretion for reasonable 
periods of time and "the pituitary appeared to become refractory to 
LRH" (Knobil, 1980). Apparently these authors did not notice our 
studies of repeated LRH administrations (Schneider & Dahlen, 1973b 
and 1975), as they make no reference to them. Working with rhesus 
monkeys, Knobil then proceeded to administer the LRH in pulses. 
While 5 pulses per hour extinguished gonadotrophin secretion, one 
pulse per hour gave the desired gonadotrophin increases. 
8.5 Summary 
By means of a system for continuous monitoring of LH and FSH 
in women we established the lowest effective dose of LRH for 
causing a release of LH and FSH (3 - 6 (g). Dose-related responses 
could be induced in the release patterns of both gonadotrophins. 
The use of the releasing hormone as a diagnostic tool was investi-
gated by measuring the responses to LRH stimulation in women with 
a variety of endocrinological disorders. Over-responsivenes as well as 
insufficient responses were noted in conditions with elevated and 
decreased endogenous activity, respectively. A nasal spray mode of 
administration for LRH was investigated and the effectiveness of the 
method checked. During the determination of dose-response curves for 
LRH in man, it was often impossible to achieve linear responses. By 
means of sequential injections spaced at different time intervals, this 
could be shown to be an effect of pituitary refractoriness to 
releasing hormone stimulation. The implications of this effect 
are discussed. 
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CHAPTER 9 
General discussion 
Elucidation of the important roles played by peptides in the 
central regulation of various endocrinological functions has led to the 
discovery and isolation of a number of hypothalamic hormones that 
regulate secretions of the anterior pituitary gland. The list of 
neuropeptides in the hypothalamus is ever increasing. Summing up 
evidence from radioimmunoassay and immunocytological experiments, 
Palkowitz (19821 cited evidence for 14 neurologically active peptides 
in the rat median eminence, at least 5 with effects on LRH secreting 
neurons. It seems that the more we learn about hypothalamic pro-
cesses, the more complicated is the overall picture. In this report we 
try to give an account of our efforts to improve the understanding 
of certain aspects of reproductive neuroendocrinology. 
9.1 Radioimmunoassay of LRH 
The availability of synthetic LRH opened up new areas to 
investigations into the mechanisms of reproduction. One of the new 
possibilities was the development of radioimmunoassays for the deca-
peptide to enable, for the first time, its precise measurement in 
biological fluids and tissues. This technique combines great simplicity 
and high sensitivity with the specificity inherent in immunological 
reactions. However, radioimmunoassays have their special problems, 
which require particular care in their development and execution. It 
has been recommended by the World Health Organization (1972) that 
in determining antiserum specificity the investigator should compare 
the results with an established bioassay and that inhibition curves for 
unknowns must be parallel to the standard curves. 
Ideally, the comparison should be made in the medium in which 
the radioimmunoassay is going to be carried out. This does not al-
ways produce a true picture of the concentration in the biological 
fluid. In plasma for instance, factors such as enzymes and other 
compounds are frequently interfering. This can take place at 
different levels. First, the compound to be measured may be meta-
bolized during storage or assay of the sample. Oxytocin for instance, 
depends on an intact molecule, and in particular on the integrity of 
its ring structure. The breakdown in the presence of oxytocinase, e.g. 
in pregnancy plasma, is much more rapid when measured by bioassay 
than as seen in a radioimmunoassay (Chard et al. 1970a). When in-
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fusing the hormone, the estimates by the two methods show more 
difference as time passes (Forsling, Boyd & Chard, 1971) Secondly, 
the assay may be influenced by some factors present in the sample 
This is particularly true for the radioimmunoassay of LRH in plasma 
(see Chapter 7) These problems can often be eliminated by immediate 
deproteimzing of the sample followed by an extraction procedure 
Consequently, we decided to include these procedures This enabled 
us to compare· the biological and the immunological assays in the 
extraction medium In our studies reported here, both criteria sug-
gested by the WHO for radioimmunoassay validation could be met 
comparison with the Ramirez-McCann bioassay, utilizing oestrogen-
progesterone primed ovanectomized rats, showed excellent agreement 
and hypothalamic extracts and synthetic LRH showed parallel in-
hibition curves 
These are essential elements of radioimmunoassay validation but, 
unfortunately, not enough The possibility that metabolic products or 
precursors may be detected must also be excluded Such compounds 
will contain elements of the structure of the original structure to 
varying degrees and it is thus conceivable that the antibodies will 
not distinguish between them and the substance itself In our studies 
we could show that our antispra were highly specific but that an 
anti- serum supplied by other investigators showed a lack of complete 
specificity in that it was specific for the N-terminal of the deca-
peptide only 
This has more than theoretical consequences as shown by the 
studies of Jeffcoate et al (1973b and 1974a) utilizing this antiserum 
for determinations of LRH in urine. The studies, employing gel 
chromatography and thin layer chromatography in addition to the 
.radioimmunoassay, suggested that the releasing hormone was present 
intact in urine Hence, urinary measurements of LRH would be ex-
pected to yield physiologically meaningful results We could, for 
instance, follow the 24-hour production pattern and look for increases 
e g at times of elevated plasma LH levels However, subsequent 
studies employing carboxymethyl-cellulose chromatography (Jeffcoate 
& Holland, 1975), showed that the immunoreactive entity was in fact 
the 3 - 10 octapeptide metabolite of LRH. This evidence was further 
confirmed by studies on the metabolic fate of LRH by Redding & 
Schelly (1972) and by Redding et al. (1973) They could show that 
LRH is partly broken down by splitting off of the dipeptide pyro-
glutamyl-histidine, which lead to the formation of the above men-
tioned octapeptide. 
Similarly. Aubert et al. (1977) and Copeland et al (1976) using 
three antisera, obtained only minor differences when assaying LRH in 
a human foetal hypothalamic specimen (1.5, 1 6 and 1 8 ng respective-
ly) whereas a urinary sample yielded widely differing results (0 7, 3.5 
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and 7 ng respectively). In other words, when assaying hypothalamic 
samples, where we can expect less degradation products than in 
urine, the choice of antiserum is not so critical. However, for assays 
in urine it is of crucial importance. 
The biological activity of LRH is lost when substitutions are 
made in the four N-terminal amino acids (Yanaihara et al. 1973a and 
1973b), indicating that groups essential for the biological activity 
reside in this part of the molecule. This means that antisera specific 
for the N-terminal only, might show better correlation with bioassays 
than an antiserum specific for the C-terminal only. On the other 
hand, the latter antiserum only responds to peptides with the intact, 
metabolically sensitive C-terminal which would make it insensitive to 
the metabolic breakdown products. It is obvious from the above that 
an antiserum, such as produced in this study, that requires both ends 
of the LRH molecule for binding, provides a very high degree of 
specificity and a large probability of correlation with bioassays. 
Another metabolic route for LRH was described by Marks & 
Stern (1974) who could show that, in addition to the previosly men-
tioned C-terminal breakdown, there are also neutral endoproteases 
capable of internal cleavage of the decapeptide. This will produce C-
as well as N-terminal fragments. As however the antisera used in this 
study required both terminals not only to be present but also to be 
attached to each other (Table V.l), the breakdown products of this 
pathway will not be detected by our LRH radioimmunoassay either. 
The only way that metabolic events could interfere with the 
results from our radioimmunoassay would be by a rapid breakdown of 
LRH in the biological environment, by binding of the releasing 
hormone or by influencing the reaction between LRH and the anti-
bodies. Such interference was noted by us and by others. The rapid 
breakdown could be largely circumvented by immediately de-
proteinizing the samples by the addition of cold ethanol. This 
treatment also initiates the extraction procedure which also removes 
compounds interfering with the radioimmunoassay and in addition 
concentrates the samples and thus increases the sensitivity. 
9.2 Immunoreactive LRH levels in peripheral plasma 
When searching the literature for "normal values" for LRH in 
plasma measured by radioimmunoassay we find a wide range of 
estimates (Table IX. 1) 
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Table IX. 1 Immunoreactive LRH in plasma 
Investigators species concentration (pg/ml) 
Kerdelhue et al. (1973a 
and 1973b) 
Keye et al. (1973) 
Crighton et al. (1973) 
Fraser et al. (1973) 
Nett et al. (1971) 
Arlmura et al. (197'·) 
Jeffcoate et al. (1974a) 
Roeenblum et al. (1975) 
Jonas et al. (1975) 
Foster et al. (1976) 
Akeel et al. (1979) 
sheep 
rats 
men 
women 
sheep 
rats 
sheep 
women 
sheep 
women 
men 
sheep 
sheep 
men 
6000 - 12000 
4000 - 5000 
68 +/- 17 
70 +/- 12 
<10 - >10000 
<10 - 900 
120 - 370 
1 - 17 
10 - 230 
0.25 - 9.5 
<5 - 40 
n.d. - 400 
30 - 220 
20 +/- 5 
n.d.- not detectable, range or mean with SEM given 
Although Table IX.I does not present a complete list of all publi­
cations on this subject, it serves to indicate the wide range of LRH 
levels in plasma that have been reported. The lower estimates are 
far more likely to have any physiological meaning. In chapter 8 we 
could show (Schneider & Dahlen 1Э72Ы that the lowest dose of exo­
genous LRH that is capable of releasing LH was approximately 5 (g. 
In an average person with a plasma volume of 2 litres, assuming that 
the LRH is distributed only in this compartment during the first 
minutes after intravenous injection, this would mean that the minimum 
effective concentration is approximately 2.5 ng/ml. Endogenous LRH, 
however, is secreted into the portal vessels, which leads to an 
approximately 500-fold dilution before it enters the general circu­
lation. This means that we can assume that a minimum effective LRH 
secretion from the hypothalamus will lead to a LRH concentration in 
the general circulation of approximately 5 pg/ml. A dose of approx. 
100 (g exogenous LRH causes maximum response. If the hypothalmus 
is capable of providing such maximal stimulation, plasma LRH values 
of up to 100 - 200 pg/ml would represent the upper limit of the 
physiological range. 
The results of Clemens et al. (1975) support the validity of the 
above calculations. They measured 200 pg/ml circulating after in­
jection of 1 (g LRH / squaremetre body surface, a dose which they 
had determined to be the minimum effective dose. Recalculated to 
match our conditions, this would lead to a value of 1 pg/ml in 
general circulation resulting from a minimal hypothalamic LRH secre­
tion capable of stimulating LH release. The minor difference as com­
pared to our calculated estimate (5 pg/ml) can probably be neglected. 
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Malacara. Seyler & Reichlin 1972, using a sensitive bioassay and 
an extraction method showed that small amounts of circulating bio-
logically active LRH is present in peripheral plasma of women and 
that increased amounts were present during mid-cycle. Approximate 
calculations from their results suggest that concentrations of 25 
pg/ml might be expected at that time. 
Considering the above, we must doubt reports with plasma LRH 
values in excess of 1000 pg/ml, such as some of those cited in Table 
IX.1. It is difficult to accept values above a few hundred pg/ml as 
having any real physiological significance. This is especially so in the 
cases where the assay was performed on unextracted plasma. In our 
studies the values are within the limits calculated on the basis of 
the results with exogenous LRH. 
In view of the high specificity of the radioimmunoassays and the 
precautions taken to eliminate interference, we consider that the 
levels of immunoreactive LRH in peripheral plasma extracts, observed 
by us and certain other investigators, are very unlikely artifacts and 
probably represent the presence of the decapeptide known as LRH. A 
different matter is the origin of the peptide. In the light of recent 
findings of extra-hypothalamic LRH in various organs, we must now 
consider that perhaps only a (small?) part of the detected LRH is of 
hypothalamic origin. It seem more likely that we are dealing with 
LRH from a number of sources. The physiological functions of LRH 
outside the hypothalamic · pituitary region are largely unknown and 
speculative. 
9.3 LRH content of the hypothalamus 
Although we did not perform any detailed anatomical studies, the 
distribution of LRH in the brain we have found is in agreement with 
that reported by others. LRH is concentrated in the medial basal 
hypothalamus, lesser amounts are found in the anterior hypothalamus 
(McCann, 1962; Crighton, Schneider & McCann, 1970; Wheaton, Kru-
lich & McCann, 1975). This distribution may be interpreted in terms 
of our present understanding of the hypothalamic control of gonado-
trophin secretion. It is generally assumed that two centres are in-
volved in this process. One centre, located in the preoptic nucleus, is 
thought to be responsible for cyclic LH functions such as the 
ovulatory surge. A second centre, including the arcuate nucleus, is 
thought to be involved with the tonic secretion of LH, i.e. the main-
tenance of basal LH levels. We consider that LRH is synthesized in 
the neuron perikarya in the suprachiasmatic - preoptic area and is 
transported via long axons down to the median eminence, from where 
it is released into the portal vessels. Another set of neurons, which 
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have their cell bodies in the arcuate nucleus, is also thought to pro-
duce LRH and to deliver it via shorter axons to the median eminence 
(Schneider & McCann, 1969; Zimmerman et al. (1974, Krulich et al. 
1977b; Paden & Silverman. 1979; King et al. 1980; Jenner & Stumpf, 
1980; Witkin, Paden & Silverman, 1983). 
In our studies on the effect of removing gonadal steroid feed-
back we have limited the measurements to the median eminence and 
surrounding structures. About 90 % of the total hypothalamic LRH is 
found in this region (Wheaton, Krulich & McCann, 1975). In view of 
the concept cited above, this is not very surprising. Furthermore, 
Ramirez et al. (1975) could show that the vast majority of hypo-
thalamic LRH is contained in nerve endings, i.e. the median eminence. 
In other words, as regards hypothalamic LRH content, it is permissi-
ble to substitute the retrochiasmatic hypothalamus used in this study. 
9.4 Role of biogenic amines in LRH secretion 
The activity of the neurosecretory LRH neurons is influenced by 
a large number of putative neurotransmitters capable of either stimu-
lating or inhibiting the release of LRH (McCann, 1982, Barraclough, 
Wise & Selmanoff, 1984). It has especially been suggested that 
dopamine and norepinephrine are involved. McCann, 1969: Gnodde & 
Schuiling, 1976; Kizer et al. 1976; Vijayan & McCann. 1978a; Ranee 
et al. 1981; Ojeda et al. 1982. Although significant advances have 
been made in this field, e.g. the involvement of endogenous opioid 
peptides (Ferin et al. 1984), the precise role of the various cate-
cholamines are still largely unknown. The questions as to whether 
there is a stimulatory or inhibitory role of dopamine and norepi-
nephrine in LRH release and whether dopamine or norepinephrine (or 
both) is involved in the triggering the release of LRH to induce the 
basal (LH-episodes) and cyclical (ovulatory LH-surge) has yet to be 
clarified. There are evidence that modifications in the steroid en-
viroment could lead to the different effects and thus might explain 
the contradictive results that have been obtained in the past (Mc-
Cann, 1983a). 
Just about the only thing that we can say with absolute certain-
ty on this subject is that the control mechanisms involved with the 
hypothalamic releasing hormones are very complex. Simple incubations 
and perifusions such as in our studies are not likely to yield meaning-
ful information unless far more attention is given to factors such as 
choice of tissue and steroid environment. Recently Drouva et al. 
(1984) could show that the hypothalamus from ovariectomized rats 
releases less LRH (in vitro and in response to depolarization with 
potassium) than that from rats receiving oestrogen replacement. The 
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studies of Leadem & Kalra (19Θ4) showed that the median eminence 
from pro-oestrus rats can release LRH into perifusate when stimu­
lated with progesterone. Similarly Kim & Ramirez (1985) could show 
LRH release from the hypothalamus of oestrogen primed rats in 
response to steroid treatment in vitro. These studies and others 
demonstrate the importance of having a carefully defined model, es­
pecially in terms of steroids, for in vitro experiment involving LRH 
release. 
This is also exemplified by the fact that when the median 
eminence is attached to the rest of the hypothalamus, progesterone 
can only stimulate LRH release (in vitro) when administered in pulses 
whereas the median eminence alone will respond also to a continuous 
exposure (Ramirez et al. 1985). In addition, this is another example of 
the effect shown in the experiments by Negro-Vilar et al. (1979) and 
Gambacciani et al. (1986) where the whole hypothalamus was much 
less responsive than the median eminence. Thus, the use of hypo­
thalamic fragments, slices, cultures or homogenates may give rise to 
false negative data as well as artefactual positive data, depending on 
the nature of the missing function. On the other hand, for some type 
of experiments we may have to employ precisely such a fragment. In 
our studies we seem to have been making the wrong choice of tissue 
(intact hypothalami). 
Other factors might also have influenced the results and gave 
rise to the poor stimulation results. Investigations by Bennet et al. 
(1975) showed that when preparing synaptosomes from hypothalamic 
tissue, dopamine could evoke a LRH response from only 1/10 of the 
cells. Thus, with 90 % of the hypothalamic cells unresponsive it is 
easy to see how contradictory results can be be obtained. Further­
more, we should remember that we are dealing with a rather arti­
ficial situation when doing in vitro experiments. This is exemplified 
by the apparent loss of viability of hypothalamic tissue seen in figure 
7.5 where large amounts of LRH is released into the medium, pre­
sumably due to tissue decay. We can also question if the perifusion 
system really provide for an equal distribution throughout the tissue 
for both life sustaining nutrients and essential factors as well as 
putative stimulants. 
The importance of having the right steroid enviroment was also 
recently demonstrated in vivo by Peduto & Makesh (1985). They, in 
analogy to one of our experiments, attempted to induce LRH release 
by means of progesterone in oestrogen primed ovariectomized rats. As 
in our experiments were levels of immunoreactive LRH in peripheral 
plasma not changed with the dose levels used by us. However, they 
were able to show that our basic concept was fundamentally sound. A 
reduction of the amount of steroids to more physiological levels did 
indeed bring about significant LRH increases. In other words, the 
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doses of the steroids for the priming are of crucial importance in 
order to show the progesterone effect. 
9.5 Clinical studies 
The nasal spray tested in our study had been developed by 
Hoechst AG for use in conditions of endogenous LRH insufficiency, 
leading to disorders of reproductive functions, e.g. azoospermia, 
failure of ovulation and delayed puberty. Our discovery, confirmed by 
others, that the pituitary is desensitized in response to repeated or 
continuous administration of the releasing hormone led to a rather 
surprising development, namely that such sprays have been used for 
anti-conception purposes (Bergquist, Nillius & Wide, 1979 & 1982), i.e. 
they are used to inhibit ovulatory processes rather than induce them. 
LRH-analogues in the same spray as we used in the trial for Hoechst 
are also being used for treatment of sex-hormone dependent carci-
nomas (Klijn & de Jong, 1982; Tolis et al. 1982) as well as endo-
metriosis (Meldrum et al. 1982). However, used in a proper mode, i.e. 
pulsatile, the LRH spray can also be used for replacement therapy 
(Hagberg & Westphal, 1982; Cacciari et al. 1982). 
It turned out that the LRH test alone does not allow for a 
complete evaluation of the hypothalamic - pituitary system in the 
course of diagnosing reproductive dysfunctions. As a result was the 
estimation of the pulsatile LH release pattern introduced to assist. 
Both approaches, monitoring either the results of endogenous LRH 
secretion or the results of exogenous LRH, have inherent limitations 
and a combination of both is needed to maximize information about 
the dysregulated gonadostat. As seen in our studies, the LRH test 
might turn out negative as a result of hypothalamic malfunction 
resulting in an LRH stimulation insufficient to maintain the proper 
receptor numbers in the pituitary and hence no LH release upon LRH 
administration. A possible cause for a false negative result would be 
that the anterior pituitary becomes refractory also to an endogenous 
pulse of LRH and hence will not react to the endogenous releasing 
hormone. When monitoring pulsatile LH patterns in order to gain an 
insight of patterns of LRH secretion from the hypothalamus, one 
assumes that the pituitary responds to every LRH pulse with a corre-
sponding LH release. This is not necessarily so. the refractory period 
demonstrated by us could lead to a blocked or non-transmitted pulse. 
It is quite possible that a dual mechanism exists for the regu-
lation of LH secretion. This could mean that a pulsatile releasing 
hormone pattern is superimposed on a refractory periodicity of the 
pituitary. The results of Clarke & Cunnings (1982) and Levine et al. 
(1982) point in this direction. These investigators could show that 
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LRH pulses are present in the sheep portal system without corre-
sponding LH episodes in the general circulation, but that LH release 
is never found without a LRH pulse. Although these results could be 
due to experimental artifacts, we have to seriously consider that the 
LRH signals are modified at the pituitary level. Factors that might be 
involved in the regulation of such effects are, obviously, steroids and 
catecholamines. Receptors for such compounds have been found in the 
anterior pituitary (Kato & Onouchi. 1977; Weiner & Ganong. 1978). 
Concentration of LRH receptors on the membranes of pituitary cells 
has also been seen to vary with steroid environment (Crowley et al. 
1985; Clayton & Catt. 1980: Moss. Crowder & Nett. 1981: Adams, 
Norman & Spies, 1981). Another obvious candidate for such effects is 
LRH. It is now clear that LRH is influencing the pituitary receptor 
levels. As we have seen this can be a down-regulation in response to 
repeated or continuous exposure. Conversely the pituitary may be 
primed by small doses in a pulsatile manner which will lead to an 
increased number of receptors. This way can hypothalamic centres 
influence the pituitary, not only by a pulse to induce an LH episode, 
but also to induce changes in sensitivity to the LRH pulse. 
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CHAPTER 10 
Summary 
10.1 English 
A radioimmunoassay for Luteinizing Hormone Releasing Hormone 
(LRH) has been been established, tested and applied. A method for 
the preparation of antibody to LRH has been worked out (chapter 3). 
This consists of administring LRH coupled to bovine serum albumin to 
rabbits by means of an intradermal multiple site injection tech- nique. 
For the labeled antigen we choose radioiodinated LRH, which could 
be prepared by the Chloramine Τ method. A subsequent Sephadex gel-
chromatographic purification step yielded a suitable tracer for the 
radioimmunoassay of LRH. 
Optimal conditions for the performance of the LRH radio­
immunoassay with regards to incubation time, incubation temperature. 
concentration of antiserum and radiolabeled LRH have been estab­
lished (chapter 4). The affinity constants of LRH for the antibody 
were determined in antisera from a number of bleedings. Two 
different methods for the separation of bound and free antigen were 
examined, the double antibody technique and solvent precipitation of 
the antibody (chapter 4). The latter technique was chosen for routine 
use. The preparation of standard curves is discussed in detail. A 
phase separation method was chosen and the type of incubation 
schedule with the best performance was selected. Three different 
antisera were compared and the precision of the assay method was 
determined. 
The specificity of the LRH-radioimmunoassay was also investi­
gated (chapter 5). The immunological specificity was established by 
measuring the ability of LRH-analogues to displace radiolabeled LRH 
from its binding to the antibodies. Of the three antisera checked, 
two were found to be highly specific in that they required both ends 
of the LRH molecule for binding, while the third was found to be 
specific for the C-terminal only. The high specificity was maintained 
for a prolonged period of time during production of antiserum. In 
order to check the biological specificity a bioassay for LRH was 
established. This required in turn the setting up of a radioimmuno­
assay for rat LH. The results obtained show excellent agreement bet­
ween the two different methods. Further validation of the LRH radio­
immunoassay followed from the parallel inhibition curves for hypo­
thalamic extracts and synthetic LRH, reported in chapter 7. 
Direct measurement of LRH in plasma by means of radioimmuno­
assay was found to have many pitfalls (chapter 6). Proteolytic en-
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zymes can cause degradation of LRH, and other (macromolecular) 
plasma components can interfere with the assays. This non-specific 
interference can largely be eliminated by the extraction procedure, 
which we have developed and validated. Continuous sampling is essen-
tial when measuring LRH in the circulation, as the releasing hormone 
seems to be secreted in a pulsatile manner and has a relatively short 
half-life. The existence of a dual hypothalamo · pituitary control 
system for gonadotrophin secretion is discussed. 
We investigated the distribution of LRH in various tissues of 
the rat (chapter 7). The highest concentrations were measured in the 
stalk median eminence. Low or undetectable levels of immuno-
assayable LRH were found in the posterior pituitary, pineal gland and 
cerebral cortex. A relationship between body weight and hypothalamic 
LRH content was established. Removal of gonadal steroid feed-back 
was found to cause a reduction in the hypothalamic LRH content, 
probably due to a lowering of the ratio of biosynthesis to release. 
Two techniques were studied for possible use in investigations of the 
regulation of LRH release from the hypothalamus: a static incubation 
method and a perifusion method. Basal release of LRH could be 
measured, but no significant responses to biogenic amines were noted. 
Causes of the latter negative findings are discussed. 
By means of a system for continuous monitoring of LH and FSH 
in women we could establish the lowest effective dose of LRH 
causing a significant release of LH and FSH (chapter B). Dose-
related responses could be induced in the release patterns of both 
gonadotrophins. The use of the releasing hormone as a diagnostic tool 
was investigated by measuring the responses to LRH stimulation in 
women with a variety of endocrinological disorders (chapter 7). Over-
responsiveness as well as insufficient responses were noted in 
conditions with elevated and decreased endogenous LRH activity, 
respectively. A nasal spray mode of administration for LRH was in-
vestigated. The effectiveness of the method was checked. While 
establishing dose-response curves for LRH in man, we were often 
unable to achieve linear responses. By means of sequential injections 
spaced at different time intervals, we could establish that this was 
an effect of pituitary refractoriness to releasing hormone stimulation. 
The implications of this effect are discussed. 
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10.2 Nederlands 
Wij hebben een radioimmunologische bepalingsmethode voor LRH 
ontwikkeld, getest en toegepast. Hiervoor hebben we een methode 
gevonden voor de bereiding van geschikte antilichamen (hoofdstuk 
3). Daartoe werd LRH gekoppeld aan runderserum albumine (BSA). Dit 
complex werd toegediend aan konijnen door middel van intradermale 
"multiple site" injectie. We kozen als tracer LRH gelabeled met radio­
actief jodium gelabeled LRH als tracer hetgeen bereid werd met de 
Chloramine Τ methode. Een hierop volgende zuiveringsstap met Sepha-
dex gel-chromatographie leverde een geschikt tracer preparaat voor 
de radioimmunologische bepaling van LRH. 
We hebben de optimale omstandigheden voor de uitvoering van 
de radioimmunologische bepaling van LRH bepaald, te weten incubatie-
tijd, incubatietemperatuur en concentraties van antiserum en radio­
actief gelabeled LRH (hoofdstuk 4). Twee verschillende methoden voor 
de scheiding van gebonden en vrij antigeen werden onderzocht, de 
"double antibody" techniek en een antilichaam-precipitatie methode. 
De laatstgenoemde techniek werd verkozen voor routine gebruik. De 
bepaling van standaard curven wordt gedetailleerd besproken. Een 
fase scheidingsmethode werd gekozen, en het type incubatieschema 
met de beste resultaten werd verkozen Drie verschillende antisera 
werden vergeleken en de nauwkeurigheit in de bepalingsmethode werd 
vastgesteld. 
De specificiteit van de radioimmunoassay werd onderzocht. De 
immunologische specificiteit werd vastgesteld door middel van meting 
van het vermogen van LRH-analogen om gelabeled LRH uit zijn 
binding met antilichamen te verdringen (hoofdstuk 5). Twee van de 
drie geteste antisera hadden een hogere graad van specificiteit dan 
de derde, doordat ze de beide uiteinden van het LRH-molekuul nodig 
hadden voor binding. Het derde bleek alleen specifiek te zijn voor het 
C-uiteinde van het molekuul. Ook kon worden vastgesteld, dat de hoge 
specificiteit voor langere tijd bleef bestaan gedurende de productie 
van antiserum. Om de biologische specificiteit te controleren werd 
een bioassay voor LRH ontwikkeld. Op zijn beurt maakte deze een 
radioimmunoassay van rat-LH nodig. De verkregen resultaten toonden 
uitstekende overeenstemming tussen de verschillende bepalings­
methoden. Meer gegevens bevestigden de validiteit van de radio­
immunoassay. Zo werd in experimenten vastgesteld dat de inhibitie­
curven van hypothalamus extracten en synthetisch LRH parallel ver­
lopen, beschreven in hoofdstuk 7. 
De weg van direkte meting van LRH in plasma door middel van 
radioimmunologische bepaling is bezaaid met voetangels en klemmen 
(hoofdstuk 6). Proteolytische enzymen in het plasma kunnen LRH af­
breken en andere (makromoleculaire) plasma componenten kunnen de 
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bepaling storen en en onbetrouwbar maken. De a-specifieke storing 
kan grotendeels te niet gedaan worden door gebruikmaking van een 
door ons ontwikkelde en beproefde extractie-procedure. Continue 
bemonstering is noodzakelijk bij meting van LRH in de bloedsomloop, 
omdat LRH op een pulsvormige wijse wordt afgescheiden en het ook 
een betrekkelijk korte halfwaardetijd heeft. Het bestaan van een 
dubbel hypothalamo - hypophysair regelsysteem voor de secretie van 
gonadotrophinen wordt besproken. 
We onderzochten de verspreiding van LRH in verschillende 
weefsels van de rat (hoofdstuk 7). De hoogste concentraties werden 
gevonden in de mediane eminens. Lage of onmeetbare concentraties 
werden gemeten in de hypofyse-achterkwab, de epifyse en de hersen-
s с hors. Een verband tussen lichaamsgewicht en LRH-gehalte van de 
hypothalamus werd vastgesteld. Het effekt van blokkering van de 
feed-back van de geslachtshormonen bleek een verlaging van de LRH 
tot gevolg te hebben. Waarschijnlijk werd dit veroorzaakt door een 
verlaging van de verhouding tussen biosynthese en secretie van het 
LRH. Twee technieken werden onderzocht voor gebruik bij het in 
onderzoek van de regulatie van de LRH secretie door de hypo­
thalamus: een statisch incubatie-systeem en een perifusie-methode. 
Basale secretie van LRH kon gemeten worden, maar een significante 
respons op biogene aminen werd niet vastgesteld. Oorzaken van deze 
bevindingen zijn besproken. 
Door middel van een systeem, waarbij LH en FSH bij vrouwen 
konstant werden gemeten, konden we de laagste effektieve dosis LRH 
vaststellen, die signifikante secretie van LH en FSH kan induceren 
(hoofdstuk 8). Een dosis-afhankelijke respons kan geïnduceerd worden 
in de secretiepatronen van beide gonadotrophinen. Het gebruik van 
LRH als een diagnostisch middel werd onderzocht door middel van 
meting van de respons op LRH-stimulatie bij vrouwen met een ver-
schillende endocrinologische afwijkingen. Overmatige respons en on-
volledige respons werden opgemerkt in omstandigheden met verhoogde 
respectievelijk verlaagde endogene LRH activiteit. Een vorm van toe-
diening van LRH door middel van een neus-spray werd ook onderzocht. 
Tijdens de bepaling van dosis-respons curven voor LRH bij de mens 
vonden we, dat het vaak onmogelijk was om lineaire responsen te 
verkrijgen. Door sequentiaale injecties met bepaalde tijdsintervallen te 
geven, konden we vaststellen dat dit het gevolg is van een refrac-
taire periode van de hypofyse als reaktie op LRH stimulatie. De 
implicaties van dit effekt worden besproken. 
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STELLINGEN 
1) Although the classical translocation model for steroid - receptor 
interactions has been convincingly disproven. the concept of an 
exclusive nuclear localization of both occupied and un-occupled 
receptor needs further validation. 
Raam et al. Eur.J.Cancer.Clin.Oncol. 18:1,1982 
Raam et al. Breast Cancer Res.Treat. 3:179,1983 
Welshons et al. Nature 307:747,1984 
Welshone et al. Endocrinology 117:2140,1985 
Robereteon et al. Endocr.Soc.Meeting 1985, Abstract Book, p20 
2) The mode of administration will determine if LH-releasing agonists 
will act in a stimulatory or inhibitory manner. 
Sopelak, Collins & Hodgen, J.Clin.Endocr.Metab. 65:557,1986 
Crowley et al. Ree.Progr.Horra.Reβ. 41:473,1985 
Monroe et al. Fértil.Steril. 43:361,1985 
3) Hyperprolactlnaemia need not result In galactorrhea and even in its 
mild or transient forms it may cause amenorrhea. 
Bohnet et al. Clin.Endocrinology 5:25,1976 
Ben-David et al. J.Clin.Endocr.Metab. 57:442,1983 
Suginami et al. J.Clin.Endocr.Metab. 62:899,1986 
4) The presence of oestradlol and oestradlol receptors in Saccharo-
myces cerevisae implies a physiological function of these compounds in 
yeast. However, since the presence of oestradlol may in fact be due 
to contaminated media components, caution should be exercised in 
Interpreting the results. 
Feldman et al. Science 224:1119,1984 
Miller et al. Endocrinology 119:1362,1986 
5) The statement that "in order to induce potassium sensitivity of 
the phosphorylated intermediate of Na/K ATPase, a simultaneous 
binding of sodium is required*1, is in error. 
Siegel et al. J.Blol.Chem. 255:3935,1980 

6) А Ыоаввау for Beult Inhibiting hornone can be invalidated by 
the fact that a wound reaction might be aa likely to induce 
apolyeie ae does ecdyaone. 
Freeman & Costlow, J.Exp.Zool. 210:333,1979 
Willems & van Deljnen, personal communication 
7) As the degree of acetylation is important for the biological 
activity of melanocyte stimulating hormone is it not sufficient to 
measure only total circulating levels of the peptide. 
Kawauchi et al. Gen.Comp.Endocr. 53:37,1904 
Pickering et al. Gen.Comp.Endocr. In press 1986 
β) When many authors of scientific publications are saying 
"abbreviations" they are in fact frequently refering to what should be 
named acronyms. 
9) One of the side effects of nuclear power is it's ability to induce 
muddled thinking. 
Twello 27 October 1986 Hans G. Dahlen 



